Pre-clinical and Clinical study on Takkolathi Chooranam for Bronchodilator Activity in the management of Eraippu (Bronchial Asthma) and Pre-clinical and Clinical study on Kumari Parpam for Haematinic Activity in the management of Pandu (Anaemia) by Rajendra Kumar, A
1 
 
INTRODUCTION: 
 
 Asthma is defined as a chronic inflammatory disease of airways that is characterized 
by increased responsiveness of the trancheo-bronchial tree to a multiplicity of stimuli1. 
 
 The common risk factors for asthma symptoms include urbanization, airway irritants 
(pollen, animal, hair, industrial smoke, vehicle exhaust fumes, dust mites in pillows and bed 
covers etc)2 .  
 
 There has been a sharp increase in the global prevalence morbidity, mortality and 
economic burden associated with asthma over the last 40 years. Approxiamately 300 million 
people worldwide currently have asthma and its prevalence increases by 50% every decade. It 
is estimated that there may be an additional 100 million persons with asthma by 20253. 
 
 According to WHO estimation 2,55,000 people died of asthma in 2005. Worldwide 
approximately 1,80,000 deaths are attributable to asthma every year. In Asia, increased 
prevalence is likely to be particularly dramatic in India and China3. 
 
 The total burden of asthma in India at an overall prevalence of 3% is estimated at over 
30 million patients. In India, there is a prevalence of about 2.4% in adults over 15 year of 
age8.  
 
 In a study, asthma prevalence was calculated as Mumbai 3.5%, Delhi 2.28%, Kanpur 
1.69% & Bangalore 3.47%6. In India, an estimated 57,000 deaths were attributable to asthma 
in 2004 and it was seen as one of the leading cause of mortality and morbidity in rural India4. 
 
 Globally the economic costs associated with asthma exceed those of tuberculosis and 
HIV/AIDS combines3. The cost of medication for asthma in India was estimated as US$ 30 
per month5. 
 
 Asthma is correlated with Eraippu in Siddha system of medicine. Takkolathi 
Chooranam” is a poly herbal Siddha medicine indicated for Eraippu which is mentioned in 
text “Agasthiyar 2000” 5th edition, October 2002 by Dr.S.Venkatarajan LIM and published 
by Saraswathi mahal noolagam15.  
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 According to Siddha basic principle, karppu suvai cures inflammatory disease of the 
throat and removes sputum (phlegm) from the lungs, veppa verium and karppu pirivu pacifies 
kapham, and prapavam of karppu is to correct deranged kapham7. 
 
 The herbs in “Takkolathi chooranam” have karppu suvai, veppa verium and karppu 
pirivu and hence have great potential in treating Eraippu.  
 
 The above drug has not been evaluated so far for Eraippu, hence the author has 
selected “Takkolathi chooranam” to evaluate bronchodilator activity, anti-histaminic activity 
and its therapeutic efficacy. 
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AIM: 
 To evaluate the safety and efficacy of Takkolathi chooranam for Bronchodilator and 
Antihistaminic activity in the management of Eraippu (Bronchial asthma)  
 
OBJECTIVE: 
 
Primary objective: 
 
 To evaluate the Bronchodilator and anti histaminic activity of Takkolathi chooranam 
for Eraippu (Bronchial asthma) in preclinical studies. 
 
Secondary objective: 
 
           The efficacy of Takkolathi chooranam has been evaluated in the following aspect. 
 
 Collection of literature evidences in Siddha aspect and Botanical aspect. 
 Biochemical Analysis 
 High Performance Thin Layer Chromatography 
 Clinical study- a pilot study on trial medicine 
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STANDARD OPERATIVE PROCEDURE:  
Collection and authentication of the raw drugs:  
             The raw drug were procured from raw drug store in Chennai and authenticated by 
competent authority of Department of Gunapadam, National Institute of Siddha, Chennai.  
Ingredients: 
             Purified Takkolam    (Illicium verum)                    -1¼ varagan    (5.25 gms) 
                 Purified Kirambhu   (Syzygium aromaticum)         - 1 ¼ varagan  (5.25 gms) 
             Purified Elakkai      (Elettaria cardamomum)         - 1¼ varagan   (5.25 gms) 
             Purified Thippili      (Piper longum)                       - 2¼ varagan    (9.45 gms) 
             Purified Siruthekku (Clerodendrum serratum)       - 5 varagan        (21 gms) 
             Purified Chukku      (Zingiber officinale)               - 10 varagan      (42 gms) 
             Purified Milagu       (Piper nigrum)                        - 12½ varagan  (52.5 gms) 
             Sugar                       (Saccharum officinarum)       - 33½ varagan  (140.7gms)           
                                                             
Purification process:  
Purification of Takkolam13: 
 Takkolam was dried in the sunlight. 
Purification of Kirambhu: 
 Kirambhu was dried in the sunlight13. 
Purification of Elakkai: 
 Elakkai was dried in sunlight13. 
Purification of Thippili: 
 Thippili was purified by soaking in the lemon juice14. 
Purification of siruthekku: 
 Siruthekku was purified by removing the outer layer and cutted into small pieces, then 
they were dried in the sunlight13. 
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Purification of Chukku: 
 Chukku was purified by removing the outer layer and soaking in the limestone 
water14.   
Purification of Milagu: 
 Milagu was soaked in buttermilk for 1hour 15 minutes and then it was fried14. 
Preparation of the medicine:  
            The raw drug was purified and pulverized by an electric grinder into 
fine powder, separately. And then it was sieved by using a fine silk cloth (vasthrakayam). The 
fine powder was purified by pittaviyal method. Then it was dried and ultra filtered by a 
cotton cloth and made into fine powder again. The powder was mixed with equal quantity of 
sugar and it was stored in a clean, dry air tight glass bottle15. 
 LABELLING:  
Name of the preparation : Takkolathi chooranam 
 
Taste    : Kaarppu 
 
Colour    : Mild yellowish colour 
 
Dose    : 6 gm b.d 
 
Adjuvant   : Luke warm water 
                         
  Duration   : 1 month 
 
Indication   : Bronchial asthma 
                         
  Date of manufacture  : The drug was prepared in three batches. 
                                                                                    13/4/12, 15/7/12, 16/10/12 
            Expiry    : 3 months from the date of manufacture 
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                         INGREDIENTS IN TAKKOLATHI CHOORANAM: 
                           Illicium verum Hook.f             Syzygium aromaticum (Linn.)  
 
    
                                 Elettaria cardamomom (Linn.) Maton        Piper longum Linn 
                       
                                   Zingiber officinale Rosc.                       Piper nigrum Linn. 
                                     
                             Clerodendrum serratum (Linn.)        Takkolathi chooranam                                                  
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¾ì§¸¡Äõ11 
 
ÀÂýÀÎõ ¯ÚôÒ: â 
 
Í¨Å:   þÉ¢ôÒ, Å¢ÚÅ¢ÚôÒ,   ¾ý¨Á:¦ÅôÀõ,   À¢¡¢×:¸¡÷ôÒ 
 
¦ºö¨¸:  Àº¢òàñÊ, ¦ÅôÀÓñ¼¡ì¸¢, ¯ÃÁ¡ì¸¢ 
 
¾ì§¸¡Äõ §ºÕõ þ¨ÃôÒ §¿¡öì¸¡É ÁÕóÐ¸û: 
1.ÀïºÀÃ½î ÝÃ½õ16 
«Ç×  : ãÅ¢Ãø «Ç×, 1 §Å¨Ç 
¾£Õõ §¿¡ö : ÍÅ¡º¸¡ºõ, À¡ñÎ, ¸¡Á¡¨Ä 
¬¾¡Ãõ : ºÃ§Àó¾¢Ã ¨Åò¾¢Â Ó¨È¸û À¡ñÎ ¸¡Á¡¨Ä º¢¸¢î¨º 
 
2.¸÷ôâÃ¡¾¢î ÝÃ½õ15 
«ÛÀ¡Éõ : §¾ý, º÷ì¸¨Ã 
¾£Õõ §¿¡ö : ºÂõ 
¬¾¡Ãõ : «¸Š¾¢Â÷ 2000 
   
3.ÅøÄ¨Ã ¦¿ö17 
«Ç×  : ¦À¡ðÎì¸ÃñÊ «Ç×, 2 §Å¨Ç 
¾£Õõ §¿¡ö : þ¨ÃôÒ, þÕÁø, ÍÅ¡º ÍÃõ, ¸¡ºõ, ¿¡ðÀð¼ ®¨Ç 
¬¾¡Ãõ : º¢ò¾ ¨Åò¾¢Âò ¾¢ÃðÎ 
 
4.¾¡Ç¢º¡¾¢î ÝÃ½õ15 
«Ç×  : ãÅ¢Ãø «Ç× 
«ÛÀ¡Éõ : §¾ý, º÷ì¸¨Ã 
¾£Õõ §¿¡ö : ÍÅ¡º¸¡ºõ, ®¨Ç 
¬¾¡Ãõ : «¸Š¾¢Â÷ 2000 
 
5. ¾ì§¸¡Ä¡¾¢ì ¸¢Â¡Æõ21 
¾£Õõ §¿¡ö : þØôÒ, §¸¡¨Æì¸ðÎ,À¡ñÎ,¸¡Á¡¨Ä 
¬¾¡Ãõ : À¾¡÷ò¾ Ì½ Å¢ûì¸õ 
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Research articles: 
1. Research on antibacterial mechanism of essential oils and dominant monomer 
components of star anise28   
2. Study on chemical component analyzed by GC-MS and antioxidation of star anise 
extracts29 
3. Extraction and Free Radical Scavenging Investigation of Total Flavonones from 
Anise Leaves30 
4. Study on the antimicrobial stability of essential oil from star anise by supercritical 
carbondioxide extraction31 
5. Chemical Composition and Antibacterial Activities of Illicium verum Against 
Antibiotic-Resistant Pathogens32  
 
¸¢Ã¡õÒ11 
 
§ÅÚ ¦ÀÂ÷¸û :     «ïÍ¸õ,¯ü¸¼õ,¸ÕÅ¡öì ¸¢Ã¡õÒ,§º¡ºõ,¾¢ÃÇ¢ ,ÅÃ¡í¸õ 
 
Í¨Å   :     ¸¡÷ôÒ, Å¢ÚÅ¢ÚôÒ,      ¾ý¨Á:¦ÅôÀõ,     À¢¡¢×:¸¡÷ôÒ 
 
¦ºö¨¸  :     Àº¢ò¾£òàñÊ, «¸ðÎÅ¡öÅ¸üÈ¢, þº¢Å¸üÈ¢ 
 
¦À¡Ð Ì½õ  : 
         "À¢ò¾ ÁÂì¸õ §À¾¢§Â¡Î Å¡ó¾¢Ôõ§À¡õ 
         Íò¾Å¢Ã¾ò ¾ì¸ÎôÒó §¾¡ýÚ§Á¡ -¦Áò¾ 
         þÄÅí¸í ¦¸¡ñ¼ÅÕì §¸ü Í¸Á¡Ìõ 
         ÁÄÁí§¸ ¸ðÎ¦ÁÉ Å¡úòÐ" 
     
      ÁÂì¸õ, §À¾¢, Å¡ó¾¢, ¬ºÉÅ¡öì¸ÎôÒ, ¦ºÅ¢§¿¡ö ¾£Õõ. 
 
¸¢Ã¡õÒ §ºÕõ þ¨ÃôÒ §¿¡öì¸¡É ÁÕóÐ¸û: 
1. «ÍÅ¡¾¢î ÝÃ½õ20  
«Ç×  : ¦ÅÕ¸Ê «Ç×, 2 §Å¨Ç, 1 Áñ¼Äõ 
«ÛÀ¡Éõ : ¦ÅûÇ¡ðÎ ¿£÷ 
¾£Õõ §¿¡ö : ®¨Ç 
¬¾¡Ãõ : «¸Š¾¢Â÷ ¨Åò¾¢Â ¸¡Å¢Âõ 1500 
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2.¾¡Ç¢ºÀò¾¢¡¢î ÝÃ½õ20  
«Ç×  : ¦ÅÕ¸Ê «Ç×,2 §Å¨Ç 
«ÛÀ¡Éõ : §¾ý, þïº¢îº¡Ú, Á¡ÐÇõÀÆîº¡Ú 
¾£Õõ §¿¡ö : þÕÁø, ¸¡ºõ, Ìð¼õ, ÌýÁõ, ¸ÃôÀý, ¸¡Á¡¨Ä 
¬¾¡Ãõ : «¸Š¾¢Â÷ ¨Åò¾¢Â ¸¡Å¢Âõ 1500 
 
3.¾¢ôÀ¢Ä¢Â¡¾¢ §Ä¸¢Âõ20  
«Ç×  : ¦¸¡ð¨¼ôÀ¡ì¸Ç×,1 §Å¨Ç,1 Áñ¼Äõ 
¾£Õõ §¿¡ö : þÕÁø,®¨Ç, ºÂõ, º¢§ÄðÎÁõ 
¬¾¡Ãõ : «¸Š¾¢Â÷ ¨Åò¾¢Â ¸¡Å¢Âõ 1500 
 
4.Á¸¡Å¢øÅ¡¾¢ §Ä¸¢Âõ20 
«Ç×  : ¦¸¡ð¨¼ôÀ¡ì¸Ç× 
¾£Õõ §¿¡ö : þÕÁø, ,®¨Ç , Ìð¼õ, ÌýÁõ, ¿£§ÃüÈõ, ÍÃÁ¡ó¨¾ 
¬¾¡Ãõ : «¸Š¾¢Â÷ ¨Åò¾¢Â ¸¡Å¢Âõ 1500 
 
5. «ŠÅ¸ó¾¢ §Ä¸¢Âõ13 
«Ç×  : Íñ¨¼ì¸¡ö À¢ÃÁ¡½õ 
¾£Õõ §¿¡ö : „Â¸¡ºõ, À¡ñÎ 
¬¾¡Ãõ : º¢¸¢îºÃòÉ ¾£Àõ 
 
²Äõ11 
 
§ÅÚ ¦ÀÂ÷¸û : ¬ïº¢, §¸¡Ãí¸õ, ÐÊ  
 
Í¨Å   : ¸¡÷ôÒ,       ¾ý¨Á:¦ÅôÀõ,      À¢¡¢×:¸¡÷ôÒ 
 
¦ºö¨¸  : Àº¢ò¾£òàñÊ, ¦ÅôÀÓñ¼¡ì¸¢, «¸ðÎÅ¡öÅ¸üÈ¢ 
 
¦À¡Ð Ì½õ  : 
    ¦¾¡ñ¨¼ Å¡ö¸×û ¾¡ÖÌ ¾í¸Ç¢ø 
    §¾¡ýÚõ §¿¡Â¾¢ º¡ÃõÀý §Á¸ò¾¡ø 
    ¯ñ¨¼ §À¡ø ±Øí ¸ðÊ ¸¢¡¢îºÃõ  
    ¯Æ¨Ä Å¡ó¾¢ º¢Äó¾¢ Å¢„ïÍÃõ 
    Àñ¨¼ ¦Åì¨¸ Å¢¾¡¸§¿¡ö ¸¡ºÓõ 
    À¡Øï §º¡Áô À¢½¢Å¢óÐ ¿ð¼Óõ 
    «ñ¨¼ Â£¨ÇÅý À¢ò¾õ þ¨Åì¦¸øÄ¡õ 
    ¬Ä Á¡í¸Áú ²Ä ÁÕó¾§¾. 
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             ¦¾¡ñ¨¼, ¾¡û, Å¡ö, ¸£úÅ¡ö þ¨Å¸Ç¢ø ¯ñ¼¡Ìõ §¿¡ö¸¨ÇÔõ, 
þÕÁø, ¦¿ïº¢ý §¸¡¨Æì¸ðÎ ¾£Õõ. 
 
²Äõ §ºÕõ þ¨ÃôÒ §¿¡öì¸¡É ÁÕóÐ¸û: 
1.¾¢ôÀ¢Ä¢Â¡¾¢î ÝÃ½õ20  
«Ç×  : ¦ÅÕ¸Ê «Ç×, 2 §Å¨Ç,20¿¡û 
«ÛÀ¡Éõ : §¾ý, ¦¿ö ,Á¡ÐÇõÀÆîº¡Ú 
¾£Õõ §¿¡ö : þÕÁø,®¨Ç, ºÂõ ,º¢§ÄðÎÁí¸û 
¬¾¡Ãõ : «¸Š¾¢Â÷ ¨Åò¾¢Â ¸¡Å¢Âõ 1500 
 
2.Å¢øÅ¡¾¢ §Ä¸¢Âõ20  
«Ç×  : ¦¸¡ð¨¼ôÀ¡ì¸Ç×,2 §Å¨Ç,1 Áñ¼Äõ 
¾£Õõ §¿¡ö : þÕÁø,  ®¨Ç , ÌýÁõ, ¿£§ÃüÈõ, ÍÃÁ¡ó¨¾ 
¬¾¡Ãõ : «¸Š¾¢Â÷ ¨Åò¾¢Â ¸¡Å¢Âõ 1500 
 
3. ¸ñ¼¡ò¾¢¡¢ §Ä¸¢Âõ20  
«Ç×  : ¦¸¡ð¨¼ôÀ¡ì¸Ç×,2 §Å¨Ç,1 Áñ¼Äõ 
¾£Õõ §¿¡ö : ÌÃø¸ðÎ,Ò¨¸îº§Ä¡Î þÕÁø, Å¡ó¾¢  
¬¾¡Ãõ : «¸Š¾¢Â÷ ¨Åò¾¢Â ¸¡Å¢Âõ 1500 
 
4.¸üâÃ¡¾¢î ÝÃ½õ23  
«ÛÀ¡Éõ : §¾ý 
¾£Õõ §¿¡ö : þ¨ÃôÒ, ¸¡ºÍÅ¡ºõ, ¦¿ïº¨¼ôÒ 
¬¾¡Ãõ : «¸Š¾¢Â÷ «ð¼Å¨½ Å¡¸¼õ 
 
¾¢ôÀ¢Ä¢11 
 
§ÅÚ¦ÀÂ÷¸û :   ¬÷¸¾¢, ¯ñºÃõ, ¯Ä¨Å¿¡º¢, ¸¡Áý, Ì§¼¡¡¢, §¸¡Ä¸õ,             
        §¸¡Ä¢, ºÃõ, º¡Ê, ÐÇÅ¢, Á¡¸¾¢, ¸¨É, §¸¡¨ÆÂÚì¸¢ 
 
ÀÂýÀÎõ ¯ÚôÒ :   ¸¡ö, «¡¢º¢ 
 
Í¨Å   :   ¸¡÷ôÒ,     ¾ý¨Á:¦ÅôÀõ,    À¢¡¢×:þÉ¢ôÒ 
 
¦ºö¨¸  :   ¦ÅôÀÓñ¼¡ì¸¢, «¸ðÎÅ¡öÅ¸üÈ¢ 
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¦À¡Ð Ì½õ  : 
                  ®¨Ç Â¢ÕÁ Ä¢¨ÃôÒô ÀºôÀ¢½¢¸û  
                 Á¡Ç ¦Å¡Æ¢Â¡Áø Å¡ðÎ§Á-Â¡ÙÓ¨È 
                 À¡í¸¡ ÂÈ¢óÐ¦ºöÅ£÷ ÀñÊ¾ò¨¾ô ÀñÊ¾§Ã 
                 §Åí¨¸Å¡öô À¡í¸¨½ ¦Áö. 
 
            þ¾É¡ø ®¨Ç, þÕÁø, þ¨ÃôÒ, ¯ôÀ¢ºõ Ó¾Ä¢ÂÉ ¿£íÌõ. 
 
¾¢ôÀ¢Ä¢ §ºÕõ þ¨ÃôÒ §¿¡öì¸¡É ÁÕóÐ¸û: 
 
1. ²Ä¡¾¢î ÝÃ½õ20  
«Ç×           :     ¦ÅÕ¸Ê «Ç× 
«ÛÀ¡Éõ  :    Ó¨ÄôÀ¡ø,Á¡ÐÇõÀÆîº¡Ú 
¾£Õõ §¿¡ö  :    þÕÁø,®¨Ç, ÍÃí¸û, ºò¾¢ 
¬¾¡Ãõ    :     «¸Š¾¢Â÷ ¨Åò¾¢Â ¸¡Å¢Âõ 1500 
 
2. ºñ¼Á¡Õ¾ §Ä¸¢Âõ20  
«Ç×       :    ¾¡ýÈ¢ì¸¡ÂÇ× 
¾£Õõ §¿¡ö  :    þÕÁø, 
¬¾¡Ãõ     :    «¸Š¾¢Â÷ ¨Åò¾¢Â ¸¡Å¢Âõ 1500 
 
3. ÍÅ¡º¸¡º ÌÇ¢¨¸22  
«Ç×  :    ÀÂÈÇ×  
«ÛÀ¡Éõ :    §¾ý, ¦¿ö ,º÷ì¸¨Ã 
¾£Õõ §¿¡ö :   þÕÁø, ÍÅ¡ºõ, ®¨Ç 
¬¾¡Ãõ :    §¾¨ÃÂ÷ ¨Åò¾¢Âõ 1000 
 
4.ÍÃÒí¸ Å¢øÅ¡¾ þÇ¸õ19  
«Ç×       :     2-4 ¸¢Ã¡õ,2 §Å¨Ç 
¾£Õõ §¿¡ö   :         þ¨ÃôÒ,þÕÁø, À¡ñÎ,¿¡º¢¸¡À£¼õ 
¬¾¡Ãõ   :     «¸Š¾¢Â÷ Å¢øÅ¡¾¢ 600 
 
Research articles: 
1. Immunomodulatory and antitumour activity of Piper longum Linn. and piperine33 
2. Histamine Release Inhibitory Activity of Piper nigrum Leaf34 
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º¢Ú§¾ìÌ11 
§ÅÚ ¦ÀÂ÷  :   ¸ñÎÀ¡Ãí¸¢ 
 
ÀÂýÀÎõ ¯ÚôÒ :   þ¨Ä, §Å÷ 
 
Í¨Å   :   ¨¸ôÒ, ÐÅ÷ôÒ,    ¾ý¨Á:¦ÅôÀõ,     À¢¡¢×:¸¡÷ôÒ 
 
¦ºö¨¸  :   ¦ÅôÀÓñ¼¡ì¸¢, ¾¡Ð¦ÅôÀ¸üÈ¢ 
 
¦À¡Ð Ì½õ  : 
                    ¸ñÎÀ¡ Ãí¸¢§ÂÛï º¢Ú§¾¸ Ìñ§¼ø, 
                    ¸¡¦Äí§¸ À¢ò¾¦Áí§¸ ¸Àó¾¡ ¦Éí§¸ 
                    ¦¾¡ñÎ ¦¾¡ðÎò ¦¾¡¼÷ÍÅ¡º ¸¡º ¦Áí§¸ 
                   ÍÃ¦Áí§¸ ¦ÅÈ¢ ¦Âí§¸ ¦¾¡É¢§¿¡ ¦Âí§¸   
                    Á¢ñÎÒ¡¢ À£¿£º¿£÷ì §¸¡¨Å ¦Âí§¸ 
                    ¦ÅÇ¢¿£Õñ ½£¦Ãí§¸ Å¢È÷¸¡ ¦Äí§¸ 
                    «ñÎÀ¼¡î º£¾ÍÃí ¸ÎôÒ ¦Áí§¸ 
                    ÂÆ¨ÄÂ¸ §¿¡¦Âí§¸ Â¨ÈÌ Å£§Ã! 
             
              þ¾É¡ø ÓìÌüÈõ, þ¨ÃôÀ¢ÕÁø, ÍÃõ, ãì¸¢ø Óý¿£÷ì§¸¡¨Å, À¢ý 
¿£÷ì§¸¡¨Å, ÌÇ¢÷ ¸¡öîºø ¾£Õõ. 
 
º¢Ú§¾ìÌ §ºÕõ þ¨ÃôÒ §¿¡öì¸¡É ÁÕóÐ¸û: 
1. Á¸¡Í¾÷ºÉî ÝÃ½õ13 
«Ç×            :      1/4 §¾¡Ä¡  
«ÛÀ¡Éõ   :       ¦Åó¿£÷ 
¾£Õõ §¿¡ö   :      ÍÅ¡º¸¡ºõ 
¬¾¡Ãõ       :      º¢¸¢îº¡ÃòÉ ¾£Àõ 
 
2. º¢í¸¡¾¢î ÝÃ½õ18  
¾£Õõ §¿¡ö   :       ÍÅ¡ºõ,¸¡ºõ, À£É¢ºõ, ºÂõ 
¬¾¡Ãõ         :     «¸Š¾¢Â÷ ¨Åò¾¢Â º¢ó¾¡Á½¢ ¦ÅñÀ¡ 4000 ±ýÛõ Á½¢ 4000 
 
3. þÄÅí¸¡¾¢î ÝÃ½õ13 
«Ç×        :      1/2 §¾¡Ä¡ , 2 §Å¨Ç, 20¿¡û 
¾£Õõ §¿¡ö  :      þ¨ÃôÒ 
¬¾¡Ãõ          :      º¢¸¢îº¡ÃòÉ ¾£Àõ 
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4. ¾¡ÀÅÉÄî ÝÃ½õ18 
¾£Õõ §¿¡ö    :     ÍÅ¡ºõ¸¡ºõ, þÕÁø  
¬¾¡Ãõ         :     «¸Š¾¢Â÷ ¨Åò¾¢Â º¢ó¾¡Á½¢ ¦ÅñÀ¡ 4000 ±ýÛõ Á½¢ 4000 
 
5. Ìñ¼Ä¡¾¢ §Ä¸¢Âõ20 
«Ç×           :     ¦¸¡ð¨¼ôÀ¡ì¸Ç× 
¾£Õõ §¿¡ö   :     ¿£§ÃüÈõ, À£É¢ºí¸û, þÕÁø 
¬¾¡Ãõ         :    «¸Š¾¢Â÷ ¨Åò¾¢Â ¸¡Å¢Âõ 1500     
  Research articles: 
 1. Antioxidant Effects of Roots of Clerodendrum serratum Linn35 
 2. In-vitro and in-vivo antiasthmatic studies of Clerodendrum serratum Linn in Guinea pigs36
 
 
ÍìÌ11 
 
§ÅÚ¦ÀÂ÷¸û : «Õì¸ý, «¾¸õ, ¬÷òÃ¸õ, ¯ÀÌøÄõ, ¸ÎÀò¾¢Ãõ,    
    ÍñÊ ¦º¡ñÊ, ¦ºªÀýÉõ, ¿ÅÍÚ, ¿¡¸Ãõ, Å¢¼ãÊÂ 
    «Á¢÷¾õ 
 
ÀÂýÀÎõ ¯ÚôÒ : ¸¢ÆíÌ (¯Ä÷ó¾Ð) 
 
Í¨Å    : ¸¡÷ôÒ ,     ¾ý¨Á:¦ÅôÀõ  ,     À¢¡¢×:¸¡÷ôÒ 
 
¦ºö¨¸  : Àº¢ò¾£òàñÊ, ¦ÅôÀÓñ¼¡ì¸¢, «¸ðÎÅ¡öÅ¸üÈ¢ 
 
¦À¡Ð Ì½õ  : 
                       Ý¨ÄÁó¾õ ¦¿ï¦º¡¢ôÒ §¾¡¼§Áô ÀõÁÆ¨Ä 
                        ãÄõ þ¨ÃôÀ¢ÕÁø ãìÌ¿£÷  -Å¡Ä¸À 
                        §¾¡¼Á¾¢ º¡Ãó ¦¾¡¼÷Å¡¾ ÌýÁ¿£÷ò 
                        §¾¡¼õ ¬ Áõ§À¡ìÌï ÍìÌ. 
 
                     Íì¸¢É¡ø þ¨ÃôÒ, þÕÁø, ¿£§ÃüÈõ, ¸¡ÐìÌò¾ø, Ó¸§¿¡ö, ¾¨Ä 
§¿¡ö, ³ÂÍÃõ §À¡õ. 
 
ÍìÌ §ºÕõ þ¨ÃôÒ §¿¡öì¸¡É ÁÕóÐ¸û: 
1. ºÁý ÝÃ½õ18  
¾£Õõ §¿¡ö :       ÍÅ¡ºõ,¸¡ºõ 
¬¾¡Ãõ :      «¸Š¾¢Â÷ ¨Åò¾¢Â º¢ó¾¡Á½¢ ¦ÅñÀ¡ 4000 ±ýÛõ Á½¢ 4000 
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2.â¿¡¸î ÝÃ½õ13 
¾£Õõ §¿¡ö    :        ºÂõ, ¸¡ºõ 
¬¾¡Ãõ     :        º¢¸¢îº¡ÃòÉ ¾£Àõ 
 
3. Å¡÷Àò¾¢Â¡¾¢  ÝÃ½õ18 
¾£Õõ §¿¡ö    :       ÍÅ¡º¸¡ºõ 
¬¾¡Ãõ     :      «¸Š¾¢Â÷ ¨Åò¾¢Â º¢ó¾¡Á½¢ ¦ÅñÀ¡ 4000 ±ýÛõ Á½¢ 4000 
 
4º¢Å¨¾î ÝÃ½õ20 
«Ç×         :     ¦ÅÕ¸Ê «Ç×,2 §Å¨Ç 
«ÛÀ¡Éõ   :     §¾ý, þïº¢îº¡Ú 
¾£Õõ §¿¡ö   :     þÕÁø,®¨Ç 
¬¾¡Ãõ          :     «¸Š¾¢Â÷ ¨Åò¾¢Â ¸¡Å¢Âõ 1500 
 
Á¢ÇÌ11 
 
§ÅÚ ¦ÀÂ÷¸û : ¸Ä¢¨É, ¸È¢, ¸¡Âõ, §¸¡Ç¸õ, ¾¢Ãí¸û, Á¢¡¢Âø,  
    ºÕÁÀò¾õ, ÅûÇ¢ºõ, Á¡ºõ, Á¨ÄÂ¡Ç¢ 
 
ÀÂýÀÎõ ¯ÚôÒ : Å¢¨¾, ¦¸¡Ê 
 
Í¨Å   : ¨¸ôÒ, ¸¡÷ôÒ,     ¾ý¨Á:¦ÅôÀõ,    À¢¡¢×:¸¡÷ôÒ 
 
¦ºö¨¸  : ¸¡ÈÖñ¼¡ì¸¢, ¦ÅôÀÓñ¼¡ì¸¢, «¸ðÎÅ¡öÅ¸üÈ¢, 
    Ó¨È¦ÅôÀ¸üÈ¢, ¾ÊôÒñ¼¡ì¸¢, Å£ì¸í¸¨Ãîº¢,    
    Å¡¾Á¼ì¸¢, ¿îº¡¢ 
 
¦À¡Ð Ì½õ  : 
                   º£¾ÍÃõ À¡ñÎ º¢§ÄòÁí ¸¢Ã¡½¢ÌýÁõ 
                   Å¡¾õ «Õº¢À¢ò¾õ Á¡ãÄõ-µÐºýÉ¢ 
                   Â¡ºÁÀŠ Á¡Ãõ «¼ý§Á¸õ ¸¡ºÁ¢¨Å 
                   ¿¡ºí ¸È¢Á¢Ç¸¢É¡ø 
 
              þ¾É¡ø ÌÇ¢÷ÍÃõ, À¡ñÎ, §¸¡¨Æ, þÕÁø, ¦ºÅ¢ÅÄ¢, þÃò¾ ÌýÁõ, 
¸¡Á¡¨Ä þ¨Å §À¡Ìõ. 
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Á¢ÇÌ §ºÕõ þ¨ÃôÒ §¿¡öì¸¡É ÁÕóÐ¸û: 
 
1. ÍÅ¡ºÌ§¼¡¡¢î ÝÃ½õ20 
«ÛÀ¡Éõ      :    §¾ý, þïº¢îº¡Ú, ¦¿ö 
¾£Õõ §¿¡ö      :    þÕÁø, ÍÅ¡º§¿¡ö¸û ,¸¡ºõ, ®¨Ç 
¬¾¡Ãõ           :    «¸Š¾¢Â÷ ¨Åò¾¢Â ¸¡Å¢Âõ 1500 
 
2. À¡Ä¡¼î ÝÃ½õ20 
«Ç×            :    ¦ÅÕ¸Ê «Ç×, 2 §Å¨Ç, 1 Áñ¼Äõ 
«ÛÀ¡Éõ    :    §¾ý, þïº¢îº¡Ú, ¦¿ö 
¾£Õõ §¿¡ö    :    þÕÁø, Å¡ó¾¢, ¦Åð¨¼ 
¬¾¡Ãõ         :    «¸Š¾¢Â÷ ¨Åò¾¢Â ¸¡Å¢Âõ 1500 
 
3. þÃºî¦ºóàÃõ22 
«Ç×           :      À½¦Å¨¼, 2 §Å¨Ç, 7 ¿¡û 
«ÛÀ¡Éõ   :      º£Ã¸ ¸¢Â¡Æõ 
¾£Õõ §¿¡ö     :     ¸¡ºõ, ºÂõ, þÕÁø, þ¨ÇôÒ 
¬¾¡Ãõ        :     §¾¨ÃÂ÷ ¨Åò¾¢Âõ 1000 
 
4. ¸ñ¼í¸ò¾¢¡¢î ÝÃ½õ23  
«Ç×        :     À¡ì¸Ç× 
¾£Õõ §¿¡ö   :     þÕÁø,ÍÅ¡º¸¡ºõ 
¬¾¡Ãõ          :    «¸Š¾¢Â÷ «ð¼Å¨½ Å¡¸¼õ 
Research articles: 
1. The antioxidant and radical scavenging activities of black pepper (Piper nigrum) 
seeds37 
2. Efficacy of piperine, an alkaloidal constituent from Piper nigrum on erythrocyte 
antioxidant status38 
3. Anti-inflammatory activity of piperine39. 
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TAKKOLAM 
 
BOTANICAL NAME24           :                 Illicium verum Hook.f 
CLASSIFICATION25: 
                    Kingdom  : Plantae– Plants 
                    Subkingdom :           Tracheobionta– Vascular plants 
                    Superdivision : Spermatophyta– Seed plants 
                    Division  : Magnoliophyta– Flowering plants 
                    Class  : Magnoliopsida– Dicotyledons 
                    Subclass  : Magnoliidae 
                    Order  : Illiciales 
                    Family  :            Illiciaceae– Star-anise family 
                    Genus  :            Illicium L.– anisetree 
                    Species  :  I.verum Hook. f. – staranise tree 
 
VERNACULAR NAMES:  Star anise, star aniseed, or Chinese star anise  
 
BOTANICAL DESCRIPTION26:  An annual herb about 0.5m high; root fusiform, and the stem is 
erect, round, leaves are petiolate, inflorescences are medium sized umbels, and fruit is ovate 
to oblong and flattened at the sides. 
 
DISTRIBUTION: A medium-sized native evergreen tree of northeast Vietnam ,southwest 
China. 
 
 PARTS USED: Fruit. 
 
CHEMICAL CONSTITUENTS: Anethole, cinnamaldehyde, 0-methoxycinnamaldehyde, p-
methoxy-cinnamaldehyde, cinnamic acid, p-methoxycinnamaldehyde, cinnamyl alcohol, 
trans-anethole, beta-caryophyllene, citronellol, estragole, eugenol methyl ether, myrcene. 
 
PHARMACOLOGICAL ACTIVITY: Antibacterial, Appetizer, Carminative, Expectorant, 
Stimulant 
 
ADULTERANTS: Japanese star anise (Illicium anisatum) is adulterated with star anise. 
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KIRAMBHU 
BOTANICAL NAME24: Syzygium aromaticum (Linn.) Merrill & Perry. 
CLASSIFICATION25: 
       Kingdom           :            Plantae– Plants 
      Subkingdom           :            Tracheobionta– Vascular plants 
      Superdivision           :            Spermatophyta– Seed plants 
      Division           :            Magnoliophyta– Flowering plants 
      Class           :            Magnoliopsida– Dicotyledons 
      Subclass           :            Rosidae 
      Order           :            Myrtales 
      Family           :            Myrtaceae– Myrtle family 
      Genus           :            Syzygium P. Br. ex Gaertn.– syzygium 
      Species           :            S.aromaticum (L.) Merr. & L.M. Perry– clove 
VERNACULAR NAMES: 
 Eng.- Clove tree,Cloves 
 Hindi- Lavanga 
 Kan.-Lavanga 
 Mal.-Karampu 
 Tam.-Kirambu, Lavangam 
 Tel.-Lavangalu 
BOTANICAL DESCRIPTION: A pyramidal or conical evergreen upto 12m high leaves simple, 
flower buds greenish to pink, fruits fleshy, dark pink drupes, seeds grooved on one side, 
obolong. 
DISTRIBUTION: It is a native of islands of Malay Archipelago, especially Moluccas. In India, 
it is reported to be grown in Tamil Nadu (Nilgris, Courtallam and Kanyakumari) and Kerala. 
 
PARTS USED: Flower buds, oil. 
 
ACTIONS: Digestive, carminative, stomachic, stimulant, aphrodisiac, appetizer, expectorant, 
emollient, rejuvenating and tonic. 
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Physical constants: Foreign matter- Not more than 2%; Total ash- Not more than 7%; Acid-
insoluble ash- Not more than 1%; Alcohol-soluble extractive- Not less than 3%; Water- 
soluble extractive- Not less than 9%; Volatile oil- Not less than 15%. 
 
CHEMICAL CONSTITUENTS: Polyoxygenated chromone C-glucoside, isobiflorin, eugenol, 
acetyleugenol, epoxydihydrocaryophyllene, caryophellene and furfural traces, naphthalene, 
ellagitannin- eugeniin, caryopyllene oxide. 
 
PHARMACOLOGICAL ACTIVITY: Anticarcinogenic, antioxidant, antibacterial, antiviral, 
radical scavenging activity, histamine release inhibitory activity. 
 
ADULTERANTS: Cloves are adulterated with unripe fruits of Cinnamomum verum. 
 
ELLAM 
BOTANICAL NAME24: Elettaria cardamomom (Linn.) Maton. 
CLASSIFICATION25: 
 
Kingdom :          Plantae– Plants 
Subkingdom :         Tracheobionta– Vascular plants 
Superdivision :         Spermatophyta– Seed plants 
Division :         Magnoliophyta– Flowering plants 
Class :         Liliopsida– Monocotyledons 
Subclass :         Zingiberidae 
Order :         Zingiberales 
Family :         Zingiberaceae– Ginger family 
Genus :         Elettaria Maton– elettaria 
Species :         E.cardamomum (L.) Maton– cardamom 
VERNACULAR NAMES: 
 Eng.- Cardamom 
 Hindi- choti ilayachi 
 Kan.-Elakki 
 Mal.-Elam 
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 Tam.-Ellakay 
 Tel.-Chinne elakulu 
BOTANICAL DESCRIPTION:  A tall herbaceous perennial, leaves 30-90cm long, flowers white 
or pale green with a central lip straked with violet, fruits trilocular, seeds 15-20 per pod. 
 
DISTRIBUTION: It is a native of the moist evergreen forests of South India, growing wild in 
the Western Ghats, between 800-1600 m. It is commonly cultivated in Kerala, Karnataka and 
Tamilnadu. 
PARTS USED: Seed 
 
ACTIONS: Seeds are aromatic, cooling, stimulant, carminative, digestive, stomachic, diuretic, 
carditonic, alexiteric, expectorant, tonic and abortifacient. 
Physical constants: Total ash- Not more than 6%; Acid- insoluble ash- Not more than 4%; 
Alcohol- soluble extractive- Not less than 2%; Water-soluble extractive- Not less than 10%; 
Volatile oil- Not less than 4%. 
CHEMICAL CONSTITUENTS: α –Pinene, sabinene, myrcene, limonene, cineol, cymene, 
methyl heptenone, linalool, linalyl acetate, α & β-terpeneol, α-terpinyl acetate, borneol, neryl 
acetate, geraniol, nerol, nerolidol, heptacosane, 1,8-cineole, camphene, terpinene, α-
humelene. 
 
PHARMACOLOGICAL ACTIVITY: Hepatoprotective, anti-inflammatory, analgesic, 
antispadmodic, antimicrobial, antifugal. 
 
SUBSTITUTES: Amomum subulatum Roxb., possesses similar properties to that of Elettaria 
cardamomum for which they are often substituted. 
 
THIPPILI 
BOTANICAL NAME24 :  Piper longum Linn 
 
CLASSIFICATION25: 
Kingdom         :         Plantae– Plants 
Subkingdom         :         Tracheobionta– Vascular plants 
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Superdivision         :         Spermatophyta– Seed plants 
Division         :         Magnoliophyta– Flowering plants 
Class         :         Magnoliopsida– Dicotyledons 
Subclass         :         Magnoliidae 
Order         :         Piperales 
Family         :         Piperaceae– Pepper family 
Genus         :         Piper L.– pepper 
Species         :         P. longum L.– Indian long pepper 
 
VERNACULAR NAMES 
 Eng.-Indian long pepper 
 Hindi-Pipli 
 Kan.-Hipli 
 Tam.-Tippili 
 Tel.-Pipallu 
BOTANICAL DESCRIPTION: A slender, aromatic climber with perennial woody roots, stems 
creeping, leaves ovate, spikes cylindrical, pedunculate,  fruits ovoid, yellowish orange. 
 
DISTRIBUTION: It occurs in hotter parts of India from Central Himalayas to Assam, 
evergreen forests of Western Ghats from Konkan to Travancore 
 
PARTS USED: Fruit, root 
 
ACTIONS: Tonic, diuretic, purgative, expectorant, anthelmintic, stomachic, digestive and 
emmenagogue. 
 
CHEMICAL CONSTITUENTS: Terpinolene, zingiberene, p-cymene, piperine, piplartine, 
triacontane, dihydro-stigmasterol, piperine and sesamin, caryophyllene, a sesquiterpene 
alcohol. 
 
PHARMACOLOGICAL ACTIVITY: Antibacterial, anti-inflammatory, antitubercular, 
anthelmintic, hypoglycaemic, hepatoprotective. 
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SIRUTHEKKU 
BOTANICAL NAME24  :  Clerodendrum serratum (Linn.) Moon 
 
CLASSIFICATION26: 
                                    Kingdom       :                Plantae 
                                    Phylum          :                Eudicota 
                                    Class              :               Angiospermae 
                                    Subclass         :               Lamiidae 
                                    Order              :               Lamiales 
                                    Family            :               Verbenaceae 
                                    Genus             :               Clerodendrum 
                                    Species           :               C.serratum  
 
VERNACULAR NAMES 
 Hindi-Bharangi 
 Kan.-Gantabarangi 
 Mal.- Cerutekku 
 Tam.-Sirutekku 
 Tel.-Barangi 
BOTANICAL DESCRIPTION: Perennial herbs or shrubs, leaves sessile or nearly so, flowers 
blue-purple or white, drupes 6 mm long, broadly obovoid, rather succulent, dark-purple when 
ripe. 
 
DISTRIBUTION: More or less throughout India, in forests upto 1500 m altitude.  
 
PARTS USED: Root, leaf. 
 
ACTIONS: Antiinflammatory, digestive, carminative, stomachic, stimulant, expectorant and 
febrifuge. 
 
CHEMICAL CONSTITUENTS: Sterratagenic acid, queretaroic acid, some phytosterols, 
saponins, ferulic acid, arabinose, scutellarein, baicalein. 
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PHARMACOLOGICAL ACTIVITY: Antihistaminic, hypotensive, bronchoconstrictor, 
antiallergic, antiasthmatic, antibiotic and stomachic. 
 
SUBSTITUTES AND ADULTERANTS: The bark of Gardenia turgida Roxb. is an adulterated to 
be sold as Bharangi bark. Substituted by root of Solanum surattense Burm.f. 
 
CHUKKU 
BOTANICAL NAME24      :        Zingiber officinale Rosc. 
CLASSIFICATION25: 
                       Kingdom                  :      Plantae– Plants 
                    Subkingdom     :        Tracheobionta– Vascular plants 
                 Superdivision     :        Spermatophyta– Seed plants 
               Division     :        Magnoliophyta– Flowering plants 
            Class     :       Liliopsida– Monocotyledons 
          Subclass      :       Zingiberidae 
        Order      :       Zingiberales 
      Family      :       Zingiberaceae– Ginger family 
   Genus      :      Zingiber Mill.– ginger 
Species      :      Z.officinale Roscoe– garden ginger 
VERNACULAR NAMES 
 Eng.-Ginger 
 Hindi-Sonth 
 Kan.-Shunthi 
 Tam.-Chukku 
 Tel.-Sonthi 
BOTANICAL DESCRIPTION: Perenial herb; leaves sessile, flowers greenish with a small acute 
, sheath 10-15 cm long, fruits oblong capsules. 
 
DISTRIBUTION: It is mostly cultivated in Kerala and run wild in some places in Western 
Ghats. 
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PARTS USED: Fresh rhizome and dried rhizome  
 
ACTIONS: The raw ginger is acrid, thermogenic, carminative, laxative and digestive. 
 
Physical constants: Dried rhizome: - Total ash- Not more than 6%; Water soluble ash- Not 
less than 1.5%; Alcohol (90%) soluble extractive- Not less than 3%; Water soluble 
extractive- Not less than 10%. 
 
CHEMICAL CONSTITUENTS: Heptane, octane, isovaleraldehyde, nonanol, ethyl pinene, 
camphene, pinene, sabinene, myrecene, limonene, sesquiphellandrene, gingerol, zingerone, 
shogaol, dihydrogingerol. 
 
PHARMACOLOGICAL ACTIVITY: Antiinflammatory, hypolipidaemic, antiemetic, antiulcer, 
antioxidant, antibacterial, hepatoprotective, hypoglycaemic. 
 
SUBSTITUTES AND ADULTERANTS: The rhizomes of Z.casummar Roxb. are sometimes used 
as substitute to Z.officinale. 
 
MILAGU 
BOTANICAL NAME24   :     Piper nigrum Linn. 
CLASSIFICATION25: 
Kingdom                    :       Plantae– Plants 
Subkingdom                    :       Tracheobionta– Vascular plants 
Superdivision                    :        Spermatophyta– Seed plants 
Division                    :        Magnoliophyta– Flowering plants 
Class                    :        Magnoliopsida– Dicotyledons 
Subclass                    :        Magnoliidae 
Order                    :        Piperales 
Family                    :        Piperaceae– Pepper family 
Genus                    :        Piper L.– pepper 
Species                    :        P.nigrum L.– black pepper 
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VERNACULAR NAMES 
 Eng.-Black pepper 
 Hindi-Kalimirch 
 Kan.-Kaalumenasu 
 Tam.-Milagu 
 Tel.-Miriyalu 
BOTANICAL DESCRIPTION: Much branched climbing shrub, leaves simple, alternate, 
cordate, flowers minute, fruits ovoid or globose, seeds globose, perisperm hard and white. 
 
DISTRIBUTION: It is mostly found cultivated in the hot and moist parts of India, Srilanka and 
other tropical countries. The plant is wild in Western Ghats and South India at 500 – 1600 m 
in evergreen forests. 
 
PARTS USED: Fruit 
 
ACTIONS: Carminative, digestive, stimulant and stomachic. 
Physical constants: Total ash- Not more than 5.0%; Acid insoluble ash- Not more than 
0.5%; Alcohol soluble extractive- Not less than 6.0%; Water soluble extractive- Not less than 
6.0%. 
CHEMICAL CONSTITUENTS: Pipernol, piperine, piperoleine A& B, pellitonin, 
methylenedioxycinnamic acid, piperettine, ascorbic acid, carotene, sitosterol. 
PHARMACOLOGICAL ACTIVITY: Antioxidant, antipyretic, anti-inflammatory, antibacterial. 
 
ADULTERANTS: Carica papaya Linn. Seeds are used to adulterate black pepper. 
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PHYSICAL PROPERTIES OF TAKKOLATHI CHOORANAM 
 The physical properties of Takkolathi Chooranam were carried at Sri Ramachandra 
University, Chennai. 
 
pH at 10% of aqueous solution: 
 Five grams of Takkolathi Chooranam was weighed accurately and placed in clear 100 
ml beaker. Then 50 ml of distilled water was added to it and dissolved well. After 30 minutes 
it was then applied in to pH mater at standard buffer solution of 4.0,7.0,9.2. 
 
Ash Values 
            The Ash values are a measure of the inorganic constituents present in the raw drug.  A 
high ash content explains its unsuitable nature to be used as a drug  
 
Total Ash 
 A little of extract was taken in a silica crucible previously ignited, cooled and 
weighed. It was incinerated by gradually increasing the heat not exceeding dull red heat 
(450°C) until free from carbon, cooled and weighed. The percentage of ash was calculated 
with reference to air- dried drug. The procedure was repeated to get the constant weight.  
 
Water soluble ash 
 The total ash was boiled with 25 ml water and filtered through ash less filter paper 
(Whatmann 4.1). It was followed by washing with hot  water .The  filter paper  was dried  
and ignited in the silica crucible, cooled and the water insoluble ash was weighed. The water-
soluble ash can be calculated by subtracting the water insoluble ash from the total ash.  
 
Acid insoluble ash 
 The total ash obtained was boiled for 5 minutes with 25 ml of (10% w/v) dilute 
hydrochloric acid and filtering through ash less filter paper (Whatmann 4.1).  The filter paper 
was ignited in the silica crucible, cooled and insoluble ash was weighed. (Table A) 
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BIO -CHEMICAL ANALYSIS OF TAKKOLATHI CHOORANAM -  
           The biochemical analysis of the Takkolathi Chooranam was carried out in the 
Biochemistry lab, NIS 
. 
S.No 
EXPERIMENT OBSERVATION INFERENCE 
1  Appearance of sample 
Light yellow in 
colour 
  
2 
Solubility: 
Sparingly soluble 
Absence of 
Silicate 
a. A little(500mg) of the sample was shaken 
well with distilled water. 
b. A little(500mg) of the sample was shaken 
well with con. HCl/Con. H2So4 
3 
Action of Heat:     
 A small amount(500mg) of the sample was 
taken in a dry test tube and heated gartly at first 
and then strong. 
 No white fumes 
evolved  
Absence of 
Carbonate 
4 
Flame Test: 
 No Bluish green 
flame appeared. 
Absence of 
Copper 
 A small amount(500mg) of the sample was 
made into a paste with con. HCl in a watch 
glass and introduced into non-luminous part of 
the Bunsen flame. 
5 
Ash Test: 
No yellow colour 
flame appeared. 
Absence of 
sodium 
 A filter paper was soaked into a mixture of 
sample and dil. cobalt nitrate solution and 
introduced into the Bunsen flame and ignited. 
 
Preparation of Extract: 
       5gm of Takkolathi Choornam was weighed accurately and placed in a 250ml clean 
beaker and added with 50ml of distilled water. Then it was boiled well for about 10 minutes. 
Then it was cooled and filtered in a 100ml volumetric flask and made up to 100ml with 
distilled water. 
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S.No EXPERIMENT OBSERVATION INFERENCE 
 I.Test For Acid Radicals   
1. 
 Test For Sulphate: 
a. 2ml of the above prepared extract 
was taken in a test tube to this added 2ml 
of 4% dil ammonium oxalate solution 
b. 2ml of the above prepared 
extracts was added with 2ml of dil-HCl 
was added until the effervescence ceases 
off. Then 2ml of dil.Barium chloride 
solution was added. 
Cloudy 
appearance 
present 
Presence  
of Sulphate 
2. 
Test For Chloride: 
  2ml of the above prepared extract was 
added with dil. HCl till the effervescence 
ceases. Then 2ml of dil.silver nitrate 
solution was added. 
No cloudy 
appearance. 
Absence  
of Chloride 
3. 
Test For Phosphate: 
  2ml of the extract was treated with 2ml 
of dil.ammonium molybdate solution 
and 2ml of con.HNo3. 
No Yellow 
appearance 
present 
Absence  
of Phosphate 
4 
. 
Test For Carbonate: 
    2ml of the extract was treated with 
2ml dil. Magnesium sulphate solution 
No Cloudy 
appearance. 
Absence  
of carbonate 
5. 
Test For Nitrate: 
  1gm of the substance was heated with 
copper turning and concentrated H2So4 
and viewed the test tube vertically down. 
 
No Brown gas 
evolved. 
 
Absence  
of Nitrate 
6. 
Test For Sulphide: 
  1gm of the substance was treated with 
2ml of con. HCL 
No Rotten Egg 
Smelling gas. 
Absence  
of Sulphide 
7. 
Test For Fluoride & Oxalate: 
  2ml of extract was added with 2ml of 
dil. Acetic acid and 2ml dil.calcium 
chloride solution and heated. 
No Cloudy 
appearance 
Absence  
of fluoride and 
oxalate 
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8. 
Test For Nitrite: 
  3drops of the extract was placed on a 
filter paper, on that-2 drops of dil.acetic 
acid and 2 drops of dil.Benzidine 
solution was placed. 
No Characteristic 
changes 
Absence  
of Nitrite 
9. 
Test For Borate: 
  2 Pinches(50mg) of the substance was 
made into paste by using dil.sulphuric 
acid and alcohol (95%) and introduced 
into the blue flame. 
No Bluish green 
colour flame. 
Absence  
of borate 
 II. Test For Basic Radicals   
1. 
Test For Lead: 
        2ml of the extract was added with 
2ml of dil.potassium iodine solution. 
No yellow 
Precipitate 
obtained. 
Absence of Lead 
2. 
Test For Copper: 
a. One pinch(50mg) of substance 
was made into paste with con. HClin a 
watch glass and introduced into the non-
luminuous part of the flame. 
No Blue colour 
flame 
No Blue colour 
precipitate 
formed. 
Absence  
of copper 
3. 
Test For Aluminium: 
  To the 2ml of extract, dil.sodium 
hydroxide was added in 5 drops to 
excess. 
No Yellow colour 
appeared. 
Absence  
of aluminium 
4. 
Test For Iron: 
a. To the 2ml of extract, 2ml of 
dil.ammonium solution was added. 
b. To the 2ml of extract 2ml  
thiocyanate solution and 2ml  of con 
HNo3 was added 
Blood red colour 
appeared. 
Presence of Iron 
5. 
Test For Zinc:  
      To 2ml of the extract, dil.sodium 
hydroxide solution was added in 5 drops 
to excess and dil.ammonium chloride 
was added.  
No White 
precipitate was  
formed 
Absence of Zinc 
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6. 
Test For Calcium:  
      2ml of the extract was added with 
2ml of 4% dil.ammonium oxalate 
solution  
Cloudy 
appearance and 
white precipitate 
was obtained 
Presence  
of calcium 
7. 
Test For Magnesium:  
         To 2ml of extract dil.sodium 
hydroxide solution was added in drops to 
excess. 
 
No white 
precipitate was  
obtained 
Absence of 
Magnesium 
8. 
Test For Ammonium: 
  To 2ml of extract 1 ml of Nessler's 
reagent and excess of dil.sodium 
hydroxide solution are added. 
No Brown colour 
appeared 
Absence of 
ammonium 
9. 
Test For Potassium:  
 A pinch(25mg) of substance was treated 
of with 2ml of dil.sodium nitrite solution 
and then treated with 2ml of dil.cobalt 
nitrate in 30% dil.glacial acetic acid. 
No Yellowish 
precipitate was 
obtained. 
Absence of 
Potassium 
10. 
Test For Sodium: 
2 pinches (50mg) of the substance was 
made into paste by using HCl and 
introduced into the blue flame of Bunsen 
burner. 
No yellow colour 
flame appeared 
Absence 
of sodium 
11. 
Test For Mercury:  
  2ml of the extract was treated with 2ml 
of dil.sodium hydroxide solution.  
No yellow 
precipitate was 
obtained 
Absence  
of mercury 
12. 
Test For Arsenic:  
  2ml of the extract was treated with 2ml 
of dil.sodium hydroxide solution. 
No brownwish 
red precipitate 
was obtained 
Absence  
of arsenic 
 III. Miscellaneous   
1. 
Test For Starch:  
 2ml of extract was treated with weak 
dil.iodine solution  
Blue colour 
developed 
Presence of starch 
2. 
Test For Reducing Sugar:  
  5ml of Benedict's qualitative solution 
was taken in a test tube and allowed to 
Brick red colour 
developed 
 Presence of 
reducing sugar 
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boil for 2 minutes and added 8 to 10 
drops of the extract and again boil it for 
2 minutes. The colour changes are noted. 
3. 
Test For The Alkaloids: 
a) 2ml of the extract was treated with 
2ml of dil.potassium iodide solution. 
b) 2ml of the extract was treated with 
2ml of dil.picric acid. 
c) 2ml of the extract was treated with 
2ml of dil.phosphotungstic acid. 
Yellow colour 
developed 
 Presence  
of Alkaloid 
4. 
Test For Tannic Acid:  
 2ml of extract was treated with 2ml of 
dil.ferric chloride solution  
black precipitate 
was obtained 
Presence 
of Tannic acid 
5. 
Test For Unsaturated Compound: 
 To the 2ml of extract 2ml of 
dil.Potassium permanganate solution 
was added.  
Potassium 
permanganate was 
not decolourised 
Absence  
of unsaturated 
compound  
6. 
Test For Amino Acid: 
  2 drops of the extract was placed on a 
filter paper and dried well. 20ml of 
Biurette reagent was added. 
violet colour 
developed 
 Presence 
of amino acids 
7. 
 
 
Test For Type Of Compound: 
2ml of the extract was treated with 2 ml 
of dil.ferric chloride solution. 
No green colour 
developed 
 
 
No red colour 
developed 
 
 
No violet colour 
developed 
 
No blue colour 
developed 
Absence of oxy 
quinole pinephrine 
and pyro catechol 
Anti pyrine, 
Aliphatic amino 
acids and meconic  
acid are absent  
Apomorphine 
salicylate and 
Resorcinol are 
absent 
Morphine, Phenol 
cresol and hydro 
uinone are absent 
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HIGH PERFORMANCE THIN LAYER CHROMATOGRAPHY 
The HPTLC of Takkolathi Chooranam was done at Sri Ramachandra University, 
Chennai. 
Significance of HPTLC fingerprinting in Standardisation 
 
 Standardisation of traditional medicine has become mandatory in the present national 
and international scientific scenario, as they have to stand competing with stringent 
regulatory methods and also clinically. HPTLC is one of the versatile chromatographic 
methods presently available for the rapid analysis of herbal drugs due to several reasons. 
Firstly the time required for the demonstration of the most of the characteristic constituents of 
a drug is very quick and short. Secondly, in addition to qualitative detection, HPTLC also 
provides semi-quantitative information on the major active constituents of a drug, thus 
enabling an assessment of drug quality. Thirdly the fingerprint obtained is suitable for 
monitoring the identity and purity of drugs and for detecting adulteration and substitution. 
Hence in order to check the identity, purity and standardise the quantity of active principles in 
the herbal extracts a HPTLC fingerprint in the formulation has been obtained.     
The distribution of phyto-constituents in a plant depends on various factors such as soil, time 
of collection period of storage, etc. So, it is necessary to standardize the extract being used 
for pharmacological studies. HPTLC serves as a convenient tool for finding out the 
distribution pattern of phyto constituents which is unique to each plant. The HPTLC finger-
printing profile establishes the identity and purity of the raw drug being used. It helps in the 
authentification of the plant material.  
Sample Preparation: 
 100 mg of extract was weighed and dissolved in 70% methanol to get a concentration 
of 10mg/ml concentration this is then used for injection.  
Chromatographic Conditions 
The finger printing has been done using the following chromatographic conditions. 
Chromatography was performed on a10x10 cm pre activated HPTLC silica gel 60F 254 plate. 
Samples were applied to the plate as 6mm wide band with an automatic TLC applicator 
Linomat 5 with N2 flow (CAMAG, Switzerland), 8mm from the bottom. Densitometric 
scanning was performed on CAMAG scanner III.The plates were pre-washed by methanol 
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and activated at 600 C for 5 minutes prior to chromatography. The slit dimension was kept at 
5 minutes x 0.45 minutes and 20 minutes scanning speed was employed. The mobile phase 
was chosen after running each plant in different mobile phases of varying polarity (Toluene, 
Toluene: Ethyl acetate and Ethyl acetate: Methanol) and 10 ml of mobile phase was used per 
chromatography. Linear ascending development was carried out in 20 cm x 10-em twin glass 
chamber saturated with the mobile phase. 
Chromatographic Analysis 
 The hydro alcoholic extracts of the plants have been prepared at a concentration of 10 
mg/10 ml in alcohol and were spotted using CAMAG Linomat 5 applicator. The method was 
optimized by selecting appropriate mobile phase for respective plant extracts and developed 
in a twin trough chamber, 20 x 10 cm at 25°C. The plates were dried by hair dryer. The 
developed plates were scanned at appropriate wavelength using CAMAG TLC scanner 3 and 
photo-documented using CAMAG REPROSTAR 3. 
Inferences: 
 The finger-printing profile establishes the identity and purity of the raw drug being 
used. It helps in the authentication of the respective plant material. The fingerprinting pattern 
is characteristic of each plant material used for pharmacological studies. The pattern clearly 
displays the variation from plant to plant. 
Inference:   
 HPTLC fingerprint of RH -1 shows four peaks at Rf values 0.25, 0.31, 0.41 & 0.95.  
The peak correspond to the Rf value 0.31 has maximum peak area of 7256.5. At this stage it 
is difficult to confirm the individual components present in the extract, but from our lab 
experience on phytochemical analysis, we suggest that the major peaks found in the 
fingerprint may be acidic glycosides / resins. Since, in the present chromatographic 
conditions, the above mentioned components will be eluted easy.  
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Chromatographic Conditions for HPTLC finger print( Graph 109) 
 
                        SampleName   :   Takkolathi chooranam 
Sample-ID                   :  109 
Stationary phase :   Silica gel F 254 
Mobile phase  :    n-Hexane: Ethyl acetate: Formic acid 60:40:2.5 ml) 
Scanning wavelength :   254,298,489 nm 
Sample concentration :   20 mg/ml 
Injecting volume :   5, 10 µl  
Development mode :   Ascending mode 
 
HPTLC Fingerprint - RH1 
 
 
254 nm                       366nm                        366 nm                       white light 
 
 
 
34 
 
ACUTE AND SUB ACUTE TOXICITY STUDY ON TAKKOLATHI CHOORANAM 
IN RODENTS 
Animals: 
  Mice of either sex weighing 25-30g and rats weighing 210-240g were obtained from 
the animal house of Vels University. The animals were used with the approval of the Institute 
animal ethics committee and obtained from Vels University, Chennai. They were fed with a 
balanced standard pellet diet and maintained under standard laboratory conditions, providing 
24-280C temperature, standard light cycle (12 h light, 12 h dark) and water ad libitum.  
 Animals were kept in cages with raised floors of wide mesh to prevent coprophagy. 
Animal welfare guidelines were observed during the maintenance period and 
experimentation. The rats were randomly assigned to control and different treatment groups, 
six animals per group. The animals were acclimatized for one week under laboratory 
conditions.  
ACUTE TOXICITY STUDY-OECD 425 GUIDELINES 
 Acute oral toxicity test for the Takkolathi Chooranam was carried out as per OECD 
Guidelines 425. As with other sequential test designs, care was taken to ensure that animals 
are available in the appropriate size and age range for the entire study. The test substance was 
administered in a single dose by gavage using a stomach tube or a suitable intubation 
cannula. The fasted body weight of each animal was determined and the dose was calculated 
according to the body weight. After the substance has been administered, food was withheld 
for a further 2 hours in mice. The animals were observed continuously for the first 4 h and 
then each hour for the next 24 h and at 6 hourly intervals for the following 48 h after 
administering of the test drug, to observe any death or changes in general behaviour and other 
physiological activities.  
 Single animals were dosed in sequence usually at 48 h intervals. However, the time 
interval between dosing is determined by the onset, duration, and severity of toxic signs. 
Treatment of an animal at the next dose was delayed until one is confident of survival of the 
previously dosed animal.  
 
Observation of toxicity signs: 
  General behavior, respiratory pattern, cardiovascular signs, motor activities, reflexes, 
change in skin and fur, mortality and the body weight changes were monitored daily. The 
time of onset, intensity, and duration of these signs, if any, was recorded. (Table 1) 
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SUB-ACUTE TOXICITY  
 In a 28-days sub acute toxicity study, twenty four either sex rats were divided into 
four groups of 6 rats each. Group I that served as normal control was administered with 
distilled water (p.o.) while groups II, III and IV were administered daily with the Takkolathi 
Chooranam (p.o.) for 28 days at a dose of 100, 200 and 400 g/kg respectively. The animals 
were then observed daily for gross behavioural changes and any other signs of subacute 
toxicity.  
 The weight of each rat was recorded on day 0 and weekly throughout the course of the 
study, food and water consumption per rat was calculated. At the end of the 28 days they 
were fasted overnight, each animal was anaesthetized with diethylether, following which they 
were then dissected and blood samples were obtained by cardiac puncture into heparinised 
tubes. The blood sample collected from each rat was centrifuged with 3000 X g at 4oC for 10 
min to separate the serum and used for the biochemical assays. (Table 2,3,4) 
Hematological and blood biochemical analysis: 
 At the end of the study, all animals were kept fasted for 16-18 h and then anesthetized 
with anesthetic ether on the 28th day. Blood samples for hematological and blood chemical 
analyses were taken from retro orbital vein. Heparinized blood samples were taken for 
determining complete blood count (white blood cell count, differential white blood cell count, 
platelet count, red blood cell count, hematocrit, and hemoglobin) by semiautomated 
hematology analyzer.  
 The serum from non-heparinized blood was carefully collected for blood chemistry 
and enzyme analysis like glucose, Creatinine, Total protein, Albumin, Total and Direct 
bilirubins, Serum glutamate-oxaloacetate transaminase (SGOT), Serum glutamate pyruvate 
transaminase (SGPT), and Alkaline phosphatase (ALP) were automatically determined using 
autoanalyzer.(Table 5,6,7) 
Necropsy:  
               All rats were sacrificed after the blood collection. The positions, shapes, sizes and 
colors of internal organs were evaluated. The Spleen, Testes, Pancreas, Lung, Liver, Brain, 
Heart, Stomach, Intestine, Bone, Ovary, and Kidney tissues were excised from all rats to 
visually detect gross lesions, and weighed to determine relative organs’ weights and 
preserved in 10% neutral formalin for histopathological assessment. The tissues were 
embedded in paraffin, and then sectioned, stained with haematoxylin and eosin and were 
examined microscopically.(Table 8). 
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Statistical analysis 
 Values were represented as mean ± SEM. Data were analysed using one-way analysis 
of variance (ANOVA) and group means were compared using the Tukey-Kramer Multiple 
Comparison test using Instat-V3 software. P values < 0.05 were considered significant. 
 
RESULTS:  
Clinical signs: Animals were not shown any significant toxic clinical signs during the dosing 
period of 28 days. 
Mortality: All animals from control and all the treated dose groups survived throughout the 
dosing period of 28 days. 
Body weight: Results of body weight determination of animals of control and different dose 
groups exhibited comparable body weight gain throughout the dosing period of 28 days. 
Food consumption: During dosing period, the quantity of food consumed by animals from 
different dose groups was found to be comparable and normal with that of control animals. 
Ophthalmoscopy: Ophthalmoscopic examination of animals in control and test product– 
treated groups did not reveal any major and remarkable abnormality. 
Functional Observations: These tests conducted on the experimental animals at termination 
and recorded did not reveal any abnormalities.  
Urine analysis: Urine analysis data of control group and treated group of animals determined 
in week 4 did not reveal any abnormalities.  
Organ Weight: Comparison of organ weights of treated animals with respective control 
animals on day 28 was found to be comparable.  
Necropsy: Gross pathological examination of animals in control as well as the treated groups 
did not reveal any abnormalities.  
Haematological investigations: The results of haematological investigations conducted on 
day 28, revealed following significant changes in the values of different parameters 
investigated when compared with those of respective controls; However, the increase or 
decrease in the values obtained was within normal biological and laboratory limits.  
Biochemical Investigations: Results of Biochemical investigations conducted on days 29 
revealed significant changes in the values of uric acid and potassium studied when compared 
with those of respective controls; however, the values obtained were within normal biological 
and laboratory limits.  
 
CONCLUSION: 
 Based on these findings, no toxic effect was observed upto 400mg/kg of Takkolathi 
Chooranam treated via oral route over a period of 28 days. So, it can be concluded that the 
Takkolathi Chooranam can be prescribed for therapeutic use in human with the dosage 
recommendations of upto 400mg/kg. body weight p.o. 
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HISTOPATHOLOGICAL SLIDES OF VARIOUS ORGANS AFTER THE 
SUBACUTE TOXICITY STUDIES 
 
BONE                                                        BRAIN 
 
HEART                                                          INTESTINE 
 
KIDNEY                                                        LIVER 
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LUNG                                                              OVARY 
 
PANCREAS                                                SPLEEN 
 
STOMACH                                                          TESTIS 
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PHARMACOLOGICAL STUDY OF TAKKOLATHI CHOORANAM 
MATERIALS AND METHODS 
 Histamine solution was freshly prepared in normal saline (NaCl, 8.5 g/l), Carboxy 
methyl cellulose (2%) (Loba chemie Pvt. Ltd). All other chemicals used were of analytical 
grade.  
Stock solution 
         The powdered Takkolathi chooranam was mixed uniformly in Carboxy Methyl 
Cellulose in saline solution to achieve 1mg/ml as main stock solution and used in this study.  
Animals 
 The Guinea pig is a species of rodent belonging to the family Caviidae and the genus 
Cavia. Despite their common name, these animals are not pigs, nor do they come from 
Guinea. Guinea pigs of either sex 350- 450 were procured from animal house, Department of 
Pharmacology, Vels University and throughout the study. Six animals were taken in each 
group and maintained under controlled environment (temperature 25±20C and 12 h dark and 
light cycle) with standard diet and water ad libitum during experiment.                                                   
All the animals used in this study were approved by CPCSEA.  
(XIII/VELS/PCOL/34/2000/CPCSEA/IAEC/08.08.2012) 
In-vitro Antihistaminic activity 
 Guinea pig was sacrificed and a segment from ileum (2 cm) was dissected from the 
terminal ileum and mounted in an organ bath containing Tyrode solution (10 ml) between 
two stainless steel hooks under 0.5 to 1g initial tension. The lower hook was fixed at the 
bottom of the organ bath and upper one was connected to an isotonic transducer. The Tyrode 
solution composition (pH 7.4) was (concentration in gm/lit.) NaCl 8.0, KCl 0.2, CaCl2 0.2, 
MgCl2 0.1, NaHCO3 1.0, NaH2PO4 0.05, and Glucose 1.0gm/liter.  
 It was continuously aerated and maintained at 37 ± 0.5ºC The equilibrium period was 
60 min and the bath solution was refreshed every 15 min. After equilibrium period, a dose 
response curve for histamine in variant molar concentrations, by maintaining 45 min time 
cycle was used. (Table 1) 
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Evaluation Of Bronchodilator Activity  
 Experimental bronchial asthma was induced in guinea pigs by exposing them to 
histamine. Overnight fasted guinea pigs of either sex (350-450) were selected and randomly  
divided in to four groups each consisting of six animals. Group 1-3 was treated as Test group 
and received of Takkolathi chooranam at the dose levels of (100, 200, 400 mg/kg). Group 4 
was considered as standard and administered with Promethazine (300mg/kg, p.o). All the 
doses were given orally. Prior to drug treatment each guinea pigs were exposed to an 
atomized fine mist of 2% w/v histamine dihydrochloride aerosol (dissolved in normal saline) 
using a nebulizer in the histamine chamber. Guinea pigs exposed to histamine aerosol showed 
progressive signs of difficulty in breathing leading to convulsions, asphyxia and death. The 
time until signs of convulsion appeared is called pre-convulsion time (PCT) and was 
determined from the time of exposure to onset of convulsions.  
As soon as pre convulsion time was noted, animals were removed from the chamber 
and placed in fresh air to recover. The percentage protection offered by treatment was 
calculated by using the following formula: Percentage protection = (1 - T1/T2) × 100. Where; 
T1 = the mean of PCT of control group animals. T2 = the mean of PCT of test group animals. 
Statistical analysis 
 Data were expressed as Mean ± SEM. Differences between groups were analyzed by 
one way analysis of variance (ANOVA) followed by Dunnet “t” test. Differences were 
considered significant when P< 0.05 and P< 0.01. 
RESULTS AND DISCUSSION 
 Mortality in the acute oral toxicity test was seen in the dose 2000mg/kg. Hence, one-
tenth, one twentieth and one fifth of the upper bound dose was considered for the further 
pharmacological study. Histamine induced bronchoconstriction is the traditional 
immunological model of antigen induced airway obstruction. Histamine when inhaled causes 
hypoxia and leads to convulsion in the guinea pigs and causes very strong smooth muscle 
contraction, profound hypotension and capillary dilation in the cardiovascular system. A 
prominent effect caused by histamine is severe bronchoconstriction in the guinea pigs that 
causes asphyxia and death. Histamine was released after degranulation of mast cell by an 
antigen exposure by antigenic stimulation causing smooth muscle contraction, increased 
vascular permeability and mucus formation. Histamine is one of the important mediator of 
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allergy, inflammation and bronchoconstriction. Targeting histamine, either prevention of its 
release from mast cell or use of histaminergic receptor antagonist becomes part of 
Antihistaminic therapy in allergic diseases.  
 
 In-vivo study of Takkolathi chooranam have been also shown the significant increase 
in pre-convulsion time due to pre-treatment with Takkolathi chooranam at the dose of 100, 
200 and 400mg/kg of body weight of guinea pigs, when the guinea pigs were exposed to 
histamine. The results of Takkolathi chooranam suggested that it is effective in reducing the 
symptoms of bronchial asthma and also improve the lung function parameters of asthmatic 
 subjects. The percentage protection of Takkolathi chooranam- 100, 200 and 400 mg/kg, is 
16.50, 21.87 and 30.38% respectively.(Table 2) 
In the present study, guinea pigs were used because of the extreme sensitivity of their 
airways to the primary mediators of bronchoconstriction, including histamine and 
leukotrienes and their ability to be sensitized to foreign proteins. Although there are various 
model of asthma, guinea pig airways react to histamine, acetylcholine, leukotrienes and other 
bronchoconstrictors in a manner similar to that seen in humans. Another similarity between 
the guinea pig model and asthmatic patients is that enhanced bronchoconstriction occurs in 
both species following sensitization, in response to β-adrenergic antagonists. Thus, the guinea 
pig model resembles the human allergic pathology in several aspects, especially in terms of 
mediator release. Histamine antagonists can be conveniently recognized and assayed by their 
ability to protect guinea pigs against lethal effects of histamine-induced bronchospasm.  
CONCLUSION 
 The Antihistaminic potency on histamine induced contraction of isolated guinea pig 
ileum was studied and it was observed that the histamine response was decreased in the 
presence of the test drug Takkolathi chooranam. Histamine when inhaled has been shown to 
induce bronchoconstriction by direct H1-receptor activation and also by a naturally mediated 
bronchoconstrictor effect via vagal reflexes. The results of present study suggested that Takkolathi 
chooranam significantly protected the Guinea pigs against histamine-induced bronchospasm. 
Takkolathi chooranam use traditionally in the management of asthma is justified. The guinea pigs 
exposed to histamine aerosol showed signs of progressive dyspnoea leading to convulsions. The two 
doses of Takkolathi chooranam significantly prolonged the latent period of convulsions following the 
exposure of histamine aerosol. The action started after 1 h of drug administration. Thus, our findings 
suggest that Takkolathi chooranam possess significant Antihistaminic activity. 
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þ¨ÃôÒ10 
§ÅÚ ¦ÀÂ÷¸û: 
 
       þØôÒ §¿¡ö ,ÍÅ¡ºõ, ¦¾¡ö×, ®¨Ç, ÍÃõ, ÍÅ¡º¸¡ºõ . 
 
 
þÂø:  
 
       þó§¿¡ö Â¡Ð¦Á¡Õ ¸¡Ã½ÓÁ¢ýÈ¢ Á¡÷¨À ÅÄ¢òÐ þÚì¸¢ÂÐ §À¡ýÈ 
§Å¾¨É¨Â ¾óÐ, ãî¨º ¦ÅÇ¢Â¢¼×õ, ¯û§Ç þØì¸×õ ÓÊÂ¡ÁüÈ¢½Ãî 
¦ºöÔõ. «ýÈ¢Ôõ ¦ÅÇ¢Â¡Ìõ ãîÍ Á¢Ìó¾ º¢ÃÁòÐ¼ý ¦ÅÇ¢Â¡ÅÐ¼ý ÌÆø, 
Â¡ú, Å£¨½ Ó¾Ä¢Â Å¡ò¾¢Âí¸Ç¢ý ´Ä¢¨Âô§À¡ø ´Ä¢ìÌõ.   
 
 
§¿¡ö ÅÕõ ÅÆ¢: 
 
 ¯¼üÌ ´ùÅ¡¾ ¯ண×, ¦ºÂø Ó¾Ä¢ÂÅüÈ¡ø ¯¼ø Åý¨Á Ì¨Èó¾ 
¿¢¨ÄÂ¢ø ³Âò¨¾ Á¢Ì¾¢ô ÀÎò¾ìÜÊÂ ¯½Å¡Öõ, ¿¼ò¨¾Â¡Öõ, 
 Òø, âñÎ, ¦¿ø, «¡¢º¢, §¸úÅÃÌ Ó¾Ä¢Â¨Å¸Ç¢ý Í¨ÉÂ¡Öõ, 
 ¾ÉìÌ ´ùÅ¡¾ ¿¡üÈô ¦À¡Õû¸¨Ç Ó¸÷Å¾¡Öõ þó§¿¡ö À¢ÈìÌõ. 
 
 
§¿¡Â¢ý ÓüÌÈ¢ Ì½í¸û: 
 
 ãì¸¢ø ¿£÷ À¡ö¾ø, 
 ÐõÁÖñ¼¡¾ø, 
 Á¡÷Ò §¿¡¾ø, 
 Á¡÷¨À þÚì¸¢ì ¸ðÊÂÐ §À¡Ä¢Õò¾ø, 
 þÂü¨¸ ãîº¡ÉÐ ¾¨¼ôÀ¼ø, 
 Å¢Ä¡ô Àì¸õ ÅÄ¢òÐ ãîÍò ¾¢½Èø, 
 ÅÂ¢ÚôÀø, 
 ¯¼ø Å¢Â÷ò¾Ä¡¸¢Â ÌÈ¢ Ì½í¸Ùñ¼¡õ. 
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§¿¡ö ±ñ: 
 
1. ÅÇ¢ þ¨ÃôÒ 
 
2. ³Â þ¨ÃôÒ 
 
3. ³ÂÅÇ¢ þ¨ÃôÒ 
 
4. ÓìÌüÈ þ¨ÃôÒ 
 
5. §Áø §¿¡ìÌ þ¨ÃôÒ 
 
ÌüÈõ Ó¾Ä¢Â §ÅÚÀ¡Î¸û : 
 
             ³ÂìÌüÈõ ¾ýÉ¢¨Ä Á¡Ú¾Ä¡Öõ, ÅÇ¢ («) ¾£ìÌüÈò¨¾§ÂÛõ («) 
«ùÅ¢Õ ÌüÈò¨¾§ÂÛõ Ð¨½ì ¦¸¡ñÎ þó§¿¡ö À¢ÈìÌõ. 
 
¿¡Ê ¿¨¼: 
 
            "¸ÀÁøÄ¡Ð ¸¡º ÍÅ¡ºõ Å¡Ã¡Ð" 
 
             "À¢ò¾§Á Á¢Ìó¾¡ Ä£¨Ç  Â¢ÕÁÖõ 
              ¦ÀÄòÐ ¿¢üÌõ" 
 
             ³Â ¿¡Ê Á¢Ìó¾¡Öõ, ÅÇ¢ ³Â ¦¾¡ó¾ò¾¡Öõ þ¨ÃôÒ §¿¡Ôñ¼¡Ìõ 
±ýÀ§¾Â¡õ. 
 
¾£Õõ ¾£Ã¡¾¨Å: 
 
          ÅÇ¢ þ¨ÃôÒ §¿¡ö ±Ç¢¾¢ø ¾£Õõ, ÁüÈ ¿¡ýÌ Å¨¸ þ¨ÃôÒ §¿¡ö¸Ùõ, ¾ì¸ 
ÁÕóÐ¸Ç¡ø ºüÚ º¢ÃÁí¸¨Ç ¿¢Å÷¾¢òÐ ¾ü¸¡Äî º¡ó¾õ ¦ºöÂÄ¡ ¦ÁÉ¢Ûõ âÃ½ 
Ì½õ ¦ÀÚÅÐ «¡¢Ð. 
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BRONCHIAL ASTHMA12 
 
             Asthma is an inflammatory disease of the small air-ways, characterized by episodic, 
reversible bronchial obstruction due to hyper-responsiveness of trancheo-bronchial tree to a 
multiplicity of intrinsic and extrinsic stimuli manifested clinically by paroxysms of poly-
phonic wheeze, dyspnoea, and cough which may be relieved spontaneously or as a result of 
therapy. 
Types 
i. Extrinsic Asthma (Atopic Asthma, Early Onset Asthma) 
ii. Intrinsic Asthma (Non-atopic Asthma, late Onset Asthma) 
Other types 
i. Nocturnal Asthma 
ii. Gastric Asthma 
iii. Exercise-induces Asthma 
iv. Episodic Asthma 
iii. Chronic Asthma 
Factors Precipitating Asthma 
 Cold air 
 Tobacco smoke 
 Dust, acrid fumes 
 Emotional stress 
 Respiratory infections (viral, bacterial) 
 Exercise 
 Drugs 
           NSAIDs especially aspirin 
           ß-blockers 
 Chemicals 
Sulfiting agents like Na or K bisulfate,sulphur dioxide,etc. 
 Allergens 
           Ingested (fish,nuts,strawberries) 
           Inhaled(dust,pollen,house dust mite) 
           Food additives (tartazine, metabisulfite preservatives, monosodium glutamate 
or ajinomoto) 
           Occupational allergens (grain-dust, wood-dust). 
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Pathophysiology: 
 
 Chronic airway inflammation as evidenced by cellular infiltration of airway by 
activated eosinophils,mast cells,macrophages and T-lymphocytes. 
 Released mediators causing bronchial smooth muscle contraction. 
 Denudation and desquamation of the epithelium forming mucous plugs that obstruct 
the airway. 
 
Clinical Features: 
 
 Poly-phonic wheeze 
 Dyspnoea 
 Cough 
 Chest tightness 
 
Differential Diagnosis: 
 
 Chronic Bronchitis 
 Emphysema 
 Cystic fibrosis 
 Pulmonary embolism 
 Cardia failure 
         
Investigations: 
 
a. Chest X-ray 
b. Pulmonary Function Tests (PFT) 
c. Peak Expiratoy Flow Rate (PEFR)   
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CLINICAL STUDY 
        Preclinical and clinical study on “TAKKOLATHI CHOORANAM” for 
“BRONCHODILATOR ACTIVITY” in the management of Eraippu (Bronchial Asthma).                                     
Approval No: NIS/IEC/2011/3/12a  
 
POPULATION AND SAMPLE SIZE: 
      20 patients of both sexes were enrolled from the Outpatient and Inpatient 
department of Ayothidass Pandithar Hospital of National Institute of Siddha, Chennai-47.  
 
SUBJECT SELECTION:  
INCLUSION CRITERIA:  
  Age           : 18-65 yrs  
  Sex            : both male and female 
  Weight       : 35-85 kgs  
  Patient having symptoms of 
 Wheezing 
 Dyspnoea 
 Cough with mild expectoration 
 Chest tightness 
  Patient who were willing to provide blood for lab investigation. 
  Patients who were willing to attend OPD once in 7 days. 
  Patient who were willing to be admitted in the hospital for 30 days. 
  Patient willing to sign the informed consent stating that he/she conscientiously 
stick to the treatment during 30 days but can opt out of the trial of his/her own conscious 
discretion. 
EXCULSION CRITERIA:                                                                                               
 Bronchiectasis 
 Pleural effusion 
 Pneumonia 
 Tuberculosis 
 Other type of asthma 
 Diabetes mellitus 
 Any other serious illness 
WITHDRAWAL CEITERIA: 
 Development of any adverse reaction  
 Occurence of any other serious illness 
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 Non co-operation of the patient 
TREATMENT: 
          The drug Takkolathi chooranam was administered internally in a dose of 6gm b.d with 
luke warm water (after food) for 30 days. 
CONDUCT OF THE CLINICAL TRIAL: 
           Bronchial asthma patients satisfying the inclusion criteria were admitted to the trial. 
Patient was informed about the trial and consent form was obtained . For In-patients, the drug 
Takkolathi chooranam was administered daily. For Out-patients, the trial drug was issued for 
seven days course. Weekly clinical assessment was done during review visit to the hospital. 
The following investigations were done before and at the end of the treatment.     
     Blood sample (Hb, TC, DC, ESR, Sugar (F, PP), AEC, T.cholesterol, RFT, LFT) 
             Peak Expiratory Flow Rate  
            Urine test (Albumin, Sugar, Deposits) 
The following investigations were done before treatment.     
              X-ray chest - PA view 
              ECG  
              Sputum AFB 
CLINICAL OBSERVATION: 
 For the clinical study of “Takkolathi Chooranam” on Eraippu, 20 patients were 
selected. 
 Among 20 patients, 14 (70 %) were in female, 6 (30%) were in male. 
 According to age wise distribution 60% were in 20-35 years, 30% were in 36- 
50 years and 10% were in 51-65 years. 
 Among 20 patients, All patients were affected from wheeze, 16 patient were affected 
from dyspnoea, 19 patient were affected with cough, 10 were affected with chest 
tightness, 17 were affected with expectoration.  
 From the clinical study, 75% patient relieved from wheeze, 75% patient relieved from 
dyspnoea, 74% patient relieved from cough, 80% patient relieved from chest 
tightness, 65% patient relieved from expectoration and no adverse effects were 
observed during trial period. 
 18 (90%) patients had a significant reduction in the PEFR after the treatment. 
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DISCUSSION 
 
 The drug Takkolathi Chooranam was selected to evaluate the Bronchodilator and 
Antihistaminic activity in the management of Eraippu (Bronchial asthma). 
 The literary evidence from the text Agathiyar 2000 strongly supports Bronchodilator 
and Antihistaminic activity of the drug. 
 
Bio-chemical analysis: 
             Biochemical analysis of the drug Takkolathi choornam reveals the presence of 
sulphate, iron, calcium, starch, reducing sugar, tannic acid, amino acid and alkaloids. 
 Iron: 
             It is necessary for the formation of heme part of hemoglobin. The main function of 
haemoglobin is the transport of respiratory gases: 
 Oxygen from the lungs to tissue 
 Carbondioxide from tissues to lungs. 
Calcium: 
 Calcium is essential for maintaining the integrity of intracellular material. 
 It decreases the passages of serum through capillaries in allergic series. Thus calcium 
is clinically used to reduce allergic exudates. 
 
HPTLC :  
 The finger-printing profile establishes the identity and purity of the raw drug being 
used. 
 The fingerprinting pattern is characteristic of each plant material used for 
pharmacological studies. The pattern clearly displays the variation from plant to plant. 
 
Toxicological studies: 
Acute oral toxicity study: 
 
 Mortality in the acute oral toxicity test was seen in the dose 2000mg/kg. Hence, one-
tenth, one twentieth and one fifth of the upper bound dose was considered for the 
further pharmacological study. 
 Takkolathi chooranam at the dose of 400mg/kg/po did not exhibit any mortality in 
rats. 
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  As per OECD 425 guidelines the dose is said to be “Unclassified” under the toxicity 
scale. Hence further study with higher doses was not executed. 
 
Sub-acute toxicity for 28 days:  
 Based on this study, no toxic effect was observed upto 400mg/kg of Takkolathi 
Chooranam treated via oral route over a period of 28 days.  
 28 days treatment with the drug did not alter the haematological and biochemical 
parameters in animals. 
 So, it can be concluded that the Takkolathi Chooranam can be prescribed for 
therapeutic use in human with the dosage recommendations of upto 400mg/kg. body 
weight p.o. 
 
Pharmacological studies: 
                  
 In-vivo study of Takkolathi chooranam have been shown the significant increase in 
pre-convulsion time (PCT) due to pre-treatment with Takkolathi chooranam at the 
dose of 100, 200 and 400mg/kg of body weight of guinea pigs.  
 
 The results of study suggested that Takkolathi chooranam significantly protected the 
Guinea pigs against histamine-induced bronchospasm. 
 
 The study suggested that the trial drug is effective in reducing the symptoms of 
bronchial asthma and also improve the lung function parameters of asthmatic animal. 
The percentage protection of Takkolathi chooranam- 100, 200 and 400 mg/kg, is 
16.50, 21.87 and 30.38% respectively. 
 
 Hence, pharmacological studies strongly supports that the drug Takkolathi chooranam 
exhibits significant Antihistaminic activity and Bronchodilator activity 
 
 
Clinical observation:  
        
 From the clinical study, 75% patient relieved from wheeze, 75% patient relieved from 
dyspnoea, 74% patient relieved from cough, 80% patient relieved from chest 
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tightness, 65% patient relieved from expectoration and no adverse effects were 
observed during trial period. 
 
 18 (90%) patients had a significant reduction in the PEFR after the treatment. 
 
Bio-statistics: 
 
 Statistically, the paired‘t’ test shows statistical significance for the symptoms before 
and after the treatment (p<0.0001).  
 
 Also, the paired‘t’ test shows statistical significance for the PEFR before and after the 
treatment (p<0.0001). 
 
 Siddha aspect: 
 
 Siddha system of medicine strongly relies on cordial relationship between suvai 
(taste) and 3 vital forces. 
 
 According to Siddha basic principle, kapha kutram is deranged in Eraippu noi, so the 
principle aim in the treatment aspect is to make the deranged vital forces into normal 
by giving the trial drug with karppu suvai and veppa verium. 
 
 Karppu suvai cures inflammatory disease of the throat and removes sputum (phlegm) 
from the lungs, veppa verium and karppu pirivu pacifies kapham, prapavam of karppu 
is to correct deranged kapham7.  
 
Hence Takkolathi chooranam is a better drug of choice in the management of Eraippu 
(Bronchial asthma)  
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SUMMARY 
 
 The drug Takkolathi chooranam has been selected for this study to evaluate its 
efficacy on the Bronchodilator and Antihistaminic activity in the management of 
Eraippu (Bronchial asthma). 
 
 The literary evidence strongly supports the Bronchodilator and Antihistaminic activity 
of Takkolathi choornam. 
 
  The qualitative and quantitative analyses were done at Biochemistry lab, NIS and Sri 
Ramachandra University, Chennai respectively. Biochemical analysis of the drug 
Takkolathi choornam reveals the presence of sulphate, iron, calcium, starch, reducing 
sugar, tannic acid, amino acid and alkaloids.  
 
 HPTLC was done at Sri Ramachandra University, Chennai. The HPTLC finger-
printing profile establishes the identity and purity of the raw drug used.  
 
 Preclinical evaluation (acute and sub-acute toxicity study) of the drug was carried out 
as per OECD guideline in Vels College of pharmacy, Chennai. In the toxicological 
studies, the drug does not exhibit any mortality upto the dose of 400 mg/kg/po. 
 
 Preclinical pharmacological study was carried out in animal model in Vels College of 
Pharmacy, Chennai. In the pharmacological studies, the drug Takkolathi chooranam 
exihibits significant Anti-histaminic and Bronchodilator activity. 
 
 As per the Siddha literature and modern science reviews and research articles, the trial 
drug has potent anti-histaminic and bronchodilator effect. 
 
 From the clinical study, 75% patient relieved from wheeze, 75% patient relieved from 
dyspnoea, 74% patient relieved from cough, 80% patient relieved from chest 
tightness, 65% patient relieved from expectoration and no adverse effects were 
observed during trial period. 
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 18 (90%) patients had a significant reduction in the PEFR after the treatment. 
 
 From the statistical analysis-paired‘t’ test, the drug Takkolathi Chooranam is 
statistically significant. Statistically, the paired ‘t’ test shows statistical significance 
for symptoms before and after the treatment.(p<0.0001) 
 
 The drug Takkolathi Chooranam  has 
  Bronchodilator Activity 
 Anti histaminic Activity 
 No side effects 
 No undoing effects 
 Encouraging clinical results. 
 
 From the clinical and statistical analysis, it is proved that the drug Takkolathi 
Chooranam has significant Antihistaminic and Bronchodilator activity in the 
management of Eraippu (Bronchial asthma). 
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CONCLUSION  
 The literary evidence from the text Agathiyar 2000 shows Takkolathi chooranam 
Antihistaminic and Bronchodilator activity. 
 
 The safety studies (acute toxicity and sub-acute toxicity studies) conducted revealed 
that the trial drug Takkolathi chooranam is safe. There were no abnormalities found in 
blood investigation and histo-pathological examination. Hence it can be reasonably 
assumed that the drug is safe for human use. 
 
 The pharmacological study conducted in animal model shows significant 
Bronchodialator activity and Antihistaminic activity. 
 
 Clinical study revealed the therapeutic efficacy of the trial drug by showing reduction 
in Eosinophil, AEC and raised ESR level significantly. There was improvement in 
other clinical symptoms before and after treatment. 
 
 There was marked improvement in PEFR range after 30 days treatment with 
Takkolathi chooranam. 
 
 There were no adverse reactions complained during the clinical trial. 
 
 Hence, the drug TAKKOLATHI CHOORANAM can be used in the management of 
ERAIPPU (Bronchial Asthma). 
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     INTRODUCTION: 
  Anaemia refers to a state in which the level of hemoglobin and RBCs in the 
bloodstream is below the normal range approximate for age and sex1.  
 Anaemia is a serious public health problem having a direct bearing on physical 
development, immuno-competence, learning behaviour, maternal mortality, work capacity, 
GI disturbances, neurocognitive impairment and impaired thermoregulation. 
  In India and other developing countries iron deficiency anaemia far out numbers all 
the other types of anaemia out together, as it constitutes 90-95% of the total2.  It 
predominantly affects adolescent girls, women of reproductive age and young children4.               
 Iron deficiency anaemia is common among lower socioeconomic group because of 
insufficient dietary intake and limited absorption of dietary iron. 
  Iron deficiency anaemia has been universally recognized as the commonest forms of 
malnutrition occurring in the world. These affect approximately 2 billion people, 80% of whom live in 
the developing world. One third of world’s population has iron deficiency. Southeast Asia has the 
highest levels at 79%. The Indian subcontinent alone contains nearly half the world's anaemic 
women3.  
  According to the National Family Health Survey, anaemia among women between 
15-49 years of age is 51.8 percent with 45.7 percent in urban areas and 53.9 percent in rural 
areas. In studies conducted in developing countries, adolescent aneamia is the greatest 
nutritional problem. In India, 55 % adolescent girls are anaemic4. 
 The data of operations research, a UNICEF project in Tamil Nadu, documented  95% 
prevalence of anaemia in Dindigul and 48% in Tirupur among the urban poor3. 
  Anaemia is correlated with Pandu in Siddha system of medicine. Kumari Parpam is 
one of the herbo-mineral formulations indicated for Pandu which is mentioned in Siddha text 
“Agasthiyar 2000”, 5th edition, October 2002 by Dr.S.Venkatarajan LIM and published by 
Saraswathi mahal noolagam7. This Parpam has been prepared from Ayam, kandham and 
gandhagam with the help of Aloe vera juice. 
  According to Siddha basic principles, function of thuvarppu suvai is purification of 
blood and it is also important for RBCs formation. Ayam and gandhagam have thuvarppu 
suvai; hence kumari Parpam has immense potential in treating Pandu. 
            As per Siddha text, Parpam has great efficacy with minimal dosage, sustained 
availability, stability over long period etc. This Parpam has not been evaluated so far for 
Pandu, hence the author has selected “Kumari Parpam” to evaluate Haematinic activity. 
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AIM: 
 
             To evaluate the safety and efficacy of Kumari Parpam for  Haematinic activity. 
in the management of Pandu (Anaemia).  
 
OBJECTIVE: 
 
Primary objective: 
 
              To evaluate the Haemetinic activity of Kumari Parpam for Pandu (Anaemia) in 
preclinical studies.. 
 
Secondary objective: 
 
        The efficacy of Kumari Parpam has been evaluated in the following aspect. 
 
 Collection of evidences in Siddha and mineralogical aspect 
 Biochemical Analysis 
 Atomic Absorption Spectrophotometer 
 Clinical study- a pilot study on trial medicine 
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STANDARD OPERATIVE PROCEDURE:  
Collection and authentication of the raw drugs:  
 The raw drug were procured from raw drug store in Chennai and authenticated by 
competent authority of Department of Gunapadam, National Institute of Siddha, Chennai.  
Ingredients: 
                     1. Purified Ayam          (Iron)                                 -5 kazhanju(25.5 gm) 
                     2. Purified Kaandham   (magnetic oxide of iron)  -5 kazhanju(25.5gm) 
                     3. Purified Gandhagam (sulphur)                           -5 kazhanju(25.5gm) 
                     4. Katrazhai charu        (Aloe vera juice)               - sufficient quantity 
                     5. Purified Indhuppu    (Sodium chloride impura)*
                     6. Purified Chukku       (Zingiber officinale)* 
                     7. Purified Milagu        (Piper nigrum) *                                       
                     8. Purified Thippili       (Piper longum)* 
                     9. Purified Omam         (Carum copticum)* 
                    10. Purified Seeragam    (Cuminum cyminum) * 
                    * The drugs in s.no 5-10 were taken in equal quantity 
 
 Purification process:  
 Purification of Ayam: 
 35gm of powder of ayam was soaked in lemon juice for 3 days and then it was 
washed. Then it was soaked in gingelly oil for 1 day and it was fried in iron vessel. Finally it 
was soaked in horse gram (Macrotyloma uniflorum) decoction for several times5. 
 Purification of Kaandham: 
 35gm of kaandham was grinded with lemon juice for ¾ hours5.   
 
Purification of Gandhagam: 
 Maruthonri karkam (Lawsonia inermis) was mixed with cow’s curd and was taken in 
a mud vessel, a cloth was tied around the mouth of the vessel .The gandhagam was placed 
over the cloth and it closed with suitable mud vessel. It was then sealed with clay pasted cloth 
and buried in a pit. Five cow dung cakes were kept over the upper mud vessel and made into 
pudam, melted gandhagam was collected in the lower mud vessel. Repeat the process for 7 
times6.  
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Purification of Indhuppu: 
 The raw drug was purified by soaking in goat’s urine for 3 nazhigai (72 minutes) and 
dried in the sunlight6. 
 Purification of Chukku: 
 The raw drug was purified by removing the outerlayer and soaking in the limestone 
water5. 
 Purification of Milagu: 
 The raw drug was soaked in buttermilk for 1hour 15 minutes and then it was fried5. 
  Purification of Thippili: 
 The raw drug was purified by soaking in the lemon juice5. 
  Purification of Omam: 
 The raw drug was purified by soaking in limestone water for 3 hours and it was fried5. 
 Purification of Seeragam: 
 The raw drug was kept in sunlight for 6 hours and then it was fried5. 
 Preparation of the medicine:  
 Purified ayam, kaandham, gandhagam were powdered and grinded with katrazhai 
charu and made into a villai. The villai was then placed in a mud vessel and it was heated for 
4 samam (12 hours) by wooden fuels7. 
 Preparation of the adjuvant: 
 The chukku, milagu, thippili, indhuppu, omam, seeragam were purified and 
pulverized by an electric grinder into fine powder, separately. And then it was sieved by 
using a fine silk cloth (vasthrakayam). The fine powder was purified by pittaviyal method. 
Then it was dried and ultra filtered by a cotton cloth and made into fine powder again. The 
powder was stored in a clean, dry air tight glass bottle7.  
LABELLING: 
                      Name of the preparation    :    Kumari Parpam 
    Colour                                :    White colour 
    Dose                                   :    488 mg b.d 
    Vehicle                               :    Honey  
                            Duration                             :    1 month 
    Indication                           :    Pandu 
    Date of manufacture          :    13-03-2012 
                            Expiry                                :    100 years from the date of manufacture 
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                AYAM: 
                      BEFORE   PURIFICATION                               AFTER PURIFICATION 
                      
                      GANDHAGAM: 
                      BEFORE PURIFICATION                    AFTER PURIFICATION 
   
                      KAANDHAM: 
                      BEFORE   PURIFICATION                 AFTER PURIFICATION 
                     
   VILLAI                                             ERIPPU                                      PARPAM 
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«Âõ 6 
 
§ÅÚ ¦ÀÂ÷¸û: 
                          «¸¢, «ÂÍ, «Â¢ø, þÊ, þÕõÒ, ®º ¦ºÂõ, ¸Õí¦¸¡ø, ¸ÕôÀ¢, ¸ÕõÒ, 
¸ÕôÒ, ¸ÕÁ½ø, ¸Õõ¦À¡ý, ¸ÂÍ, ¸¡Ä¢ø ¦¿¸¢Çõ, ¬¾¢, ºòÐ, º¢§Ã¡ºÃõ, º¢ð¼õ, ¾¢ÕõÀ¢, 
Ðñ¼õ, À¢ñ¼õ, §Ä¡¸õ, Å¡úâÁ¢ ¿¡¾õ    
 
Í¨Å:                ¦ÀÕõÀ¡ý¨Á ÐÅ÷ôÒ, º¢ÚÀ¡ý¨Á ÒÇ¢ôÒì ¨¸ôÒ,    ¾ý¨Á:¦ÅôÀõ 
 
¦ºö¨¸:           Àº¢Ôñ¼¡ì¸¢, ¯¼ø ¯ÃÁ¡ì¸¢, ÌÕ¾¢ô ¦ÀÕì¸¢, ¯¼ø §¾üÈ¢ 
   
¦À¡ÐìÌ½õ: 
"À¡ñÎ¦Åñ Ìð¼õ ÀÕóàÄ §¿¡ö§º¡¨À 
 Á¡ñÊ¼î¦ºö Áó¾í¸¡ Á¡¨ÄÌýÁõ âñ¼ 
 ¦ÀÕó¾¡Ð ¿ð¼Óõ§À¡õ §À¾¢Àº¢ Ôñ¼¡í 
 ¸Õó¾¡Ð ¿ð¼Á¢Îí ¸¡ø" 
 
                       þÕõÀ¢É¡ø À¢ò¾ À¡ñÎ, ¦Åñ Ìð¼õ, «¾¢àÄ§¿¡ö, §º¡¨À, Áó¾õ, 
¸¡Á¡¨Ä, ÌýÁõ ¿£íÌõ. 
 
«Âõ §ºÕõ À¡ñÎ §¿¡öì¸¡É ÁÕóÐ¸û: 
 
1.ÁñÎÃ Å¼¸õ11 
«Ç×        :   ¸Æüº¢ì¸¡ö «Ç× 
«ÛÀ¡Éõ   :  §¾ý, ¦¿ö,§Á¡÷ 
¾£Õõ §¿¡ö   :  À¢ò¾ À¡ñÎ,¸¡Á¡¨Ä,Á§¸¡¾Ãõ,ÌýÁõ,¦ÀÕÅÂ¢Ú 
¬¾¡Ãõ     :   ºÃ§Àó¾¢Ã ¨Åò¾¢Â Ó¨È¸û À¡ñÎ ¸¡Á¡¨Ä º¢¸¢î¨º  
 
2. «Âî ¦ºõÒ ¦ºóàÃõ12 
¾£Õõ §¿¡ö      :           À¡ñÎ 
¬¾¡Ãõ           :   §À¡¸¦ÃØáÚ  
 
3. «ÂÁ¡¾¢ Å¼¸õ13 
«Ç×       :   Íñ¨¼ì¸¡ö «Ç× 
«ÛÀ¡Éõ  :   ±Õ¨Á¾Â¢÷ 
¾£Õõ §¿¡ö  :  À¡ñÎ, ÀòÐ Å¨¸ ¸¡Á¡¨Ä 
¬¾¡Ãõ  :         «¸Š¾¢Â÷ ÅøÄ¡¾¢ 600 
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4.¾í¸ «Âî ¦ºóàÃõ14 
«Ç×              :  1/4 -1/2 ÌýÈ¢ «Ç× 
«ÛÀ¡Éõ      :  §¾ý,¦¿ö 
¾£Õõ §¿¡ö      :  À¡ñÎ,  ¸¡Á¡¨Ä 
¬¾¡Ãõ           :    º¢¸ ¢îº¡ÃòÉ ¾£Àõ  
 
 
¸ó¾¸õ 6 
 
§ÅÚ ¦ÀÂ÷¸û: ¸¡¡¢¨ÆÂ¢ý ¿¡¾õ, À¨Ã Å£¡¢Âõ,  «¾£¾ôÀ¢Ã¸¡ºõ, À£ƒõ, ¦ºøÅ¢Å¢óÐ, ºì¾¢, 
ºì¾¢À£ºõ, ¦ºóàÃò¾¡¾¢, ¾Éõ, §¾Å¢ÔÃõ, ¿¡¾õ, ¿¡üÈõ 
 
Í¨Å  :¨¸ôÒ, ÐÅ÷ôÒ 
 
¦ºö¨¸: À¢ò¾¿£÷ ¦ÀÕì¸¢,  ÁÄÁ¢Çì¸¢, ¯¼ø §¾üÈ¢,Å¢Â÷¨Å ¦ÀÕì¸¢, ¸¢ÕÁ¢ ¿¡º¢É¢ 
 
¦À¡ÐìÌ½õ: 
                   "¦¿øÄ¢ì¸¡öì ¸ó¾¢ìÌ ¿£ûÀ¾¢¦Éñ Ìð¼Áó¾õ 
                    Åø¨Ä ¸Å¢¨ºÌýÁ Å¡Ô¸ñ§½¡ö-¦À¡øÄ¡ 
                    Å¢¼ì¸ÊÅý §Á¸§¿¡ö Å£ÚÍÃõ §À¾¢ 
                    ¾¢¼ì¸¢Ã¸ ½£¸Àõ§À¡ó §¾÷." 
 
                     Á¡¾÷ Á¸¨Å ÅÇ÷ôÀÐ§À¡ §ÄÔ¼õ¨À    
                     Â¡¾ÃÅ¡ ¸ò§¾üÈ¢ Â¡ì¨¸Â¢É¡ø -Á£¾¡¸ 
                     §ÁÅ¢  Â¼÷§¿¡Â¢ý ¦ÅôÀò¨¾ Á¡üÚ¾Ä¡ü 
                     §ÈÅ¢ÔÃ ¦ÁýÀÐ¼ø §¾÷." 
 
                     ¦¿øÄ¢ì¸¡öì ¸ó¾¸ò¾¢É¡ø À¾¢¦ÉñÌð¼õ, Áó¾õ, ¸øÄ£Ãø Å£ì¸õ, 
¸Å¢¨º, ÌýÁÅ¡Ô, Å¡¾ ÍÃõ ¿£íÌõ. 
 
¸ó¾¸õ §ºÕõ À¡ñÎ §¿¡öì¸¡É ÁÕóÐ¸û: 
1.ÍÅ÷½âÀ¾¢ ÌÇ¢¨ ¸14 
«Ç×         :  Àî¨ºÀÂ¢Ú «Ç× 
¾£Õõ §¿¡ö   :  À¡ñÎ, Á§¸¡¾Ãõ,¿£¡¢Æ¢×,®¨Ç,¸¡ºõ 
¬¾¡Ãõ       :  º¢¸¢îº¡ÃòÉ ¾£Àõ  
 
2.ÁñÎÃî ¦ºóàÃõ15 
«Ç×         :  2 À½¦Å¨¼ 
«ÛÀ¡Éõ  :  ¾¢¡¢¸ ÎÌ ÝÃ½õ,§¾ý 
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¾£Õõ §¿¡ö   :  À¡ñÎ 
¬¾¡Ãõ       :  «¸Š¾¢Â÷ ¨Åò¾¢Â Ãò¾¢É ÍÕì¸õ  
 
3.Ý¾¦¸ó¾¢¾¡Ã ¦ºóàÃõ16 
«Ç×           :  À½¦Å¨¼, 7 ¿¡û 
«ÛÀ¡Éõ   :  ¦Åó¿£÷ 
¾£Õõ §¿¡ö   :  À¡ñÎ 
¬¾¡Ãõ         :  §¾¨ÃÂ÷ ¨Åò¾¢Âõ 1000 
 
4.þÃº ¦ºóàÃõ18 
«Ç×         :  244 ¸¢Ã¡õ 
«ÛÀ¡Éõ   :  §¾ý 
¾£Õõ §¿¡ö    :  À¡ñÎ,¸¡Á¡¨Ä,¦ÀÕÅÂ¢Ú,¸Å¢¨º,«¸¨Å 
¬¾¡Ãõ           :  «¸Š¾¢Â÷ «ð¼Å¨½ Å¡¸¼õ  
 
5.§Ä¡¸î ¦ºóàÃõ11 
«Ç×           :  3 «¡¢º¢ ±¨¼ 
«ÛÀ¡Éõ   : §¾ý 
¾£Õõ §¿¡ö   :          À¡ñÎ,§º¡¨¸,¸¡Á¡¨Ä,¦ÀÕÅÂ¢Ú 
¬¾¡Ãõ         :  ºÃ§Àó¾¢Ã ¨Åò¾¢ö Ó¨È¸û À¡ñÎ ¸¡Á¡¨Ä º¢¸¢î¨º  
 
 
¸¡ó¾õ 6 
 
§ÅÚ ¦ÀÂ÷¸û: 
                      º¢Å§Ä¡¸î §ºÅ¸ý, ¾Ã½¢ìÌ ¿¡¾õ, Ý¾ «íÌºõ,  ¿Å§Ä¡¸ò ÐÃðÊ, 
¸¡Âº¢ò¾¢ìÌô À¡ò¾¢Ã Å¡ý, ÓÕ¸ý ÒÃ¡½õ 
 
¦À¡ÐìÌ½õ: 
                     "¸¡ó¾ò¾¡ü §º¡¨ÀÌýÁí ¸¡Á¢Ä§Á ¸õÀ¡ñÎ 
                      §º÷ó¾¾¢¡¢ §¾¡¼¦Åð¨¼ º£¾í¸¡ø-µöó¾Àº¢ 
                      §ÀÕ¾Ãí ¸ñ§½¡ö À¢ÃÁ¢Â¿£ Ã¡¨ÁÔõ§À¡õ 
                      µ¡¢É¢¨È Â¡ÔÙÚõ ¯ý." 
 
                     ¸¡ó¾ì¸ø Å£ì¸õ, ÌýÁõ, ¸¡Á¡¨Ä §Á¸õ, À¡ñÎ, Óò§¾¡¼õ, Á§¸¡¾Ãõ 
¿£íÌõ 
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¸¡ó¾õ §ºÕõ À¡ñÎ §¿¡öì¸¡É ÁÕóÐ¸û: 
 
1.ÄðÍÁ¢ ¿¡Ã¡Â½ Á¡ò¾¢¨Ã14 
«Ç×         :  Á¢ÇÌ («) ¯ÙóÐ À¢ÃÁ¡Éõ 
«ÛÀ¡Éõ   :  §¸¡¿£÷ 
¾£Õõ §¿¡ö   :  À¡ñÎ,¸¡Á¡¨Ä 
¬¾¡Ãõ       :  º¢¸¢îº¡ÃòÉ ¾£Àõ  
 
2.¸¡ó¾î ¦ºóàÃõ19 
«Ç×          :  À½¦Å¨¼,2 §Å¨Ç,1 Áñ¼Äõ 
«ÛÀ¡Éõ   :  §¾ý 
¾£Õõ §¿¡ö   :  À¢ò¾ À¡ñÎ 
¬¾¡Ãõ        :  «¸Š¾¢Â÷ À¡¢âÃ½õ 400  
 
3.¸¡¢ôÀ¡É¡¾¢ §Ä¸¢Âõ17 
«Ç×              :  ¦¸¡ð¨¼ôÀ¡ì¸Ç×,2 §Å¨Ç 
«ÛÀ¡Éõ      :  §¾ý 
¾£Õõ §¿¡ö      : À¢ò¾ À¡ñÎ,¸¡Á¡¨Ä,ÌýÁõ 
¬¾¡Ãõ           :         «¸Š¾¢Â÷ ¨Åò¾¢Â º¢ó¾¡Á½¢ ¦ÅñÀ¡ 4000 ±ýÛõ Á½¢ 4000 
 
4. ¾¢¡¢ã÷ò¾¢ ¦ºóàÃõ14 
«Ç×              :  1-1 1/2 ÌýÈ¢ 
«ÛÀ¡Éõ      :  §¾ý,¦¿ö 
¾£Õõ §¿¡ö      :  À¡ñÎ,§º¡¨¸,¸¡Á¡¨Ä 
¬¾¡Ãõ           :   º¢¸ ¢îº¡ÃòÉ ¾£Àõ  
 
5.«Ãô¦À¡ÊÂ¡¾¢ Å¼¸õ17 
«Ç×            :  ÒÇ¢Âí¦¸¡ð¨¼ÂÇ× 
«ÛÀ¡Éõ    : ¨¸Â¡ó¾¸¨Ãî º¡Ú 
¾£Õõ §¿¡ö     : À¢ò¾ À¡ñÎ,§º¡¨¸ 
¬¾¡Ãõ          : «¸Š¾¢Â÷ ¨Åò¾¢Â º¢ó¾¡Á½¢ ¦ÅñÀ¡ 4000 ±ýÛõ Á½¢ 4000 
 
 
¸üÈ¡¨Æ 8 
 
§ÅÚ ¦ÀÂ÷: ¸ýÉ¢, ÌÁ¡¢ 
 
ÀÂýÀÎõ ¯ÚôÒ: À¡ø, Á¼ü§º¡Ú, º¡Ú, §Å÷ 
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Í¨Å : º¢Ú ¨¸ôÒ,      ¾ý¨Á : ¾ðÀõ,      À¢¡¢×: þÉ¢ôÒ 
 
¦ºö¨¸:  ¯ÃÁ¡ì¸¢, ¯¼ü§ÈüÈ¢, ¿£÷ÁÄ§À¡ì¸¢, ÕÐ ¯ñ¼¡ì¸¢ 
 
¦À¡Ð Ì½õ: 
                      ¦À¡øÄ¡§Á ¸í¸ÀõÒ ØîÝ¨Ä Ìð¼Ãºõ 
                      «øÄ¡÷Áò ¾õÀ¸ó¾ ÃíÌýÁõ  ±øÄ¡õÅ¢ð 
                      §¼Ì Á¢¡¢ìÌ ¦Á¡¢îºü ¸¢¡¢îºÃÓ 
                      Á¡Ì Á¡¢ìÌ ÁÕñÎ 
 
                      þ¾É¡ø Å¡¾§Á¸õ, ¸Õ§Á¸õ, ¸¢ÕÁ¢Ìò¾ø, ¦ÀÕÅ¢Â¡¾¢, ãÄõ, 
¯ýÁ¡¾õ, À¸ó¾Ãõ, ÌýÁõ þ¨Å §À¡õ. 
 
¸üÈ¡¨Æîº¡Ú §ºÕõ À¡ñÎì¸¡É ÁÕóÐ¸û 20 
 
1. ¬ÚÓ¸î¦ºóàÃõ 
«Ç×  : À½¦Å¨¼ 
«ÛÀ¡Éõ :  ¾¢¡¢¸ ÎÌòàû, §¾ý 
¾£Õõ §¿¡ö : À¡ñÎ, §º¡¨¸, ±¡¢ÌýÁõ, Ý¨Ä 
¬¾¡Ãõ :  º¢ò¾ ¨Åò¾¢Â ¾¢ÃðÎ 
 
2. Á¸¡Åºó¾ÌÍÁ¡¸Ãõ 
«Ç×  :  ÌýÈ¢ÂÇ× 
«ÛÀ¡Éõ : ÓôÀ¨Ä ÝÃ½õ 
¾£Õõ §¿¡ö : À¡ñÎ 
¬¾¡Ãõ : º¢ò¾ ¨Åò¾¢Â ¾¢ÃðÎ 
 
3. âÃ½ ºó¾¢§Ã¡¾Âõ 
«Ç×  :  ÀÂÈÇ× 
«ÛÀ¡Éõ :  ¦Åñ¦½ö («) º÷ì¸¨Ã 
¾£Õõ §¿¡ö : À¡ñÎ, ±ñ Å¨¸ ÌýÁõ, §º¡¨À 
¬¾¡Ãõ :  º¢ò¾ ¨Åò¾¢Â ¾¢ÃðÎ 
 
4. Àî¨ºì¸üâÃ Á¡ò¾¢¨ Ã 
«Ç×  :  ¯Ùó¾Ç× 
«ÛÀ¡Éõ :  §¾ý («) þïº¢îº¡Ú 
¾£Õõ §¿¡ö :  Å¡¾õ, À¢ò¾õ-40, §ºòÐÁõ96 
¬¾¡Ãõ :  º¢ò¾ ¨Åò¾¢Â ¾¢ÃðÎ 
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IRON 21, 22, 23 
Chemical Formula: Fe 
Empirical formula: Fe0+ 
 
Vernacular names:  
                 Tamil    :         Irimbu 
                 Sans     :         Lauha,Hyam 
                 Malay   :         Basi 
                 Telu       :         Inumu 
                 Urdu     :         Lohchun 
Source:   
 Widely distributed in both the organic and inorganic kingdoms. 
 Found in nearly all rocks, soils, etc, variously combined with oxygen as haematite, 
with sulphur as iron pyrites. 
 Found in the ashes of plants and even the blood (RBC of the blood) of animals and 
also in the bile, chyle, gastric juice, lymph, milk, pigment of the eye, and in the urine. 
 The largest iron resources in the world are in China, Russia, Brazil, Canada, Australia, 
and India. 
Physical properties  
 Iron is a silvery-white or grayish metal. 
 It is ductile and malleable. 
 Iron has a very high tensile strength.  
Meltingpoint : 1,536°C(2,797°F) 
Boilingpoint : 3,000°C(5,400°F). 
Color: : Iron black, Dark gray, Steel gray 
Density: : 7.3 - 7.9, Average = 7.6  
Diaphaneity: : Opaque  
Fracture: 
: 
Hackly - Jagged, torn surfaces, (e.g. fractured 
metals).  
Hardness: : 4-5 - Fluorite-Apatite  
Luminescence: : Non-fluorescent.  
Luster: : Metallic 
Magnetism: : Naturally strong  
Streak: : Gray  
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Chemical properties  
 Iron is a very active metal. It readily combines with oxygen in moist air. The product 
of this reaction, iron oxide (Fe 2 O 3 ), is known as rust. 
 Iron also reacts with very hot water and steam to produce hydrogen gas. It also 
dissolves in most acids and reacts with many other elements.  
 
Action: 
 Iron improves the quality of blood 
 Iron stimulates the functional activity of all the organs of the body and is therefore a 
valuable general tonic. 
 
 
MAGNETITE24,25 
 
Chemical Formula:  Fe++Fe+++2O4  
Empirical Formula:  Fe3+2Fe2+O4  
Physical properties  
 
Cleavage                 : None  
Color                       : Grayish black, Iron black.  
Density                    : 5.1 - 5.2, Average = 5.15  
Diaphaneity            : Opaque  
Fracture                   : Sub Conchoidal - Fractures developed in brittle materials 
characterized by semi-curving surfaces.  
Hardness                 : 5.5-6 - Knife Blade-Orthoclase  
Luminescence         : Non-fluorescent.  
Luster                       : Metallic  
Magnetism               : Naturally strong  
Streak                       : 
Curie temperature    : 
black  
 858 K (585 °C; 1,085 °F). 
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Chemical properties: 
 
                   Magnetite reacts with oxygen to produce hematite, and the mineral pair forms a 
buffer that can control oxygen fugacity. 
 
Source: 
                     Magnetite also occurs in many sedimentary rocks, including banded iron 
formations. 
 
SULPHUR23,26,27 
 
Chemical Formula  : S 
Empirical Formula : S8 
 
Vernacular names: 
                                   Tamil        :         Gandakam 
                                   Sans          :         Gandhaka 
                                    Mal          :         Gendagum 
                                    Tel           :         Gandhakam 
                                    Hindi       :          Gandak 
                                    Eng          :          Brimstone 
 
   Source: 
 A non-metallic element found free in beds of gypsum and in a state of sublimation in 
regions of extinct volcanoes ; also in combination with several ores called pyrites, as 
sulphates and sulphides of iron, copper, lead, zinc, mercury etc. 
 
 In India it occurs naturally in some parts in Nepal,  Kashmir, Afghanistan,  and in 
Burma. 
   Physical properties  
 
      Melting point    :              115.21 ° 
      Boiling point     :              444.6 °C  
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                  Color                    :   Yellow, Yellowish brown, Reddish, Greenish.  
Density                  :  2.05 - 2.09, Average = 2.06  
  Diaphaneity          :   Transparent to translucent  
                  Fracture                :  Sectile - Curved scrapings produced by a knife blade  
                  Hardness              :  1.5-2.5 - Hardness very near Gypsum  
                  Luminescence      :   Non-fluorescent.  
                  Luster                   :   Resinous  
                  Streak                   :   White  
 
Chemical properties: 
 Sulfur burns with a blue flame concomitant with formation of sulfur dioxide, notable 
for its peculiar suffocating odor.  
 
 Sulfur is insoluble in water but soluble in carbon disulfide and, to a lesser extent, in 
other  nonpolar organic solvents, such as benzene and toluene.  
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BOTANICAL NAME28:Aloe vera (Linn.) Burm.f; 
CLASSIFICATION: 
                                    Kingdom                 :         Plantae 
                                    Subkingdom            :        Tracheobionta 
                                    Superdivision          :        Spermatophyta 
                                    Division                   :        Magnoliophyta 
                                    Class                        :        Liliopsida 
                                    Subclass                   :        liliidae 
                                    Order                       :         liliales 
                                    Family                     :        Aloaceae 
                                    Genus                      :        Aloe  
                                    Species                    :         Aloe vera 
VERNACULAR NAMES: 
 Eng.- Indian aloe,Curacao aloe,Barbados aloe 
 Hindi- Ghikunwar,Ghikumari; 
 Kan.-Kathaligida, 
 Mal.-Kattuvala, 
 Tam.-Kattalai, 
 Tel.-Kalabanda 
 
BOTANICAL DESCRIPTION: Leaves radical, inflorescence 90-135 cm long,simple or 
few branched,Racemes terminal, flowers yellow or orange,about 2.5 cm long, capsules 
cylindrical. 
 
DISTRIBUTION: Cultivated throughout India, grow wild on the coasts of Bombay,Gujarat 
and South India. 
 
PARTS USED: Leaf, leaf-juice, dried juice of leaf 
 
ACTIONS : The plant is bitter, sweet, cooling, anthelmintic, aperients, carminative, 
deobstruent, depurative, diuretic, stomanchic, emmenagogue, ophthalmic. 
Physical constants: Foreign matter-Not more than 2%; Total ash-Not more than 5 %; Acid 
insoluble ash-Not more than 2%; Alcohol soluble extractive- Not less than 60 %; Moisture 
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content – Not more than 10 % of its weight when dried to constant weight at 105 degree 
Celsius. 
CHEMICAL CONSTITUENTS: Hydroxyanthraquinone-barbaloin and ϒ-hydroxyaloin 
isomers. The other constituents include aloe emodin, chrysophanol, chromone derivatives – 
aloeresin B with its p-coumaryl derivatives oleoresin A and C and the aglycone aloesone. 
 
ACTION: Anti inflammatory, hepatoprotective, antibacterial and cathartic. 
 
ADULTERANTS: Marketed drug may be adulterated with black catechu [Acacia catechu 
Wild.], pieces of irons and stones. 
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PHYSICAL PROPERTIES OF KUMARI PARPAM 
  The physical properties of Kumari Parpam was carried out at Sri Ramachandra 
University, Chennai. 
 
pH at 10% of aqueous solution: 
 Five grams of  Kumari Parpam was weighed accurately and placed in clear 100 ml 
beaker. Then 50 ml of distilled water was added to it and dissolved well. After 30 minutes it 
was then applied in to pH mater at standard buffer solution of 4.0, 7.0, 9.2. 
 
Ash Values 
 The Ash values are a measure of the inorganic constituents present in the raw drug.  A 
high ash content explains its unsuitable nature to be used as a drug. 
 
Total Ash 
 A little of extract was taken in a silica crucible previously ignited, cooled and 
weighed. It was incinerated by gradually increasing the heat not exceeding dull red heat 
(450°C) until free from carbon, cooled and weighed. The percentage of ash was calculated 
with reference to air- dried drug. The procedure was repeated to get the constant weight. 
 
Water soluble ash 
 The total ash was boiled with 25 ml water and filtered through ash less filter paper 
(Whatmann 4.1). It was followed by washing with hot  water .The  filter paper  was dried  
and ignited in the silica crucible, cooled and the water insoluble ash was weighed. The water-
soluble ash can be calculated by subtracting the water insoluble ash from the total ash.  
 
Acid insoluble ash 
 The total ash obtained was boiled for 5 minutes with 25 ml of (10% w/v) dilute 
hydrochloric acid and filtering through ash less filter paper (Whatmann 4.1).  The filter paper 
was ignited in the silica crucible, cooled and insoluble ash was weighed. (Table B) 
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BIO -CHEMICAL ANALYSIS OF KUMARI PARPAM 
 The biochemical analysis of the Kumari Parpam was carried out in the Biochemistry 
lab, NIS.  
S.No EXPERIMENT OBSERVATION INFERENCE 
1.         Appearance of sample white in colour  
2. Solubility: 
a. A little(500mg) of the sample 
was shaken well with distilled water. 
b. A little(500mg) of the sample 
was shaken well with con. HCl/Con. 
H2So4 
Sparingly soluble Absence of Silicate 
3. Action of Heat: 
   A small amount(500mg) of the 
sample was taken in a dry test tube and 
heated gartly at first and then strong. 
 
 No white fumes 
evolved  
 
 
Absence of Carbonate 
 
4. Flame Test: 
  A small amount(500mg) of the 
sample was made into a paste with con. 
HCl in a watch glass and introduced 
into non-luminous part of the Bunsen 
flame. 
 No Bluish green 
flame appeared. 
Absence of Copper 
5. Ash Test: 
   A filter paper was soaked into a 
mixture of sample and dil. cobalt 
nitrate solution and introduced into the 
Bunsen flame and ignited. 
Yellow colour 
flame appeared. 
Presence of sodium 
Preparation of Extract: 
 5gm of Kumari Parpam was weighed accurately and placed in a 250ml clean beaker 
and added with 50ml of distilled water. Then it was boiled well for about 10 minutes. Then it 
was cooled and filtered in a 100ml volumetric flask and made up to 100ml with distilled 
water. 
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S.No EXPERIMENT OBSERVATION INFERENCE 
 I.Test For Acid Radicals   
1. 
 Test For Sulphate: 
a. 2ml of the above prepared extract 
was taken in a test tube to this added 2ml 
of 4% dil ammonium oxalate solution 
b. 2ml of the above prepared extracts 
was added with 2ml of dil-HCl was added 
until the effervescence ceases off. Then 
2ml of dil.Barium chloride solution was 
added. 
 Cloudy 
appearance present 
Presence  
of Sulphate 
2. 
Test For Chloride: 
  2ml of the above prepared extract was 
added with dil. HCl till the effervescence 
ceases. Then 2ml of dil.silver nitrate 
solution was added. 
Cloudy appearance 
present 
Presence  
of Chloride 
3. 
Test For Phosphate: 
  2ml of the extract was treated with 2ml of 
dil.ammonium molybdate solution and 2ml 
of con.HNo3. 
 No Yellow 
appearance. 
Absence of 
Phosphate 
4 
. 
Test For Carbonate: 
    2ml of the extract was treated with 2ml 
dil. Magnesium sulphate solution 
No Cloudy 
appearance. 
Absence  
of carbonate 
5. 
Test For Nitrate: 
  1gm of the substance was heated with 
copper turning and concentrated H2So4 
and viewed the test tube vertically down. 
 
No Brown gas 
evolved. 
 
Absence  
of Nitrate 
6. 
Test For Sulphide: 
  1gm of the substance was treated with 
2ml of con. HCL 
No Rotten Egg 
Smelling gas. 
Absence  
of Sulphide 
7. 
Test For Fluoride & Oxalate: 
  2ml of extract was added with 2ml of dil. 
Acetic acid and 2ml dil.calcium chloride 
solution and heated. 
 No cloudy 
appearance present 
Absence  
of fluoride and 
oxalate 
8. Test For Nitrite: No Characteristic Absence  
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  3drops of the extract was placed on a 
filter paper, on that-2 drops of dil.acetic 
acid and 2 drops of dil.Benzidine solution 
was placed. 
changes of Nitrite 
9. 
Test For Borate: 
2 Pinches(50mg) of the substance was 
made into paste by using dil.sulphuric acid 
and alcohol (95%) and introduced into the 
blue flame. 
No Bluish green 
colour flame. 
Absence  
of borate 
 II. Test For Basic Radicals   
1. 
Test For Lead: 
        2ml of the extract was added with 2ml 
of dil.potassium iodine solution. 
No yellow 
Precipitate 
obtained. 
Absence of Lead 
2. 
Test For Copper: 
a. One pinch(50mg) of substance was 
made into paste with con. HClin a watch 
glass and introduced into the non-
luminuous part of the flame. 
No Blue colour 
flame 
No Blue colour 
precipitate formed. 
 
Absence  
of copper 
 
 
3. 
Test For Aluminium: 
  To the 2ml of extract, dil.sodium 
hydroxide was added in 5 drops to excess. 
NoYellow colour 
appeared. 
Absence   
of aluminium 
4. 
Test For Iron: 
a.   To the 2ml of extract, 2ml of 
dil.ammonium solution was added. 
b.    To the 2ml of extract 2ml  thiocyanate 
solution and 2ml  of con HNo3 was added 
Blood red colour 
appeared. 
Presence of Iron 
5. 
Test For Zinc:  
To 2ml of the extract, dil.sodium hydroxide 
solution was added in 5 drops to excess and 
dil.ammonium chloride was added.  
No White precipitate 
was  formed 
 
Absence of Zinc 
6. 
Test For Calcium:  
      2ml of the extract was added with 2ml 
of 4% dil.ammonium oxalate solution  
Cloudy appearance 
and white 
precipitate was 
obtained 
 
Presence  
of calcium 
7. 
Test For Magnesium:  
         To 2ml of extract dil.sodium 
No White 
precipitate was  
Absence  
of Magnesium 
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hydroxide solution was added in drops to 
excess. 
obtained 
8. 
Test For Ammonium: 
  To 2ml of extract 1 ml of Nessler's 
reagent and excess of dil.sodium 
hydroxide solution are added. 
No Brown colour 
appeared 
Absence  
 of ammonium 
9. 
Test For Potassium:  
   A pinch(25mg) of substance was treated 
of with 2ml of dil.sodium nitrite solution 
and then treated with 2ml of dil.cobalt 
nitrate in 30% dil.glacial acetic acid. 
No Yellowish 
precipitate was 
obtained. 
Absence  
of Potassium 
10. 
Test For Sodium: 
    2 pinches (50mg) of the substance was 
made into paste by using HCl and 
introduced into the blue flame of Bunsen 
burner. 
 yellow colour 
flame appeared 
 Presence  
of sodium 
11. 
Test For Mercury:  
   2ml of the extract was treated with 2ml 
of dil.sodium hydroxide solution.  
No yellow 
precipitate was 
obtained 
Absence  
of mercury 
12. 
Test For Arsenic:  
   2ml of the extract was treated with 2ml 
of dil.sodium hydroxide solution. 
No brownwish red 
precipitate was 
obtained 
Absence  
of arsenic 
 III.Miscellaneous   
1. 
Test For Starch:  
  2ml of extract was treated with weak 
dil.iodine solution  
 
No  blue colour 
developed 
 
Absence  
of starch 
2. 
Test For Reducing Sugar:  
    5ml of Benedict's qualitative solution 
was taken in a test tube and allowed to boil 
for 2 minutes and added 8 to 10 drops of 
the extract and again boil it for 2 minutes. 
The colour changes are noted. 
Brick red colour 
not developed 
Absence of  
reducing sugar 
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3. 
Test For The Alkaloids: 
a) 2ml of the extract was treated with  2ml 
of dil.potassium iodide solution. 
b)  2ml of the extract was treated with  2ml 
of dil.picric acid. 
c)  2ml of the extract was treated with 2ml 
of dil.phosphotungstic acid. 
Yellow colour 
developed 
Presence  
of Alkaloid 
4. 
Test For Tannic Acid:  
2ml of extract was treated with 2ml of 
dil.ferric chloride solution  
 No black 
precipitate was 
obtained 
Presence  
of Tannic acid 
5. 
Test For Unsaturated Compound: 
  To the 2ml of extract 2ml of 
dil.Potassium permanganate solution was 
added.  
 
Potassium 
permanganate was 
not decolourised 
 
Absence  
of unsaturated 
compound  
6. 
Test For Amino Acid: 
    2 drops of the extract was placed on a 
filter paper and dried well. 20ml of  
Biurette reagent was added. 
 
violet colour 
developed 
Presence  
of amino acids 
7. 
Test For Type Of Compound: 
2ml of the extract was treated with 2 ml of 
dil.ferric chloride solution. 
No green colour 
developed 
 
 
No red colour 
developed 
 
 
 
No violet colour 
developed 
 
No blue colour 
developed 
Absence of oxy 
quinole 
pinephrine and 
pyro catechol 
Anti pyrine, 
Aliphatic amino 
acids and 
meconic  
acid are absent  
Apomorphine 
salicylate and 
Resorcinol are 
absent 
Morphine, 
Phenol cresol 
and hydro uinone 
are absent 
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ATOMIC ABSORPTION SPECTROPHOTOMETER ON KUMARI PARPAM 
 Atomic Absorption Spectrophotometer of Kumari Parpam was carried out at Sri 
Ramachandra University, Chennai. 
 
Elemental Analysis using Atomic Absorption Spectrophotometer: 
 The elemental analysis of digested samples have been determined by Atomic 
Absorption Spectrophotometer (AAS model 400 Perkin Elmer) at the Sri Ramachandra 
University, Chennai.  The element Fe has been analyzed.  In this method the sample, in the 
form of a homogeneous liquid, is introduced into a flame where thermal and chemical 
reactions create “free” atoms capable of absorbing, emitting or fluorescing at characteristic 
wavelengths.   
 
 In Atomic Absorption Spectrophotometer (AAS) the majority of free atoms in the 
commonly used flames were in the ground state, but that the flames did not also have enough 
energy to excite these atoms.  A light source emitting a narrow spectral line of the 
characteristic energy is used to excite the free atoms formed in the flame.  The decrease in 
energy (absorption) is then measured. 
 
 In AAS the wave length (nm), Flame type, Atomizer, Measurement mode, Lamp 
source and calibration range (ppm) of different elements have been used, are listed in table. 
 
Instrumental conditions for elemental analysis 
 
Parameter Fe 
Wavelength (nm) 248.3 
Flame composition A-Ac 
Atomizer 
Standard Burner 
Head 
Measurement mode Absorbance 
Calibration Range (ppm) 0.04 - 2 
Lamp source HCL 
 
A - Ac: Air-Acetylene; HCL: Hallow cathode lamp; EDL: Electrode less discharge lamp 
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METHODOLOGY  
I. Microwave Digestion For Elemental Analysis 
Model Name: Multiwave3000 
Digestion Procedure: 
200mg of the given sample is placed in a digestion vessel, acid is added and the 
mixture is heated for several minutes. After the digestion, the samples are diluted to a specific 
volume. If too much sample is used in wet digestion, the reaction mixture can become 
violent. The samples are placed in digestion vessels that fit directly into digestion racks. 
There are several different acids or mixtures of acids used for digestion, the most common of 
which is concentrated Hydrochloric acid. The samples are heated slowly at a high 
temperature. After digestion, the samples are diluted to the appropriate volume with 
deionized H2O.  
II. Elemental Analysis using Atomic Absorption Spectrophotometer 
 The elemental analysis of digested samples have been determined by Atomic 
Absorption Spectrophotometer- Flame technique (AAS model 400 Perkin Elmer). Working 
standard solutions of Fe was prepared from stock standard solution of 1000 ppm from 
MERCK.  Using blank solution to zero the instrument performs the Calibration.  The 
standards are then analyzed and their absorbance recorded.  A graph of Absorbance Vs 
Concentration is plotted.  Calibration of the instrument was repeated periodically during 
operation.  A blank reading was also taken and necessary correction was made during the 
calculation of concentration of various elements. (Table C) 
 The digested material was made upto 100 ml for analysis in an (AAS) atomic 
absorption spectrophotometer (Perkin Elmer). The results were calibrated using standard 
calibration curve. 
 In AAS the Wave Length (nm), Flame type, Lamp source and Calibration range 
(ppm) of different elements have been used, are listed in table. 
Instrumental conditions for elemental analysis 
Element Wavelength nm Light source Flame type 
Iron 386 HCL Air/Ac 
 
Air/Ac: Air-Acetylene; HCL: Hallow cathode lamp 
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ACUTE AND SUB ACUTE TOXICITY STUDY ON KUMARI PARPAM IN 
RODENTS 
Animals:  
             Mice of either sex weighing 25-30g and rats weighing 210-240g were obtained from 
the animal house of Vels University. The animals were used with the approval of the Institute 
animal ethics committee and obtained from Vels University, Chennai. They were fed with a 
balanced standard pellet diet and maintained under standard laboratory conditions, providing 
24-280C temperature, standard light cycle (12 h light, 12 h dark) and water ad libitum. 
Animals were kept in cages with raised floors of wide mesh to prevent coprophagy. Animal 
welfare guidelines were observed during the maintenance period and experimentation. The 
rats were randomly assigned to control and different treatment groups, six animals per group. 
(Approval number: XIII/VELS/PCOL/35/2000/CPCSEA/IAEC/08.08.2012).. The animals 
were acclimatized for one week under laboratory conditions. 
ACUTE TOXICITY STUDY-OECD 425 GUIDELINES 
 Acute oral toxicity test for the Kumari Parpam was carried out as per OECD 
Guidelines 425. As with other sequential test designs, care was taken to ensure that animals 
were available in the appropriate size and age range for the entire study. The test substance 
was administered in a single dose by gavage using a stomach tube or a suitable intubation 
cannula. The fasted body weight of each animal was determined and the dose was calculated 
according to the body weight. After the substance has been administered, food was withheld 
for a further 2 hours in mice. The animals were observed continuously for the first 4 h and 
then each hour for the next 24 h and at 6 hourly intervals for the following 48 h after 
administering of the test drug, to observe any death or changes in general behaviour and other 
physiological activities. Single animals were dosed in sequence usually at 48 h intervals. 
However, the time interval between dosing was determined by the onset, duration, and 
severity of toxic signs. Treatment of an animal at the next dose was delayed until one was 
confident of survival of the previously dosed animal.  
 
Observation of toxicity signs: 
  General behavior, respiratory pattern, cardiovascular signs, motor activities, reflexes, 
change in skin and fur, mortality and the body weight changes were monitored daily. The 
time of onset, intensity, and duration of these signs, if any, was recorded (Table 1).  
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SUB-ACUTE TOXICITY:  
 In a 28-days sub acute toxicity study, twenty four either sex (3+3) rats were divided 
into four groups of 6 rats each. Group I that served as normal control was administered with 
distilled water (p.o.) while groups II, III and IV were administered daily with the Kumari 
Parpam (p.o.) for 28 days at a dose of 50, 100, 200 mg/kg respectively. The animals were 
then observed daily for gross behavioural changes and any other signs of subacute toxicity. 
The weight of each rat was recorded on day 0 and weekly throughout the course of the study, 
food and water consumption per rat was calculated. At the end of the 28 days they were 
fasted overnight, each animal was anaesthetized with diethylether, following which they were 
then dissected and blood samples were obtained by cardiac puncture into heparinised tubes. 
The blood sample collected from each rat was centrifuged with 3000 X g at 4oC for 10 min to 
separate the serum and used for the biochemical assays. (Table 2,3,4) 
 
Hematological and blood biochemical analyses:  
 At the end of the study, all animals were kept fasted for 16-18 h and then anesthetized 
with anesthetic ether on the 28th day. Blood samples for hematological and blood chemical 
analyses were taken from retro orbital vein. Heparinized blood samples were taken for 
determining complete blood count (white blood cell count, differential white blood cell count, 
platelet count, red blood cell count, hematocrit, and hemoglobin) by semiautomated 
hematology analyzer. The serum from non-heparinized blood was carefully collected for 
blood chemistry and enzyme analysis (glucose, blood urea nitrogen (BUN), creatinine, total 
protein, albumin, total and direct bilirubins, serum glutamate-oxaloacetate transaminase 
(SGOT), serum glutamate pyruvate transaminase (SGPT), and alkaline phosphatase (ALP)) 
were automatically determined using autoanalyzer. (Table 5,6,7 ). 
Necropsy:  
 All rats were sacrificed after the blood collection. The positions, shapes, sizes and 
colors of internal organs were evaluated. The Spleen, Testes, Pancrea, Lung, Liver, Brain, 
Heart, Stomach, Intestine, Bone, Ovary, and Kidney tissues were excised from all rats to 
visually detect gross lesions, and weighed to determine relative organs’ weights and 
preserved in 10% neutral formalin for histopathological assessment. The tissues were 
embedded in paraffin, and then sectioned, stained with haematoxylin and eosin and were 
examined microscopically.(Table 8) 
Statistical analysis: 
 Values were represented as mean ± SEM. Data were analysed using one-way analysis 
of variance (ANOVA) and group means were compared using the Tukey-Kramer Multiple 
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Comparisms Test using GraphPad Instat-V3 software. P values < 0.05 were considered 
significant. 
 
RESULTS 
1) All the animals from control and all the treated dose groups up to 200 mg/kg survived 
throughout the dosing period of 28 days. 
2) No signs of major or significant intoxication were observed in animals from lower to 
higher dose groups during the dosing period of 28 days. 
3) Animals from all the treated dose groups exhibited comparable body weight gain with 
that of controls throughout the dosing period of 28 days. 
4) Food consumption of control and treated animals was found to be comparable 
throughout the dosing period of 28days. 
5) Ophthalmoscopic examination, conducted prior to and at the end of dosing period on 
animals from control and all the treated dose groups did not reveal any abnormality. 
6) Haematological analysis conducted at the end of the dosing period on day 28, 
revealed significant abnormalities attributable to the treatment with higher dose. 
7) Biochemical analysis conducted at the end of the dosing period on day 28, revealed 
remarkable abnormalities in urea level. 
8) Functional observation tests conducted at termination revealed no major 
abnormalities. 
9) Urine analysis, conducted at the end of the dosing period in week 4 and at the end of 
recovery period, revealed no abnormality. 
10) Organ weight data of animals sacrificed at the end of the dosing period was found to 
be comparable with that of respective controls. 
11) Gross pathological examination did not reveal any significant abnormality. 
12) Histopathological examination did not reveal any abnormality. 
CONCLUSION: 
      Based on these findings, it was decided as no toxic effect was observed upto 200 mg/kg  
of Kumari Parpam treated via oral route over a period of 28 days. So, it can be concluded that 
the Kumari Parpam can be prescribed for therapeutic use in human with the dosage 
recommendations of upto 200 mg/kg. body weight p.o. 
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HISTOPATHOLOGICAL SLIDES OF VARIOUS ORGANS AFTER THE 
SUBACUTE TOXICITY STUDIES 
 
BONE                                                           BRAIN 
 
HEART                                                      INTESTINE
 
KIDNEY                                                         LIVER 
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LUNG                                                       OVARY 
 
PANCREAS                                     SPLEEN 
 
STOMACH                                           TESTIS 
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PHARMACOLOGICAL STUDY ON KUMARI PARPAM 
MATERIALS AND METHODS: 
 Drug and Stock solution 
 The Kumari Parpam was prepared as per the procedure in traditional Siddha text 
recommendation and made into suspension form using CMC as a suspending agent and used 
in this study. The resulting suspension was then grounded and filtered. The filtrate was stored 
in a refrigerator until use. The suspension was further diluted with 2% CMC so as to achieve 
200mg/ml stock concentration. 
 
Animals: 
 Male albino rats (150-180g) and Mice of either sex weighing 25-30g were used for 
the study. The rats were housed in wire-mesh cages with a 12 h light/dark cycle. They had 
continuous access to food and water during the entire period of experimentation. (Approval 
number: XIII/VELS/PCOL/35/2000/CPCSEA/IAEC/08.08.2012). 
 
Evaluation of Haematinic Activity : 
 Six rats were kept as normal control group (Group 1), while 24 rats were made 
anaemic by oral intubations of phenylhydrazine (10 mg/kg body weight) daily for seven days. 
Rats that developed anaemia with haemoglobin concentration <14 g/dl were recruited for the 
study. Anaemic rats were randomly divided into 5 groups (2 to 6) and treated as follows: 
Group 1: received distilled water (1 ml) daily (normal control), Group 2: received 2% CMC 
(1 ml) daily (anaemic control), Group 3: received oral single dose of the Kumari Parpam 50 
mg/kg body weight/day Group 4: received oral single dose of the Kumari Parpam 100 mg/kg, 
Group 5: received oral single dose of the Kumari Parpam 200 mg/kg Group 6: received oral 
single dose of the heamatinic syrup 2ml/kg body weight/day. The treatment was continued 
for 2 weeks.  
Haematological investigation: 
 Before and after treatment with drug Kumari Parpam blood was collected from the 
retro orbital vein of experimental animals after an overnight fast (T=0) and after 1 and 2 
weeks of treatment with Kumari Parpam, was used for the determination of red blood cell 
count (RBC), haemoglobin (Hb) concentration and packed cell volume (PCV). The mean cell 
volume (MCV), mean cell haemoglobin (MCH) and the mean cell haemoglobin 
concentration (MCHC) were calculated. 
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Statistical analysis 
 Experimental data was analysed using analysis of variance (ANOVA) and Dunnet’s 
‘t’ test to determine significant differences between means. The statistical analysis system 
(INSTAT-V3) package was used for this analysis. 
RESULTS AND DISCUSSION 
 Mortality in the acute oral toxicity test was seen in the dose 1000mg/kg. Hence, one-
tenth, one twentieth and one fifth of the upper bound dose was considered for the further 
pharmacological study. It has been reported that phenyl hydrazine causes oxidative damage 
to red cells by increasing the formation of reactive oxygen species.  
 The changes in the haematological parameters of the rats during the study are 
tabulated. The RBC, Hb, and PCV of rats administered Phenylhydrazine decreased 
significantly (P<0.01) while the MCV and MCH increased giving rise to macrocytic anaemia 
(P<0.05). Kumari Parpam at the dose of 50, 100, 200 mg/kg showed good percentage of 
improving in haemoglobin level, which was almost equivalent to standard treated group 
indicating correction of anaemia induced by Phenyl hydrazine after 14 days treatment.  
 Treatment with Kumari Parpam at the dose levels 100 and 200mg/kg for 14 day 
showed significant increase in RBC (p<0.01) compared to positive control and it was 
comparable to standard drug used in this study. Phenylhydrazine altered the haematological 
parameters by haemolysis characterized by decrease in haemoglobin concentration, total 
RBC counts and PCV on day 7. However, the haematological parameters were restored to 
normal range after treatment with Kumari Parpam for 14 days.  Effective changes was 
observed after one week of treatment of anaemic rats with Kumari Parpam reversed the 
influence of Phenylhydrazine resulting to a significant (P<0.05) increase in RBC, Hb, and 
PCV. The Hb, RBC and PCV reached near normal at the second week of the treatment.    
 Rats treated with Phenylhydrazine (10mg/kg/day for 7 days) resulted in a marked 
haemolytic anaemia characterised by decreased RBC, Hb and PCV. The main function of the 
RBC is the transportation of oxygen in to the tissues of the body. At such, any pathological or 
physiological condition that affects the RBC alters its function and this may be detrimental to 
the body. In this study Phenylhydrazine altered the function of RBC by haemolysis 
characterised by decreased levels of RBC, Hb and PCV. However, this effect was restored 
after one week of Kumari Parpam treatment. Also the recovery was progressive such that 
after 1week of continuous treatment, the Hb concentration and PCV were higher in the 
treated groups than in the normal control group.  
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CONCLUSION 
 In order to provide effective, safe and cheap drug and to prove the traditional claim 
for the treatment of anemic conditions the Kumari Parpam at a dose of 50, 100 and 200 
mg/kg (p.o.), was evaluated and found significantly increased the haemoglobin, haematocrit, 
and RBC count in anaemic rats indicating the Haematinic effect. The rapid and progressive 
recovery of anaemic rats responding to treatment of Kumari Parpam may be due to increased 
erythropoiesis. However, the mechanism of action by which Kumari Parpam produced its 
effect on increasing RBC, Hb and PCV in experimental animals need to be evaluated in a 
scientific manner using specific experimental animal models and also clinical trials are 
required to understand the exact molecular mechanisms of action. Based on the results it can 
be concluded that the Kumari Parpam is a good drug of choice for the anemia at the dose 
level of 100 mg/kg. (Table 1,2, 3). 
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¦ÅÙôÒ §¿¡ö 9 
 
§ÅÚ ¦ÀÂ÷¸û:  
           ¦Åñ¨Á §¿¡ö, À¡ñÎ, ¦ÅñÀ¡ñ¼õ ±ýÀÅÉÅ¡õ. 
 
þÂø:  
          þÂü¨¸ ¿¢Èõ Á¡È¢, ¯¼ø ¦ÅÙòÐ, ¸ñ, ¿¸ì¸ñ þ¨Å¸¨Ç ¿£ì¸¢ô 
À¡÷ì¸¢ø ÌÕ¾¢Â¢ýÈ¢ ¦ÅÙò¾¢ÕìÌõ §¿¡Â¡õ. 
 
§¿¡ö ÅÕõ ÅÆ¢: 
 
 ÌÕ¾¢Â¢ý Åý¨Á¨Âì Ì¨Èì¸ì ÜÊÂ ¯ôÒ, ÒÇ¢ôÒî Í¨ÅÔûÇ 
¦À¡Õû¸¨Ç Á¢Ì¾¢Â¡¸ ¯ñ½ø 
 ÍÃõ, §À¾¢, Å¡ó¾¢, ¸£ø Å¡Ô Ó¾Ä¢Â §¿¡ö¸Ç¢ø ÐýÀôÀ¼ø  
 ÌÕ¾¢¨Â «Ç× ¸¼óÐ ¦ÅÇ¢Â¡ìÌõ ¦ÀÕõÀ¡Î, ÌÕ¾¢ «Æø §¿¡ö, ÌÕ¾¢ì 
¸Æ¢îºø, ÌÕ¾¢ Å¡ó¾¢, Ó¨Ç §¿¡ö Ó¾Ä¢Â §¿¡ö¸Ç¢ø ÐýÀôÀ¼ø 
  ¦ÅðÎôÀð¼ ¸¡Âí¸Ç¢Ä¢ÕóÐ ÌÕ¾¢ Á¢Ì¾¢Â¡¸ ¦ÅÇ¢ôÀ¼ø 
  ¿ïÍò ¾ý¨ÁÔûÇ ÁÕóÐ¸¨Ç ¿¡û «Ç×ìÌ Á¢ïº¢ ¯ñ½ø 
  ¯¼¨Ä þ¨Çì¸î ¦ºöÔõ ÅÂ¢üÚô ÒØ §¿¡ö, ¿¢½ì ¸Æ¢îºÄ¡¸¢Â §¿¡ö¸Ç¢ø 
ÐýÀôÀ¼ø 
  ÌÕ¾¢ô ¦ÀÕì¨¸ì ¦¸Îì¸ì ÜÊÂ ®Ãø §¿¡Â¢ø ÅÕóÐ¾ø 
  Ò¨¸Â¢¨Ä, ¦ÅüÈ¢¨Ä À¡ìÌ, Áñ, º¡õÀø, ¾¢Õ¿£Ú, ¸üâÃõ Ó¾Ä¢Â¨Å¸¨Ç 
«¾¢¸õ ¦¸¡ûÇø ¬¸¢Â þì¸¡Ã½í¸Ç¡ø ¦ÅÙôÒ §¿¡Ôñ¼¡Ìõ. 
 
«றி ணuக:  
 உணவாதிv ெசயகளா தtற மி|¢ ¯திய} நிற{ைத­ எைடைய­ 
ெக{¢, உட´t ேவzய  ஊyட{ைத­  ெகாடாம  உடைல ெவ¶tகv 
ெச­,  
 சி²¢ £ர  நடtகி§ காக  ஓத 
  ெப¯¬v வாuக 
  உணவ வ¯~பமி}ைம 
  வா மyட 
 தைல ற 
  கz இ¯ள 
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  மயtக 
  மாƫ© ¢{த 
 உடலிைள{த ஆகிய றி ணuகைளt காy. 
 
ேநா எz: 
1. வள~பாz  
2. அழ பாz  
3. ஐய~பாz  
4. «tறபாz  
5. நx  பாz 
6. மñ§ñ பாz 
 
த¯ தராதைவ: 
                  நx ெவ¶~© ேநா  த¯ வ¢ அƬ¢, மற ஐ|¢ ெவ¶~© ேநாக தtக 
ம¯|¢களா எளதி ணமா. 
 
ÌüÈõ Ó¾Ä¢Â §ÅÚÀ¡Î¸û : 
               §¾¡ÖìÌ  ¿¢Èò¨¾ì ¦¸¡ÎìÌõ «Æø (þÃïº¾ À¢ò¾õ) ¦ÁÄ¢óÐ, 
¿¢Èò¾¢Öõ ±¨¼Â¢Öõ Ì¨ÈóÐ  ¾£ÌüÈò¨¾ ¦ÀÕì¸¢ «¾ÉÇÅ¡¸ ÁüÈ¨ÈÂ  
ÌüÈí¸Ùõ ¾ýÉ¢¨Ä ¾¢¡¢óÐ, ÀÃ×¸¡Ä¢ý Åý¨Á¨Âì ¦¸ÎòÐ þó§¿¡¨Â  
¯ñ¼¡ìÌõ. 
 
நா நைட: 
                   “தான«ள ேச{¢ம|தா னளகி ெவ~ப 
                    சயமைள இ¯மம| தார காச.....பாz” 
 
                   “கzடாேயா சிேலபன{தி வாத நா...பாz” 
 
                   “சிற~பான ப{ததி வாத நா.. ... பாz” 
 
                    “இடமான ேச{¢ம{தி ப{த நா.. .. பாz” 
 
                      ேச{¢மநா (ஐய) இளகி நி}றா´, ேச{¢மவாத ெதா|த (ஐயவள) 
ஏப§, ப{தவாத ெதா|த (அழவள) ஏப§, ேச{¢ம ப{த ெதா|த (ஐயழ) 
ஏப§, வாத மிதி­ட} சீதள ேசƫ|தா´ பாzேராக உப{திையt றிt.  
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                                           ANAEMIA 10  
 
                   Anaemia may be defined as a state in which the blood haemoglobin level is 
below the normal range for the patient’age and sex (Males < 12g/dL; females<10g/dL). 
 
Causes of Anaemia:- 
 Decreased or ineffective marrow production 
a. Inadequate iron, B12 or folate,trace elements (zinc,cobalt) 
b. Hypoplasia of bone marrow 
c. Infiltration by malignant cells 
 
 Peripheral causes (increases RBC destruction or loss) 
a. Blood loss 
b. Haemolysis 
c. Hypersplenism 
 
Classification of Anaemia:-  
i. Microcytic Anaemias (MCV < 80 fL) 
ii. Macrocytic Anaemias (MCV > 100 fL) 
iii. Normocytic Anaemias (MCV 80-100 fL) 
 
Iron Deficiency Anaemia 
                   Haemoglobin is normally the largest iron compartment of the body. Hb is 0.34% 
iron by weight. In an adult,total iron content of Hb compartment is about 2 gm. 
 
Iron Metabolism 
                    Iron taken in diet is absorbed at all parts of GI tract especially duodenal mucosa. 
Acid medium favours iron absorption. Acid medium favours formation of soluble 
macromolecular complexes of iron with vitamin C,sugar,amino acid or bile in the duodenum. 
Only 10% of the ingested iron is absorbed. Normal serum iron level is 50 to 150 mg/dl. 
  
Frank iron deficiency increases absorption by 30 – 40% and in iron overload, absorption 
decrease. 
 Iron absorption is increased in the below: 
i. Ferrous state 
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ii. Increases erythropoiesis 
iii. Iron deficiency. 
 Iron absorption is decreased in below: 
i. Ferric state 
ii. In the presence of phosphates and phytates 
iii. Bone marrow hypoplasia. 
             
  The absorbed iron is stored in the form of ferritin (water soluble form) and 
haemosiderin (water insoluble form) 
 
Causes of Iron Deficiency 
1. Increased iron utilization (increased demand) 
o Postnatal growth spurt 
o Adolescent growth spurt 
o  Erythropoietin therapy 
2. Physiologic iron loss 
o Menstruation 
o Pregnancy 
3. Pathologic iron loss 
o Gastrointestinal bleeding 
o Genitourinary bleeding 
o Pulmonary haemosiderosis 
o Intravascular haemolysis 
o Phlebotomy for polycythaemia rubra vera 
4. Decrease iron intake 
o Cereal rich diet 
o Pica, food fads, malabsorption 
o Acute or chronic inflammation. 
 
Stages in Iron Deficiency Anaemia 
There are three stages in the development of iron deficiency anaemia. 
1. Negative iron balance 
2. Iron deficient erythropoiesis 
3. Iron deficeint anaemia. 
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Clinical Features 
 
Patients may have  
 angular stomatitis 
 atrophic glossitis 
 koilonychia 
 brittle hair 
 pruritis 
 pica 
 Plummer-Vinson syndrome(postcricoid web) or  
 menorrhagia. 
 
Investigations: 
 Hemoglobin 
 Hematocrit value (PCV) 
 MCV,MCH, MCHC 
 Peripheral smear study 
 Serum ferritin 
 Total iron binding capacity 
 Serum transferrin 
 Serum Iron 
 
 
 
 
 
 
 
 
91 
 
CLINICAL STUDY 
 Preclinical and clinical study on “KUMARI PARPAM” for “HAEMATINIC ACTIVITY” 
in the management of  Pandu (Anaemia). 
Approval No. NIS/ IEC/ 2011/ 3/ 12b 
 
POPULATION AND SAMPLE SIZE: 
   20 patients of both sexes were enrolled from the Outpatient and Inpatient 
department of Ayothidass Pandithar Hospital of National Institute of Siddha, Chennai-47.  
 
SUBJECT SELECTION: 
 INCLUSION CRITERIA:  
 Age      : 18-65 yrs  
 Sex       : both male and female  
Weight : 35-85 kgs  
                        Patient having symptoms of 
 Tiredness 
 Dyspnoea on exertion 
 Giddiness 
 Headache 
 Insomnia 
 Palpitation 
 Poor appetite 
                        Patient who are willing to provide blood for lab investigation.  
             Patients who are willing to attend OPD once in 7 days.  
             Patient willing to sign the informed consent stating that he/she  
conscientiously stick to the treatment during 30 days but can opt out of the trial of his/her 
own conscious discretion. 
 
EXCULSION CRITERIA: 
 Pregnancy and lactation 
 Known case of cirrhosis and chronic renal failure 
 Patient receiving Anti-tuberculosis drugs 
 Known case of Hypothyroidism 
 Chronic blood loss 
 Any other serious illness 
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 WITHDRAWAL CRITERIA: 
 Development of any adverse reaction  
 Occurence of any other serious illness 
 Non co-operation of the patient 
 
TREATMENT: 
 The drug Kumari Parpam was administered internally in a dose of 488 mg b.d with 
honey (after food) for 30 days. 
 
CONDUCT OF THE CLINICAL TRIAL: 
Anaemia patients satisfying the inclusion criteria were admitted to the trial. Patient 
was informed about the trial and consent form was obtained. For Out-patients the trial drug 
was issued for seven days course. Weekly clinical assessment was done during review visit to 
the hospital. 
 
The following investigations were done before and at the end of the treatment.        
 Blood sample (Hb, TC, DC, ESR, HCT/PCV, MCV, MCH, MCHC, and smear study, 
Sugar (F, PP), AEC, T.cholesterol, RFT and LFT) 
 Urine test (Albumin, Sugar, Deposits) 
 Motion test (ova, cyst, albumin) 
 
CLINICAL OBSERVATION: 
 
 For the clinical study of “Kumari Parpam” on Pandu, 20 patients were selected. 
 Among 20 patients, 18(70 %) were in female, 2(30%) were in male. 
 According to age wise distribution 30%were in 20-35 years, 55% were in 36-50years 
and 15% were in 51-65 years. 
 Among 20 patients, 18 patients were pallor, 13 patients were affected from 
breathlessness, 20 patients were affected from tiredness, 19 patients were affected 
with giddiness, 18 patients were affected from anorexia, 6 patients were affected with 
pica, and 15 were affected with palpitation.  
 
 From the clinical study, 61%  patient relieved from pallor, 69% patient relieved from 
breathlessness, 60% patient relieved from tiredness, 63%  patient relieved from 
giddiness, 66.7% patient relieved from anorexia, 66.7% patient relieved from pica, 
66.7% patient relieved from palpitation and no adverse effects were observed during 
trial period. 
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DISCUSSION 
 The drug Kumari Parpam was selected to find out the Haematinic activity in the 
management of Pandu (Anaemia). 
  The literary evidence from the text Agathiyar 2000 strongly supports Haematinic 
activity of the drug.   
Bio-chemical analysis: 
      Biochemical analysis of the drug Kumari Parpam reveals the presence of sulphate, 
sodium, chloride, iron, calcium, tannic acid, amino acid and alkaloids. 
Iron: 
 It helps in the formation of heme, which is joined with globin to form the 
haemoglobin. 
 It is one of the RBC maturation factor. 
Calcium: 
 It increases iron absorption from GIT. 
Sulphate: 
 It is useful for the absorption of iron from mucosa. 
Atomic Absorption Spectrophotometer: 
 The elemental analysis of digested sample has been determined by Atomic 
Absorption   Spectrophotometer. 
 By AAS, Iron content (Fe ppm) in the trial drug was caluculated as 0.132ppm. This 
strongly supports the Haematinic activity of the drug Kumari Parpam. 
 
Toxicological studies: 
Acute oral toxicity study: 
 Mortality in the acute oral toxicity test was seen in the dose 1000mg/kg. Hence, one-
tenth, one twentieth and one fifth of the upper bound dose was considered for the 
further pharmacological study. 
  As per OECD 425 guidelines the dose is said to be “Unclassified” under the toxicity 
scale. Hence further study with higher doses was not executed. 
Sub-acute toxicity for 28 days: 
 
 Based on this study,  no toxic effect was observed upto 200 mg/kg  of Kumari Parpam 
treated via oral route over a period of 28 days.  
 28 days treatment with the drug did not alter the haematological and biochemical 
parameters in animals.  
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 So, it can be concluded that the Kumari Parpam can be prescribed for therapeutic use 
in human with the dosage recommendations of upto 200 mg/kg. body weight p.o. 
Pharmacological studies: 
 Kumari Parpam at the dose of 50, 100 and 200 mg/kg showed good percentage of 
improvement in haemoglobin level, which was almost equivalent to standard treated 
group indicating correction of anaemia induced by Phenyl hydrazine after 14 days 
treatment. 
 The Kumari Parpam at a dose of 50, 100 and 200 mg/kg (p.o.), was evaluated and 
found significantly increased the haemoglobin, haematocrit, and RBC count in 
anaemic rats indicating the Haematinic effect.  
  Based on the results it can be concluded that the Kumari Parpam is a good drug of 
choice for the anemia at the dose level of 100mg/kg. 
Clinical observation:                 
 From the clinical study, 61%  patient relieved from pallor, 69% patient relieved from 
breathlessness, 60% patient relieved from tiredness, 63%  patient relieved from 
giddiness, 66.7% patient relieved from anorexia, 66.7% patient relieved from pica, 
66.7% patient relieved from palpitation and no adverse effects were observed during 
trial period. 
Bio-statistics: 
 Statistically, the paired‘t’ test shows statistical significance for the symptomsbefore 
and after the treatment.(p<0.0001).  
 Also, the paired ‘t’ test shows statistical significance for the Hb level before and after 
the treatment (p<0.0001). 
 
 Siddha aspect: 
 Siddha system of medicine strongly relies on cordial relationship between suvai and 3 
vital forces. 
 The principle aim in the treatment aspect is to make the deranged vital forces into 
normal by giving the trial drug that has thuvarppu suvai. 
 According to Siddha basic principles, function of thuvarppu suvai is the purification 
of blood and it is also important for RBCs formation. 
      
 Hence KUMARI PARPAM is a better drug of choice in the management of PANDU 
(Anaemia). 
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SUMMARY 
 
 The drug Kumari Parpam has been selected for this study to evaluate its efficacy on the 
Haematinic activity in the management of Pandu (Anaemia).  
 The literary evidence strongly supports the Haematinic activity of Kumari Parpam. 
 The qualitative and quantitative analysis were done at Biochemistry lab,NIS and Sri 
Ramachandra University, Chennai respectively. Biochemical analysis of the drug Kumari 
Parpam reveals the presence of sulphate sodium, chloride, iron, calcium, tannic acid, 
amino acid  and alkaloids.  
 The elemental analysis of sample has been determined by Atomic Absorption 
Spectrophotometer and it was  done  at Sri Ramachandra University, Chennai. 
 Preclinical evaluation (acute and sub-acute toxicity study) of the drug was carried out as 
per OECD guideline in Vels College of pharmacy, Chennai. In the toxicological studies, 
the drug does not exhibit any mortality upto the dose of 400 mg/kg/po. 
 Preclinical pharmacological study was carried out in animal model in Vels College of 
Pharmacy, Chennai. In the pharmacological studies, the drug Kumari Parpam exihibits 
significant Haematinic activity. 
 From the clinical study, 61%  patient relieved from pallor, 69% patient relieved from 
breathlessness, 60% patient relieved from tiredness, 63%  patient relieved from giddiness, 
66.7% patient relieved from anorexia, 66.7% patient relieved from pica, 66.7% patient 
relieved from palpitation and no adverse effects were observed during trial period. 
 From the statistical analysis-paired‘t’ test, the drug Kumari Parpam is statistically 
significant. Statistically, the paired‘t’ test shows statistical significance for symptoms 
before and after the treatment.(p<0.0001) 
 The drug Kumari Parpam has 
 Haematinic activity 
 No side effects 
 No undoing effects 
 Encouraging clinical results. 
 From the clinical and statistical analysis it is proved that the drug KUMARI PARPAM is 
statistically significant on Haematinic activity in the management of  PANDU (Anaemia). 
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CONCLUSION 
 
 The literary evidence from the text Agathiyar 2000 shows Kumari Parpam has 
Haematinic activity. 
 
 The safety studies (acute toxicity and sub-acute toxicity) studies conducted revealed 
that the trial drug Kumari Parpam is safe. There were no abnormalities found in blood 
investigation and histo-pathological examination. Hence it can be reasonably assumed 
that the drug is safe for human use. 
 
 From Atomic Absorption Spectrophotometer, iron content of the trial drug, was 
calculated as 0.132ppm, which shows its Haematinic activity. 
 
 The pharmacological study conducted in animal model shows significant Haematinic 
activity. 
 
 Clinical study revealed the therapeutic efficacy of the trial drug by showing raise in 
Haemoglobin, Haematocrit value, TRBC significantly. There was improvement in 
other clinical symptoms before and after treatment. 
 
 There were no adverse reactions complained during the clinical trial. 
 
 Hence, the drug KUMARI PARPAM can be used in the management of PANDU 
(Anaemia). 
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PHYSICAL PROPERTIES: (Table A) 
 
S.NO Characteristic test Results 
1 pH 5.06 
2 Ash Value 0.95 
3 Water soluble ash 0.00 
4 Acid insoluble ash 0.04 
 
QUALITATIVE ANALYSIS: 
 
S.NO PARAMETERS RESULTS 
1 Calcium Present 
2 Sulphate Present 
3 Magnesium Absent 
4 Iron Present 
5 Aminoacids Absent 
6 Starch Present 
7 Flavonoids Absent 
8 Phosphate Absent 
9 Tannic acid Present 
10 Glucose Present 
 
109 – HPTLC Profile 
 
 
254nm 
254nm 3D display 
 
5µl (254nm) 
 
10 µl (254nm) 
298nm 
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298 nm 3D display 
 
5µl (298nm) 
 
10µl (298nm) 
Derivatisation (298nm) 
 
100 
 
298 nm 3D display 
 
 
Derivatisation 5µl (298nm) 
 
Derivatisation 10µl (298nm) 
Derivatisation (498nm) 
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489 nm 3D display 
 
Derivatisation 5µl (498nm) 
 
Derivatisation 10µl (498nm) 
  Fingerprint chromatogram of RH -1 at 404nm 
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Table 1: Dose finding experiment and its behavioral Signs of Toxicity 
 
No 
Dose 
mg/kg 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 
1 500 + - - + - + - - - - - - - - - - - - - - 
2 1000 + - - + - + - - - - - - - - - - - - - - 
3 2000 + - - + - + - - - - - - - - - - + - - - 
1. Alertness 2. Aggressiveness 3. Pile erection 4. Grooming 5. Gripping  6. Touch Response 7. Decreased Motor 
Activity 8. Tremors 9. Convulsions 10. Muscle Spasm 11. Catatonia 12. Muscle relaxant 13. Hypnosis 14. 
Analgesia 15.Lacrimation 16. Exophthalmos 17. Diarrhoea 18. Writhing 19. Respiration 20. Mortality 
 
 
Table 2. Body wt (g) of albino rats exposed to Takkolathi Chooranam for 28days. 
 
Dose (mg/kg/day) 
Days 
1 7 14 21 28 
Control 124.724.22 122.625.12 125.105.12 127.124.88 128.125.00 
100 126.154.16 125.304.00 128.205.13 131.007.15 135.216.46 
200 123.353.46 125.615.52 125.874.54 128.325.10 129.007.25 
400 132.205.77 134.115.15 136.424.82 135.195.43 135.208.00 
Values are mean  S.E.M. (Dunnet’t' test). nsP > 0.05; Vs Control N=6. 
 
Table 3. Food (g/day) intake of rats exposed to Takkolathi Chooranam for 28days. 
 
Dose (mg/kg/day) 
Days (gms/rats) 
1 7 14 21 28 
Control 46.122.40 45.362.72 45.982.28 45.082.28 47.113.46 
100 44.402.56 45.122.44 45.582.36 47.312.45 48.313.85 
200 42.152.48 42.452.88 46.222.54 46.993.00 46.213.12 
400 44.062.77 45.202.76 47.302.66 48.022.54 48.643.02 
Values are mean  S.E.M. (Dunnet’t' test). nsP > 0.05; Vs Control N=6. 
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Table 4. Water (ml/day) intake of rats exposed to Takkolathi Chooranam for 28days. 
 
 
Days(ml/rat) 
Dose (mg/kg/day) 
1 7 14 21 28 
Control 50.122.48 51.643.58 52.463.10 52.113.23 53.003.35 
100 51.562.55 51.123.10 51.003.69 52.463.18 54.552.46 
200 51.242.96 53.103.05 52.223.44 52.362.82 55.123.21 
400 50.483.02 52.823.12 50.123.02 51.553.12 55.663.12 
Values are mean  S.E.M. (Dunnet’t' test). nsP > 0.05; Vs Control N=6. 
 
 
Table 5. Hematological parameters after 28days treatment with Takkolathi Chooranam in rats. 
 
Parameter Control 100 mg/kg 200 mg/kg 400 mg/kg 
RBC (millions/cu.mm) 5.21±0.38 5.10±0.30 5.48±0.36 5.98±0.28 
Hb (g/dl) 13.25±0.31 13.56±1.1 13.32±1.4 13.10±1.2 
PCV (%) 45.02±1.46 44.2±2.0 44.58±2.2 45.12±2.4 
WBC(cells/cu.mm) 7375±440.17 7425±329.2 7224±325.1 7458±425.2 
Neutrophil (%) 52.45±4.22 54.21 ±3.21 49.34±3.14 48.64±3.42 
Lymphocytes (%) 40.00±2.23 41.2±3.1 47.21±3.2 48.11±3.5 
Eosinophil’s (%) 6.24±0.66 5.68±0.54 5.95±0.45 5.77±0.42 
Monocytes (%) 4.1±0.2 3.2±0.2* 3.4±0.3 3.3±0.2 
Basophils (%) 0±0 0±0 0±0 0±0 
Platelets (105 cells/cu.mm) 1.46±0.06 1.55±0.07 1.78±0.05** 1.46±0.04 
MCV(Fl) 79.2±2.0 81.5±1.5 80.1±2.1 82.2±2.4 
MCHC (pg) 25.2±1.2 24.00±1.4 25.2±1.0 26.05±1.5 
Values are mean of 6 animals  S.E.M. (Dunnett's test). *P<0.05; **P<0.01. N=6. 
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Table 6. Effect of treatment with Takkolathi Chooranam biochemical (LFT, RFT, and 
Lipid Profile) Parameters in rats. 
 
Parameter Control 100 mg/kg 200 mg/kg 400 mg/kg 
Glucose (mg/dL) 78.11±7.00 72.53±6.88 69.56±8.04 74.30±7.12 
Total Bilirubin (mg/dL) 0.2060.05 0.2040.06 0.2050.05 0.2000.04 
Bilirubin direct (mg/dL) 0.10.03 0.10.03 0.10.04 0.10.04 
Creatinine (mg/dL) 0.92±0.04 0.93±0.05 0.94±0.03 0.95±0.04 
BUN (mg/dL) 19.20±1.55 18.58±1.12 18.75±1.56 18.41±1.32 
AST (IU/L) 126.1±7.10 124.2±6.05 127.1±5.00 122.4±5.02 
ALT (IU/L) 34.10±3.21 32.88±2.79 34.46±2.58 35.96±2.47 
ALP (IU/L) 77.05±4.29 68.12±4.00 66.52±4.34 67.10±4.20 
Total cholestrol (mg/dL) 59.18±5.44 57.00±5.21 56.75±5.00 57.10±4.92 
Total protein (g/dL) 7.99±0.70 7.48±0.58 7.52±0.72 7.64±0.70 
Albumin (g/dL) 2.54±0.05 2.70±0.06 2.72±0.04* 2.68±0.04 
Urea(mg/dL) 54.482.98 56.083.88 55.142.55 56.451.77 
Uric acid (mg/dL) 1.940.10 1.280.15** 1.310.14** 1.280.12** 
Na m.mol 142.645.12 141.75.06 140.724.56 140.214.88 
K m.mol 21.462.37 18.201.82 21.201.99 20.202.54** 
Cl m.mol 100.005.10 100.445.00 98.785.42 100.125.00 
HDL(mg/dL) 13.161.45 13.081.56 13.431.12 13.002.88 
LDL(mg/dL) 42.222.80 42.293.08 42.003.61 42.203.00 
VLDL(mg/dl) 16.452.00 16.162.48 16.361.97 15.881.56 
Triglycerides (mg/dl) 87.523.02 86.102.09 87.163.00 87.472.62 
Values are mean of 6 animals  S.E.M. (Dunnet's test). *P<0.05; **P<0.01. Vs Control group  
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Table-7 Urine Analysis 
 
Parameters Control 100 mg/kg 200 mg/kg 400 mg/kg 
Colour Yellow Yellow Yellow Yellow 
Transparency Clear Slightly turbid Slightly cloudy Slightly turbid 
Specific gravity 1.01 1.01 1.01 1.01 
PH >7.2 >8.0 >8.0 >9.0 
Protein Nil 3+ 3+ 3+ 
Glucose Nil Nil Nil Nil 
Bilirubin -ve -ve -ve -ve 
Ketones -ve +ve +ve +ve 
Blood Absent Absent Absent Absent 
Urobilinogen Normal Abnormal Abnormal Abnormal 
Pus cells 0-cells/HPF 1-cell/HPF 2-cells/HPF 1-cell/HPF 
RBCs Nil Nil 0-1cells/HPF Nil 
Epithelial cells Nil 1-cell/HPF Nil 1-cell/HPF 
Crystals Nil Nil Nil Nil 
Casts Nil Nil Nil Nil 
Others Bacteria seen Bacteria seen Bacteria seen Bacteria seen 
Values are mean of 6 animals  S.E.M. (Dunnett's test). *P<0.05; **P<0.01. vs. control group  
 
Table 8. Effect of oral administration of Takkolathi Chooranam on organ weight 
 
Dose (mg/kg) Control 100 mg/kg 200 mg/kg 400 mg/kg 
Heart(g) 0.69±0.06 0.58±0.11 0.60±0.09 0.59±0.04 
Liver(g) 4.52±0.52 4.19±0.41 4.92±0.60 4.82±0.45 
Lung(g) 0.74±0.04 0.68±0.06 0.72±0.05 0.68±0.1 
Spleen(g) 0.64±0.12 0.69±0.04 0.71±0.06 0.66±0.05 
Kidney(g) 1.28±0.3 1.23±0.03 1.26±0.2 1.42±0.05 
Testis(g) 1.02±0.03 0.98±0.05 0.92±0.04 0.94±0.03 
Ovary(g) 0.04±0.01 0.04±0.01 0.04±0.02 0.04±0.02 
Brain 0.79±0.06 0.76±0.05 0.77±0.04 0.75±0.04 
Pancreas 1.44±0.06 1.35±0.07 1.38±0.09 1.42±0.10 
Uterus 0.70±0.08 0.74±0.09 0.71±0.05 0.70±0.06 
Values are mean  S.E.M. (Dunnet’t' test). nsP > 0.05; Vs Control N=6. 
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PHARMACOLOGICAL STUDY 
 
Table-1: Effect of Takkolathi Chooranam on isolated Guinea pig ileum preparation 
  
Sl. 
No 
Dose of Histamine (µg/ml) 
Percent of maximum response 
Histamine alone Histamine+Takkolathi Chooranam (% of Inhibition) 
1 10 1.85±0.17 1.12±0.12 (38.88%)* 
2 20 2.21±0.21 1.56±0.63 (31.81%)* 
3 40 2.86±0.32 1.70±0.44 (40.55%)* 
Values are expressed in mean ± SEM, *p< 0.01 compared with histamine induced 
contraction (28mm as 100%); n=3.    
 
 
 
Table-2: Bronchodilator effect of Takkolathi chooranam on Histamine induced 
Bronchoconstriction. 
 
Treatment 
Pre-Treatment 
Exposition in seconds 
Post-Treatment 
Exposition in seconds 
% Protection 
Takkolathi Chooranam 100mg/kg. p.o. 94.27 ±3.48 112.91±4.11 16.50% 
Takkolathi Chooranam  200mg/kg. p.o. 102.56±3.82 131.28±4.76** 21.87% 
Takkolathi Chooranam 400mg/kg. p.o. 97.21±4.00 139.63±5.02** 30.38% 
Promethazine  
105.50±4.33 162.42±5.12** 35.04% 
(300mg/kg, p.o) 
 
N=6; Values are expressed as mean ± SEM; *Significant between pre and post treatment time 
(Student’s –‘t’) **P<0.01. 
 
 
 
 
 
ANTI HISTAMINE ACTIVITY OF TAKKOLATHI CHOORANAM IN GUINEA 
PIG: 
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 STATISTICAL ANALYSIS: 
Paired t test for Symptoms before and after treatment for Eraippu patients:  
 
Variable Obs Mean Std.dev t.value P value 
BTSym 20 4.1 1.071 
13.21 P<0.0001 
ATSym 20 1.15 1.424 
                   
 
Symptoms before treatment is 4.10  and after treatment is 1.15 which is statistically 
significant(p<0.0001). 
 
Paired t test for PEFR before and after treatment for Eraippu patients: 
 
Variable Obs Mean Std.dev t.value P value 
BT PEFR 20 183.5 21.831 
-8.73 P<0.0001 
AT PEFR 20 226.5 26.413 
 
 
PEFR before treatment is 183.50 and after treatment is 226.50 which is statistically 
significant(p<0.0001). 
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                                CLINICAL STUDY 
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AGE DISTRIBUTION 
Percentage
1 20-35
2 36-50
3 51-65
30%
70%
GENDER DISTRIBUTION  
No of patients
1 M
2 F
GENDER DISTRIBUTION 
SL 
No Gender 
No of 
patients Percentage 
1 M 6 30 
2 F 14 70 
AGE DISTRIBUTION 
SL 
No 
Age 
(years) Percentage 
1 20-35 60 
2 36-50 30 
3 51-65 10 
  
IMPROVEMENT SHOWING SIGNS & SYMPTOMS BEFORE AND AFTER 
TREATMENT OF ERAIPPU PATIENTS 
SL 
No Symptoms 
No of patients with symptoms 
Improvement 
percentage BT 
AT 
No 
Improvement Improvement 
1 Wheeze 20 5 15 75 
2 Dyspnoea 16 4 12 75 
3 Cough 19 5 14 74 
4 Chest tightness 10 2 8 80 
5 Expectoration 17 6 11 65 
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PROGNOSIS IN SIGNS AND SYMPTOMS OF BRONCHIAL ASTHMA 
SL 
NO 
OP/IP 
No 
Name Wheeze Dyspnoea Cough Chest 
Tightness 
Expectoration 
BT AT BT AT BT AT BT AT BT AT 
1 3951 Mrs.G.Dhanaselvi + - + - + + + - + - 
2 4241 Miss.Chitra + - + + + + + + + + 
3 4263 Mrs.Muniyammal + - - - + - - - + - 
4 4271 Mrs.Esweri + + + - + - + - + + 
5 C82597 Mr.R.Ranjit + - + - + - - - + - 
6 C83283 Mrs.Sujatha + - + - + + + - + + 
7 C83365 Mrs.G.Revathy + - - - + - - - + - 
8 C83360 Mr.Bharathi Mohan + - + - + - - - + - 
9 C80148 Mrs.B.Komala + - + - + - + - + + 
10 C78368 Mrs.Dhanalakshmi + - + - + - - - + - 
11 C84545 Mr.P.Hariharan + - - - + - - - - - 
12 C86210 Mrs.B.Sirumbai + + + + + - + - + - 
13 C85376 Mrs.Amuthavalli + + + - + + + + + - 
14 C85322 Mrs.K.Panchatcharam + + + - + - + - + + 
15 C93190 Mrs.S.Venda + - + - + - - - + - 
16 C89071 Mr.M.Muralidharan + - + - - - - - - - 
17 C85704 Mrs.A.R.Anandhi + + + + + + + - + + 
18 C85145 Mr.Selvapalani + - - - + - - - + - 
19 C88370 Miss.Asmathnisha + - + - + - - - - - 
20 C58877 Mr.Sathish Kumar + - + + + - + - + - 
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LAB INVESTINGATIONS – BEFORE TREATMENT BRONCHIAL ASTHMA PATIENTS 
SL 
No 
OP/IP 
No Age/Sex Hb TC 
Dc (in %) ESR (mm/hr) BS (mg/dl) 
AEC  Urea Creat  OT  PT Al.P  T.Chol  
Urine 
P L E M 1/2 1 F PP/R Alb Sug 
Dep 
Pus 
cells 
Epi 
cells 
1 3951 34/F 11.2 12000 70 22 6 2 6 14 80 130 450 20 0.7 25 22 168 170 Nil Nil 1-2 1-2 
2 4241 28/F 12.3 10000 60 28 12 0 6 12 92 120 420 28 0.9 33 30 130 194 Nil Nil 1-2 1-2 
3 4263 35/F 10.5 10500 70 23 7 0 4 8 100 130 350 20 0.7 25 22 96 210 Nil Nil 1-2 2-3 
4 4271 42/F 11.8 11000 66 26 8 0 6 12 98 126 630 16 0.8 21 18 130 206 Nil Nil 1-2 2-3 
5 C82597 33/M 10.8 11000 71 21 8 0 6 10 102 131 500 21 0.7 26 23 120 214 Nil Nil 2-3 1-2 
6 C83283 42/F 14.3 8000 67 25 6 2 8 14 104 127 180 17 0.6 22 19 168 218 Nil Nil 1-2 1-2 
7 C83365 47/F 13.8 8500 64 29 6 1 40 16 99 124 266 28 0.9 33 30 192 208 Nil Nil 1-2 1-2 
8 C83360 25/M 13.9 11300 74 15 11 0 6 18 101 134 412 24 0.8 29 26 216 212 Nil Nil 2-3 1-2 
9 C80148 30/F 13 9000 72 22 6 0 8 10 100 132 444 22 0.7 27 24 120 210 Nil Nil 1-2 2-3 
10 C78368 48/F 10 9400 70 23 5 2 6 10 98 130 233 20 0.7 25 22 120 206 Nil Nil 1-2 1-2 
11 C84545 39/M 14 7000 69 23 8 0 12 18 103 129 560 19 0.6 24 21 216 216 Nil Nil 2-3 2-3 
12 C86210 58/F 10.8 6800 63 31 6 0 8 20 106 123 388 32 1.1 37 34 240 222 Nil Nil 2-3 1-2 
13 C85376 25/F 12.8 10200 66 19 14 1 12 18 110 126 777 24 0.8 29 26 216 210 Nil Nil 1-2 1-2 
14 C85322 54/F 13 9700 69 19 12 0 12 16 104 129 540 19 0.6 24 21 192 218 Nil Nil 1-2 1-2 
15 C93190 25/F 12.5 6900 73 20 6 1 8 12 98 133 460 23 0.8 28 25 144 206 Nil Nil 1-2 2-3 
16 C89071 30/M 14.2 7800 70 25 5 0 6 10 96 130 356 20 0.7 25 22 120 202 Nil Nil 2-3 1-2 
17 C85704 31/F 9.8 8200 64 31 5 0 8 16 84 124 288 35 1.2 40 37 192 178 Nil Nil 1-2 1-2 
18 C85145 39/M 13.8 9200 62 20 15 3 8 10 110 122 420 22 0.7 27 24 120 203 Nil Nil 1-2 1-2 
19 C88370 20/F 10.2 10400 68 27 5 0 6 12 108 128 322 18 0.6 23 20 144 226 Nil Nil 2-3 2-3 
20 C58877 24/M 14 6800 70 21 8 1 8 12 104 130 350 20 0.7 25 22 123 218 Nil Nil 1-2 1-2 
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LAB INVESTINGATIONS – AFTER TREATMENT BRONCHIAL ASTHMA PATIENTS 
SL 
No 
OP/IP 
No Age/Sex Hb  TC 
Dc (in %) ESR (mm/hr) 
BS 
(mg/dl) 
AEC  Urea Creat  OT    PT  Al.P T.Chol  
Urine 
P L E M 1/2 1 F PP/R Alb Sug 
Dep 
Pus 
cells 
Epi 
cells 
1 3951 34/F 11.4 12000 74 22 3 1 6 12 81 137 165 20 0.7 25 24 171 172 Nil Nil 1-2 1-2 
2 4241 28/F 12.5 10000 66 28 6 0 4 10 90 129 244 28 0.9 21 32 133 196 Nil Nil 1-2 1-2 
3 4263 35/F 10.7 10500 70 23 5 2 6 4 92 133 240 20 0.7 22 24 99 212 Nil Nil 1-2 2-3 
4 4271 42/F 12 11000 70 26 4 0 3 10 92 133 420 16 0.8 25 20 133 208 Nil Nil 1-2 2-3 
5 C82597 33/M 11 11000 74 21 5 0 2 12 92 137 350 21 0.7 24 25 123 216 Nil Nil 2-3 1-2 
6 C83283 42/F 14.5 8000 72 25 3 0 6 12 95 135 150 17 0.6 25 21 171 220 Nil Nil 1-2 1-2 
7 C83365 47/F 14 8500 63 29 6 2 8 12 94 126 270 28 0.9 26 32 195 210 Nil Nil 1-2 1-2 
8 C83360 25/M 14.1 11300 78 15 6 1 4 14 88 141 310 24 0.8 27 28 219 214 Nil Nil 2-3 1-2 
9 C80148 30/F 13.2 9000 72 22 5 1 8 12 91 135 222 22 0.7 29 26 123 212 Nil Nil 1-2 2-3 
10 C78368 48/F 10.2 9400 69 23 6 2 6 8 91 132 230 20 0.7 29 24 123 208 Nil Nil 1-2 1-2 
11 C84545 39/M 14.2 7000 71 23 6 0 8 12 93 134 300 19 0.6 33 23 219 218 Nil Nil 2-3 2-3 
12 C86210 58/F 11 6800 63 31 4 2 4 16 99 126 190 32 1.1 24 36 243 224 Nil Nil 2-3 1-2 
13 C85376 25/F 13 10200 70 19 10 1 6 12 95 133 400 24 0.8 25 28 219 212 Nil Nil 1-2 1-2 
14 C85322 54/F 13.2 9700 72 19 8 1 8 12 92 135 269 19 0.6 28 23 195 220 Nil Nil 1-2 1-2 
15 C93190 25/F 12.7 6900 77 20 2 1 4 8 89 140 193 23 0.8 33 27 147 208 Nil Nil 1-2 2-3 
16 C89071 30/M 14.4 7800 69 25 5 1 4 6 91 132 290 20 0.7 37 24 123 204 Nil Nil 2-3 1-2 
17 C85704 31/F 10 8200 63 31 4 2 2 4 88 126 189 35 1.2 40 39 195 180 Nil Nil 1-2 1-2 
18 C85145 39/M 14 9200 72 20 8 0 4 8 95 135 280 22 0.7 27 26 123 205 Nil Nil 1-2 1-2 
19 C88370 20/F 10.4 10400 68 27 5 0 2 10 98 131 166 18 0.6 23 22 147 228 Nil Nil 2-3 2-3 
20 C58877 24/M 14.2 6800 73 21 5 1 4 12 93 136 211 20 0.7 25 24 126 220 Nil Nil 1-2 1-2 
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LAB INVESTIGATIONS – PEFR BRONCHIAL ASTHMA PATIENTS 
SL 
No 
OP/IP 
No Name Age/Sex 
Peak Expiratory Flow 
Rate 
Before 
treatment 
After 
treatment 
1 3951 Mrs.G.Dhanaselvi 34/F 150 180 
2 4241 Miss.Chitra 28/F 160 210 
3 4263 Mrs.Muniyammal 35/F 170 220 
4 4271 Mrs.Esweri 42/F 170 230 
5 C82597 Mr.R.Ranjit 33/M 180 180 
6 C83283 Mrs.Sujatha 42/F 170 210 
7 C83365 Mrs.G.Revathy 47/F 190 220 
8 C83360 Mr.Bharathi Mohan 25/M 200 250 
9 C80148 Mrs.B.Komala 30/F 180 230 
10 C78368 Mrs.Dhanalakshmi 48/F 230 250 
11 C84545 Mr.P.Hariharan 39/M 190 260 
12 C86210 Mrs.B.Sirumbai 58/F 170 220 
13 C85376 Mrs.Amuthavalli 25/F 200 200 
14 C85322 Mrs.K.Panchatcharam 54/F 160 220 
15 C93190 Mrs.S.Venda 25/F 190 270 
16 C89071 Mr.M.Muralidharan 30/M 200 280 
17 C85704 Mrs.A.R.Anandhi 31/F 180 220 
18 C85145 Mr.Selvapalani 39/M 220 230 
19 C88370 Miss.Asmathnisha 20/F 160 210 
20 C58877 Mr.Sathish Kumar 24/M 220 240 
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PHYSICAL PROPERTIES: (Table B) 
S.NO Characteristic test Results 
1 pH 3.90 
2 Ash Value 0.06 
3 Water soluble ash 0.03 
4 Acid insoluble ash 0.03 
 
QUALITATIVE ANALYSIS: 
S.NO PARAMETERS RESULTS 
1 Calcium Present 
2 Sulphate Present 
3 Sodium Present 
4 Iron Present 
5 Chloride Absent 
6 Starch Present 
7 Flavonoids Absent 
8 Aminoacids Absent 
9 Tannic acid Present 
10 Glucose Absent 
    
Table C: 
ATOMIC ABSORPTION SPECTROPHOTOMETER 
METAL CONTENT: 
SAMPLE NAME Fe (ppm) Zn (ppm) K(ppm) Na (ppm) Ca (ppm) Mg (ppm) 
KUMARI PARPAM 0.13 - - - - - 
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Table 1: Dose finding experiment and its behavioral Signs of Toxicity 
No 
Dose 
mg/kg 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 
1 500 + - - + - + - - - - - - - - - - - - - - 
2 1000 + - - + - + - - - - - - - - - - - - - - 
3 2000 + - - + - + - - - - - - - - - - - - -  - 
1. Alertness 2. Aggressiveness 3. Pile erection 4. Grooming  5. Gripping  6. Touch Response 
7. Decreased Motor Activity 8. Tremors 9. Convulsions 10. Muscle Spasm 11. Catatonia 12. 
Muscle relaxant 13. Hypnosis 14. Analgesia 15.Lacrimation 16. Exophthalmos 17. Diarrhoea 
18. Writhing 19. Respiration 20. Mortality 
 
 
Table 2. Body wt (g) of rats exposed to Kumari Parpam for 28days. 
Dose 
(mg/kg/day) 
Days 
1 7 14 21 28 
Control 112.545.05 110.566.00 114.825.25 118.058.11 123.005.69 
50 117.076.31 119.215.15 122.195.76 125.6410.00 126.566.08 
100 114.265.44 118.136.88 121.086.15 124.187.14 127.378.14 
200 112.137.27 115.625.34 118.126.98 121.026.33 124.517.32 
Values are mean  S.E.M. (Dunnet’t' test). nsP > 0.05; Vs Control N=6. 
 
 
 
Table 3. Food (g/day) intake of rats exposed to Kumari Parpam for 28days. 
Dose 
(mg/kg/day) 
Days (gms/rats) 
1 7 14 21 28 
Control 47.222.45 48.122.17 46.102.28 47.612.44 47.853.22 
50 45.202.62 45.752.40 46.242.45 47.452.96 48.103.46 
100 42.342.12 42.402.47 44.452.34 45.842.10 46.453.21 
200 42.522.25 44.112.84 46.472.54 45.332.12 45.663.00 
Values are mean  S.E.M. (Dunnet’t' test). nsP > 0.05; Vs Control N=6. 
 
 
 
117 
 
 
Table 4. Water (ml/day) intake of rats exposed to Kumari Parpam for 28days. 
  Days(ml/rat) 
Dose 
(mg/kg/day) 
1 7 14 21 28 
Control 51.242.75 52.122.86 55.283.18 58.373.18 45.113.33 
50 50.422.58 50.863.02 45.234.00 42.213.42** 40.492.48 
100 48.982.96 49.583.78 40.873.39* 47.123.12 40.173.24 
200 52.443.12 54.003.12 55.323.00 45.254.00* 42.163.00 
 Values are mean  S.E.M. (Dunnet ’t' test). *P<0.05; **P<0.01. Vs Control N=6. 
 
 
Table 5. Hematological parameters after 28days treatment with Kumari Parpam in rats. 
 
Parameter Control 50 mg/kg 100 mg/kg 200 mg/kg 
RBC (millions/cu.mm) 5.13±0.41 5.15±0.41 5.26±0.32 5.32±0.41 
Hb (g/dl) 13.01±0.28 13.83±0.98 14.0±1.1 14.12±1.0 
PCV (%) 42.11±1.05 44.5±4.1 44.0±2.5 45.15±1.2 
WBC(cells/cu.mm) 7368±434.12 8045±337.2 8428±415.7 8643±452.3 
Neutrophil (%) 54.45±4.58 42.24 ±2.7 47.22±3.0 47.10±3.2 
Lymphocytes (%) 38.01±1.40 51.2±3.03* 47.31±3.4 46.18±3.2 
Eosinophil’s (%) 7.2±0.41 5.1±0.75* 5.3±0.41* 5.10±0.43* 
Monocytes (%) 4.0±0.3 3.2±0.4 3.0±0.3 2.4±0.2** 
Basophils (%) 0±0 0±0 0±0 0±0 
Platelets (105 
cells/cu.mm) 
1.41±0.05 1.80±0.07* 1.82±0.06* 2.0±0.19** 
MCV(Fl) 76.1±2.2 82.6±2.0 81.5±2.2 83.2±5.2 
MCHC (pg) 26.2±1.8 25.82±1.5 28.24±1.6 30.00±2.0 
 Values are mean  S.E.M. (Dunnet ’t' test). *P<0.05; **P<0.01. Vs Control N=6. 
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Table 6. Effect of treatment with Kumari Parpam biochemical (LFT, RFT, Lipid Profile) 
Parameters in rats. 
 
       Parameter Control 50 mg/kg 100 mg/kg 200 mg/kg 
Glucose (mg/dL) 72.42±6.20 68.42±7.32 66.32±7.13 67.42±7.28 
Total Bilirubin(mg/dL) 0.2050.05 0.2140.06 0.2120.05 0.2160.04 
Bilirubin direct 
(mg/dL) 
0.10.04 0.10.05 0.10.04 0.10.05 
Creatinine (mg/dL) 0.90±0.06 0.89±0.05 0.98±0.03* 0.98±0.03* 
BUN (mg/dL) 19.22±1.68 18.50±1.19 17.83±1.80 18.20±1.61 
AST (IU/L) 134.8±6.24 121.3±6.33 119.3±6.12 122.0±4.07 
ALT (IU/L) 38.22±3.50 32.18±2.60 30.14±2.56 31.62±2.28 
ALP (IU/L) 79.30±4.32 72.65±4.32 66.32±4.36 65.40±4.15 
Total cholestrol 
(mg/dL) 
55.81±5.78 57.61±5.68 55.84±5.21 59.61±4.88 
Total protein (g/dL) 8.42±0.27 7.90±0.23 7.53±0.75 7.46±0.72 
Albumin (g/dL) 2.68±0.08 2.72±0.05 2.74±0.06 2.72±0.05 
Urea(mg/dL) 55.241.53 54.243.64 62.122.15** 53.801.65 
Uric acid (mg/dL) 1.60.12 1.60.18 2.60.14** 2.20.18** 
Na m.mol 140.825.20 141.55.04 142.145.12 141.165.12 
K m.mol 20.202.88 19.401.42 20.01.48 20.102.24 
Cl m.mol 100.054.24 102.205.21 98.804.72 101.244.16 
HDL(mg/dL) 13.021.44 13.201.70 13.021.45 13.202.12 
LDL(mg/dL) 42.002.83 44.153.56 42.313.92 43.203.34 
VLDL(mg/dl) 16.382.62 15.822.34 16.001.64 15.061.28 
Triglycerides (mg/dl) 87.243.00 85.142.20 86.283.24 88.402.70 
 Values are mean  S.E.M. (Dunnet ’t' test). *P<0.05; **P<0.01. Vs Control  
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Table-7 Urine Analysis 
Parameters Control 50 mg/kg 100 mg/kg 200 mg/kg 
Colour Yellow Yellow Yellow Yellow 
Transparency Clear Slightly turbid Slightly cloudy Slightly turbid 
Specific gravity 1.01 1.01 1.01 1.01 
PH >7.2 >8.0 >8.0 >9.0 
Protein Nil 3+ 3+ 3+ 
Glucose Nil Nil Nil Nil 
Bilirubin -ve -ve -ve -ve 
Ketones -ve +ve +ve +ve 
Blood Absent Absent Absent Absent 
Urobilinogen Normal Abnormal Abnormal Abnormal 
Pus cells 0-cells/HPF 1-cell/HPF 2-cells/HPF 1-cell/HPF 
RBCs Nil Nil 0-1cells/HPF Nil 
Epithelial cells Nil 1-cell/HPF Nil 1-cell/HPF 
Crystals Nil Nil Nil Nil 
Casts Nil Nil Nil Nil 
Others Bacteria seen Bacteria seen Bacteria seen Bacteria seen 
 
Table 8. Effect of Kumari Parpam on organ weight 
Dose (mg/kg) Control 50 mg/kg 100 mg/kg 200 mg/kg 
Heart(g) 0.67±0.09 0.57±0.12 0.61±0.08 0.58±0.05 
Liver(g) 4.50±0.50 4.17±0.44 4.90±0.60 4.80±0.42 
Lung(g) 0.7±0.05 0.65±0.05 0.70±0.05 0.67±0.04 
Spleen(g) 0.64±0.05 0.67±0.04 0.70±0.06 0.68±0.05 
Kidney(g) 1.02±0.03 1.04±0.04 1.16±0.4 1.22±0.05 
Testis(g) 1.00±0.03 0.94±0.05 0.93±0.04 0.95±0.03 
Ovary(g) 0.04±0.02 0.04±0.01 0.04±0.02 0.04±0.02 
Brain 0.77±0.06 0.67±0.04 0.69±0.03 0.72±0.05 
Pancreas 1.42±0.07 1.36±0.08 1.41±0.11 1.61±0.10 
Uterus 0.69±0.07 0.84±0.08 0.72±0.06 0.72±0.07 
Values are mean  S.E.M. (Dunnet’t' test). nsP > 0.05; Vs Control N=6. 
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Pharmacological study: 
 
 
 
Table 1: Effect of Phenylhydrazine (10mg/kg, p.o. daily for 7 days) alone on 
Hematological parameters. 
Parameters 
Group 1 
(Normal) 
Group 2 
(Anemic) 
Group 3 
(Anemic) 
Group 4 
(Anemic) 
Group 5 
(Anemic) 
Group 6 
(Anemic) 
Hb (g/dl) 
18.24 ± 
0.52 
13.4±0.30** 13.68±0.28** 13.22±0.42** 12.98±0.30** 
12.64 ± 
0.32** 
PCV (%) 
54.10 
±1.73 
40.54 ± 
2.48** 
41.50 ± 
1.68** 
41.34 ± 
2.44** 
40.51 ± 
2.12** 
40.34 ± 
2.87** 
RBC 
(x106/ml) 
6.53 ± 0.19 4.28 ± 0.32** 4.10 ± 0.22** 4.85 ± 0.25** 4.76 ± 0.24** 4.22 ± 0.39** 
MCV (fl) 
72.70 ± 
2.88 
83.24±4.2 87.45±7.00 87.16±3.10 86.98±7.33 90.01± 3.40 
MCH (pg) 
23.81 ± 
1.69 
29.36±1.44 29.45±1.75 30.15±1.23* 30.17±0.92* 30.12 ± 2.54* 
MCHC (g/dl) 
34.12 ± 
0.48 
33.17±0.6 33.32±0.85 34.00±1.62 34.30±3.22 30.77 ± 1.41 
Values are mean  S.E.M. (Dunnet’t' test). *P<0.05; **P<0.01 Vs Control N=6. 
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Table 2:Hematological parameter of rats after Seven days treatment with Kumari Parpam. 
Parameters  
Group 1 
(Normal) 
Group 2 
(Anemic 
Control) 
Group 3 
(50 mg/kg) 
Group 4 
(100 mg/kg) 
Group 5 
(200 mg/kg) 
Group 6 
(Heamatinic 
syrup) 
Hb (g/dl) 19.33 ±1.23* 14.12±1.02 16.12±0.55 16.98±1.00 17.00 ± 0.86 21.46 ±2.00** 
PCV (%) 55.26 ±1.48* 44.72±2.4 45.12±2.36 47.10±2.64 47.10±3.22 57.02 ±2.41** 
RBC 
(x106/ml) 
7.35±0.20* 5.10±0.24 6.88±0.20 7.12±0.13* 8.02±0.17** 8.11±1.10** 
MCV (fl) 79.12±2.41  78.5±2.6 81.0±1.4 78.1±2.8 76.16±5.6 74.45±2.13  
MCH (pg) 24.94±1.56  27.3±1.6 24.91±1.1 29.6±1.3 30.15±2.3 22.15±1.22  
MCHC 
(g/dl) 
33.17±1.34  30.48±1.22  26.10±1.4 25.12±1.0 28.5±1.0 31.64±2.4 
 Values are mean  S.E.M. (Dunnet’t' test). *P<0.05; **P<0.01 Vs Control N=6. 
Table 3:Hematological parameters of rats after 14 days treatment with Kumari 
Parpam. 
Parameters  
Group 1 
(Normal) 
Group 2 
(Anemic 
Control) 
Group 3 
(50 mg/kg) 
Group 4 
(100 mg/kg) 
Group 5 
(200 mg/kg) 
Group 6 
(Heamatinic 
syrup) 
Hb (g/dl) 
18.33 
±1.41** 
10.15 ± 1.10 
20.65 ± 
0.90** 
20.44 ± 
0.85** 
20.12 ± 
1.65** 
21.58 ±1.50** 
PCV (%) 46.44 ± 1.24 43.20±1.12 42.10±3.8 42.34±2.0 44.11±1.4 57.37 ± 1.12 
RBC 
(x106/ml) 
4.92±0.30 4.90±0.34 4.78±0.32 4.67±0.25 4.70±0.24 5.54±0.27 
MCV (fl) 75.44±2.15** 92.88±2.49 90.32±2.01 77.45±1.50** 80.20±2.48** 75.41±2.45** 
MCH (pg) 27.10±2.56 34.00±2.01 30.12±1.88 26.71±1.50 27.00±1.46 28.30±2.79 
MCHC 
(g/dl) 
32.02±2.61 33.77±1.02 33.23±1.46 33.65±0.77 33.10±2.34 33.51±2.18 
Values are mean  S.E.M. (Dunnet’t' test). **P<0.01 Vs Control N=6. 
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STATISTICAL ANALYSIS: 
 
Paired t test for Symptoms before and after treatment for Pandu patient: 
 
Variable Obs Mean Std.dev t.value P value 
BTSym 20 5.45 1.432 
9.054 P<0.0001 
ATSym 20 2.8 1.609 
 
Symptoms before treatment is 5.45 and after treatment is 2.80 which is statistically 
significant (p<0.0001). 
 
Paired t test for Hb before and after treatment for Pandu patient: 
 
Variable Obs Mean Std.dev t.value P value 
BT Hb 20 8.58 0.9595 
-16.6 P<0.0001 
AT  Hb 20 9.515 9.515 
 
Hb before treatment is 8.580   and after treatment is 9.515 which is statistically significant 
(p<0.0001). 
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CLINICAL STUDY 
 
 
 
 
 
 
                                                  
                        
 
 
30%
55%
15%
AGE DISTRIBUTION 
Percentage
1 20-35
2 36-50
3 51-65
10%
90%
GENDER DISTRIBUTION 
No of Patients
1 M
2 F
GENDER DISTRIBUTION 
SL 
No Gender 
No of 
Patients Percentage 
1 M 2 10 
2 F 18 90 
AGE DISTRIBUTION 
SL No Age (years) Percentage 
1 20-35 30 
2 36-50 55 
3 51-65 15 
 IMPROVEMENT SHOWING SIGNS & SYMPTOMS BEFORE AND AFTER 
TREATMENT OF PAANDU  PATIENTS 
SL No Symptoms 
No of patients with symptoms 
Improvement 
percentage BT 
AT 
No 
Improvement Improvement 
1 Pallor 18 7 11 61 
2 Breathlessness 13 4 9 69 
3 Tiredness 20 8 12 60 
4 Giddiness 19 7 12 63 
5 Anorexia 18 6 12 66.7 
6 Pica 6 2 4 66.7 
7 Palpitation 15 5 10 66.7 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
0
5
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15
20
25
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                                  PROGNOSIS IN SIGNS AND SYMPTOMS OF ANAEMIA 
SL 
NO OP No Name 
Pallor Breathlessness Tiredness Giddiness Anorexia Pica Palpitation 
BT AT BT AT BT AT BT AT BT AT BT AT BT AT 
1 C83474 Mrs.V.Padma + + + + + - + - + + + + + + 
2 C85480 Mrs.R.Arputham + - - - + - + - + - - - + - 
3 C85924 Mrs.Dhatchayini + - - - + + + + + - - - + + 
4 C098088 Mrs.C.Athilakshmi + - + - + - - - + - - - - - 
5 C99770 Miss.S.Sudha + + + - + + + - + + + + + - 
6 C97890 Mrs.P.Saratha + - + + + + + + + - + - + - 
7 C97884 Mr.M.Ravi + + + - + + + - + + - - + - 
8 C89948 Mrs.R.Panjali - - - - + - + - - - + + - - 
9 C90117 Mrs.K.G.Govindammal + + + - + - + + + - - - - - 
10 D00452 Mr.P.Loganathan + - - - + + + - + - - - + + 
11 C98655 Mrs.K.S.Rani - - - - + - + + - - - - - - 
12 C91131 Mrs.S.Mythili + - + - + - + + + + - - + + 
13 C9941 Mrs.Lally Baskaran + + + + + - + - + - + + + - 
14 C00347 Mrs.I.Banu + - + - + - + - + - - - + + 
15 C95755 Mrs.S.Maruthi + + + + + + + + + - + - + - 
16 C67253 Mrs.R.Malliga + - - - + - + - + - - - + - 
17 C002479 Mrs.K.Gomathi + - - - + - + - + - - - - - 
18 C90388 Mrs.A.Shanthi + - + - + + + + + - - - + - 
19 C001189 Mrs.L.Shoba + - + - + - + - + - - - + + 
20 C97754 Mrs.M.Muthulakshmi + + + + + + + + + - - - + - 
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                   LAB INVESTINGATIONS – BEFORE TREATMENT ANAEMIA PATIENTS 
SL 
No OP No Age/Sex TC 
Dc (in %) ESR (mm/hr) BS (mg/dl) 
Urea  Creat  OT  PT  Al.P  T.Chol  
Urine 
P L E M 1/2 1 F PP/R Alb Sug 
Dep 
Pus 
cells 
Epi 
cells 
1 C83474 50/F 7500 60 39 1 0 16 32 99 129 26 0.6 29 26 234 193 NIL NIL 1-2 2-3 
2 C85480 60/F 8200 66 31 2 1 12 16 91 121 27 0.5 30 27 188 153 NIL NIL 1-2 1-2 
3 C85924 42/F 9200 71 28 1 0 14 20 88 118 26 0.8 29 28 168 158 NIL NIL 2-3 2-3 
4 C098088 45/F 10400 64 29 5 2 10 16 89 119 30 0.9 33 32 174 151 NIL NIL 1-2 1-2 
5 C99770 20/F 7600 61 33 4 2 14 20 93 123 29 0.7 32 28 199 163 NIL NIL 1-2 1-2 
6 C97890 65/F 6800 54 43 2 1 8 12 103 133 27 0.8 30 29 256 157 NIL NIL 2-3 2-3 
7 C97884 23/M 7200 58 35 5 2 14 22 95 125 30 0.8 33 32 212 169 NIL NIL 1-2 1-2 
8 C89948 45/F 8400 67 28 4 1 8 14 88 118 29 0.6 32 31 167 146 NIL NIL 2-3 1-2 
9 C90117 45/F 9100 72 26 2 0 6 12 86 116 27 0.7 30 27 156 140 NIL NIL 2-3 2-3 
10 D00452 62/M 7900 63 32 4 1 12 16 92 122 29 0.9 32 31 191 154 NIL NIL 1-2 1-2 
11 C98655 34/F 10500 67 32 1 0 10 18 92 122 26 1 29 25 192 158 NIL NIL 1-2 2-3 
12 C91131 43/F 8800 70 26 3 1 6 10 86 116 28 0.6 31 30 154 136 NIL NIL 1-2 1-2 
13 C9941 45/F 9400 67 29 3 1 10 18 89 119 28 0.8 31 26 174 155 NIL NIL 1-2 2-3 
14 C00347 46/F 7600 61 32 5 2 14 20 92 122 30 1 33 32 193 162 NIL NIL 2-3 1-2 
15 C95755 30/F 9900 69 28 2 1 8 12 88 118 27 0.9 30 27 168 142 NIL NIL 1-2 2-3 
16 C67253 38/F 10200 71 25 3 1 6 10 85 115 28 1 31 30 150 135 NIL NIL 1-2 2-3 
17 C002479 48/F 10100 62 37 1 0 8 12 97 127 26 0.7 29 28 222 151 NIL NIL 1-2 2-3 
18 C90388 35/F 9300 73 20 5 2 14 20 80 110 30 0.9 33 26 120 150 NIL NIL 2-3 2-3 
19 C001189 33/F 8200 66 29 4 1 12 20 89 119 29 0.6 32 29 176 159 NIL NIL 1-2 1-2 
20 C97754 49/F 9700 71 25 3 1 8 16 85 115 28 0.8 31 28 150 147 NIL NIL 1-2 2-3 
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                                   LAB INVESTINGATIONS – AFTER TREATMENT ANAEMIA PATIENTS 
SL 
No OP  No Age/Sex TC 
Dc (in %) ESR (mm/hr) BS (mg/dl) 
Urea  Creat  OT  PT  Al.P  T.Chol  
Urine 
P L    E M 1/2 1 F PP/R Alb Sug 
Dep 
Pus 
cells 
Epi 
cells 
1 C83474 50/F 7400 62 37 1 0 12 26 100 130 26 0.7 29 26 222 192 NIL NIL 1-2 2-3 
2 C85480 60/F 8400 69 28 2 1 10 16 93 123 28 0.5 31 26 178 151 NIL NIL 1-2 1-2 
3 C85924 42/F 9500 69 30 1 0 10 16 89 119 26 0.8 29 28 158 157 NIL NIL 2-3 2-3 
4 C098088 45/F 10200 68 25 5 2 8 14 94 124 32 1 35 30 166 146 NIL NIL 1-2 1-2 
5 C99770 20/F 7700 58 36 4 2 8 12 97 127 31 0.7 34 26 191 159 NIL NIL 1-2 1-2 
6 C97890 65/F 6700 53 44 2 1 2 4 105 135 28 0.8 31 28 254 155 NIL NIL 2-3 2-3 
7 C97884 23/M 7400 62 31 5 2 10 18 100 130 32 0.7 35 30 202 164 NIL NIL 1-2 1-2 
8 C89948 45/F 8700 69 26 4 1 8 12 92 122 30 0.6 33 30 159 142 NIL NIL 2-3 1-2 
9 C90117 45/F 8900 70 28 2 0 4 6 88 118 27 0.7 30 27 152 138 NIL NIL 2-3 2-3 
10 D00452 62/M 8000 61 34 4 1 6 10 96 126 30 0.9 33 30 185 150 NIL NIL 1-2 1-2 
11 C98655 34/F 10400 71 28 1 0 4 10 93 123 26 1 29 25 188 157 NIL NIL 1-2 2-3 
12 C91131 43/F 9000 67 29 3 1 2 4 89 119 29 0.6 32 29 152 133 NIL NIL 1-2 1-2 
13 C9941 45/F 9700 66 30 3 1 8 14 92 122 29 0.8 32 25 166 152 NIL NIL 1-2 2-3 
14 C00347 46/F 7400 65 28 5 2 6 14 97 127 32 1 35 30 187 157 NIL NIL 2-3 1-2 
15 C95755 30/F 10000 71 26 2 1 2 4 90 120 28 0.9 31 26 166 140 NIL NIL 1-2 2-3 
16 C67253 38/F 10100 74 22 3 1 6 10 88 118 29 1 32 29 144 132 NIL NIL 1-2 2-3 
17 C002479 48/F 10300 60 39 1 0 4 6 98 128 26 0.8 29 28 218 150 NIL NIL 1-2 2-3 
18 C90388 35/F 9600 71 22 5 2 6 12 85 115 32 0.7 35 24 114 145 NIL NIL 2-3 2-3 
19 C001189 33/F 8000 63 32 4 1 10 16 93 123 30 0.6 33 28 166 155 NIL NIL 1-2 1-2 
20 C97754 49/F 9800 70 26 3 1 2 12 88 118 29 0.7 32 27 148 144 NIL NIL 1-2 2-3 
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LAB INVESTIGATIONS - ANAEMIA 
SL 
NO OP No Name 
Hb (gm%) 
TRbc 
(millions/µl) HCT/PCV (%) MCV (fl) MCH (pg) MCHC (gm/dl) Smear Study 
BT AT BT AT BT AT BT AT BT AT BT AT BT AT 
1 C83474 Mrs.V.Padma 7.5 8.3 3.8 3.8 28.9 29 70.4 70.5 21.1 22 29.7 29.8 + + 
2 C85480 Mrs.R.Arputham 9.6 10.2 4.1 4.1 29 30 71.2 71 22.1 23 28 29 + - 
3 C85924 Mrs.Dhatchayini 8.5 9.2 4.2 4.2 30 30.1 69.1 70 20.3 21 29.1 29 + + 
4 C098088 Mrs.C.Athilakshmi 9.3 10.2 4 4.1 28.4 29 72 72.1 21 20.6 28.3 28.4 + - 
5 C99770 Miss.S.Sudha 7.2 8 4 4.1 24.6 25 71.9 72 24.1 25 27.9 28 + + 
6 C97890 Mrs.P.Saratha 7.2 8 3.9 4 26 26.1 65.4 66 23.2 24 28.1 28 + + 
7 C97884 Mr.M.Ravi 7 7.8 3.8 3.9 25 25.1 68.3 69 22.8 23 28.1 28.9 + + 
8 C89948 Mrs.R.Panjali 9.9 10.5 3.8 3.8 32 32.1 66.9 67 23.1 24 29.3 30.1 + - 
9 C90117 Mrs.K.G.Govindammal 9.7 10.4 4.1 4.1 33 33.2 69.9 69.8 22 23 30.4 31 + - 
10 D00452 Mr.P.Loganathan 9.2 10.4 3.9 4 31.1 32 69.8 70 20 21 29.8 30 + - 
11 C98655 Mrs.K.S.Rani 9.8 10.6 4.4 4.4 32.5 32 67.3 68 21.3 22 28.1 29 + - 
12 C91131 Mrs.S.Mythili 9 10.2 3.9 3.9 31 31.1 65.9 66 21.1 21.4 28.3 29.9 + - 
13 C9941 Mrs.Lally Baskaran 9 10.1 4 4 30 31.2 66 67 23.9 24.1 28.3 28.4 + - 
14 C00347 Mrs.I.Banu 8.8 9.8 4.1 4.1 29.6 30.4 65.2 66 24 24.4 29.3 29.9 + + 
15 C95755 Mrs.S.Maruthi 7.6 8.8 4.2 4.2 29 30 69 69.3 19.8 20 28.5 29 + + 
16 C67253 Mrs.R.Malliga 8.6 9.6 4.3 4.3 31.4 32 68 68.5 19.9 21 27 27.5 + + 
17 C002479 Mrs.K.Gomathi 9.2 10.4 4.1 4.1 32.3 33 69.4 70 20 21 27 27 + - 
18 C90388 Mrs.A.Shanthi 7.6 9.2 4 4 25.9 26 70.8 71 19.7 20.3 27.4 27.8 + + 
19 C001189 Mrs.L.Shoba 9.1 10 3.9 3.9 30 30.2 69.1 69 18 19 28.1 28 + + 
20 C97754 Mrs.M.Muthulakshmi 7.8 8.6 3.7 3.8 28 28.2 68.5 69 19 19.3 29.5 29.6 + + 
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